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End stage renal failure is a devastating condition, for which there 
are only two treatment options: dialysis or renal transplantation. 
Compared to dialysis, renal transplantation is still the treatment of 
choice in terms of survival and quality of life. In 1954, the first successful 
kidney transplantation was performed between identical twins (1). The 
number of kidney transplantations has tremendously increased since, in 
particular enabled by the development of effective immunosuppressive 
regimens. In 2010, a total of 867 renal transplantations were performed 
in the Netherlands (2). Despite this, 892 patients were still on the 
waiting list by the end of that year (2). Currently, median graft survival 
time is approximately 9-10 years, which underscores the importance 
to improve graft survival rates. New immunosuppressive strategies, 
more sophisticated surgical techniques and improved patient care 
have significantly contributed to a better first year survival of renal 
allografts by prevention of acute rejection (3). However, partly as a 
consequence of the improvement of short-term graft survival, chronic 
transplant dysfunction (CTD) is now the major problem after renal 
transplantation (4). CTD is the most common cause of late graft loss 
in renal transplant patients and accounts for approximately 33% of all 
graft losses (4).
CHRONIC TRANSPLANT DYSFUNCTION
Clinically, renal CTD is defined as a gradual deterioration of graft 
function, manifested by a progressive decline in glomerular filtration 
rate, coincided by proteinuria and hypertension (4). The histopathologic 
changes of CTD involve all parts of the renal parenchyma including the 
blood vessels, glomeruli, interstitium and tubules (5) (Figures 1,2,3). 
The histopathologic lesions are the result of a wound-healing response 
to injury caused by ischemia/reperfusion, early acute rejection episodes 
and the continuous alloresponse. This entire process is accompanied 
by loss of renal functional capacity (4,6). During transplantation-
related injury, several repair mechanisms are initiated in the kidney 
in order to recover from damage. However, persisting injury to the 
transplanted kidney leads to chronic tissue remodeling and eventually 
to the formation of fibrotic lesions. The continual processes causing 
damage to the kidney include activation of resident kidney cells and 
the infiltration of inflammatory monocytes/macrophages and T cells 
towards the injured sites. These inflammatory cells become allo-
reactive and, as a consequence, produce inflammatory and fibrogenic 
cytokines and growth factors. This further results in the production 
of large amounts of extra-cellular matrix (ECM) components by 
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1resident activated mesenchymal cells, such as interstitial pericytes and fibroblasts (7). Continuous deposition of ECM finally results in scar 
tissue formation and loss of the normal renal architecture eventually 
leading to the collapse of renal parenchyma and loss of kidney function.
Histopathologic changes accompanying chronic transplant dys-
function
Arterial remodeling in the transplanted kidney results in the 
development of transplant vasculopathy (TV, Figure 1), which basically 
is the formation of a neointima between the endothelial cell (EC) layer 
and the internal elastic lamina. This neointima predominantly consists 
of α-smooth muscle actin (α-SMA)-positive cells that secrete ECM, 
intermingled with recipient-derived mononuclear cells such as T cells 
and macrophages. This process further leads to luminal occlusion and 
stenosis and eventually to ischemic graft failure.
The glomeruli in the transplanted kidney with CTD develop focal 
segmental glomerulosclerosis (FSGS, Figure 2) which is scarring of the 
glomerular tuft (8). FSGS is the final common pathway of glomerular 
damage in various native kidney diseases, but also occurs after renal 
transplantation. FSGS can develop in the transplanted kidney in the 
absence of pre-existing FSGS; this is referred to as de novo FSGS 
(9,10). The presence of de novo FSGS is associated with transplant 
dysfunction and early graft loss (9,10). Chronic transplant injury can 
also lead to transplant glomerulopathy. Transplant glomerulopathy was 
first described in 1963 (11) and is characterized by enlarged glomeruli, 
mesangial matrix expansion and duplication and thickening of the 
glomerular basement membranes (12). 
Chronic tissue remodeling of the interstitium and tubules of the 
transplanted kidney results in interstitial fibrosis and tubular atrophy 
(IF/TA, Figure 3) (13). IF/TA is manifested by the deposition of interstitial 
ECM in association with the accumulation of inflammatory cells, tubular 
atrophy and loss of peritubular capillaries. Interstitial fibroblasts and 
pericytes start proliferating and transform to myofibroblasts after 
which they are considered to be the major cells responsible for the 
production of ECM. Although epithelial-to-mesenchymal transition 
is claimed to be involved in this process the BANFF committee has 
recently decided to consider this term as misleading (14), since 
there is no prove that transformed epithelial cells actually cross the 
tubular basement membrane. Nevertheless, the widened interstitial 
spaces fills with fibrillar matrix molecules predominantly consisting of 
collagen type I and III and fibronectin resulting in scar formation. This 
process obviously has a detrimental effect on functional aspects of the 
transplanted kidney. 
Current therapies after transplantation focus on halting or slowing 
down the process of renal fibrosis. No therapy is available to regress 
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the development of renal fibrosis. Therefore, it is important to know 
which cell types and which cellular mechanisms play a key role in the 
development of renal fibrosis after transplantation. Advanced insight 
into the mechanisms of renal fibrosis is required for the development 
of novel anti-fibrosis therapies and can help to design therapies aimed 
at regeneration rather than pathologic remodeling of the transplanted 
kidney. Ideally, novel therapies are only directed to the cells responsible 
for the development of fibrosis. It is thus important to reveal the 
origin of cells which contribute to fibrosis in the transplanted kidney. 
A particular issue which needs to be resolved is whether these cells 
originate from the donor (i.e. the kidney itself) or the recipient, as this 
could potentially lead to vastly different prevention strategies.
ORIGIN OF CELLS IN CHRONIC TRANSPLANT DYS-
FUNCTION
Origin of cells in transplant vasculopathy
The development of TV is initiated by injury to the vascular 
endothelium of the graft. This assumption is based on the fact that 
graft ECs are crucial in maintaining normal vessel function by inhibiting 
thrombus formation and leukocyte adhesion and by regulating vessel 
tone by resistance arteries. Also, graft ECs are the first cells that are 
encountered by the host immune system. Therefore, EC damage, and 
subsequent dysfunction of allograft ECs, may play an important role in 
the pathogenesis of CTD (15). Prevention of EC damage and subsequent 
dysfunction of these cells might even prevent the development of TV. 
The regeneration of damaged ECs occurs by replacement by either 
donor or recipient-derived cells (Figure 1). Evidence for the replacement 
of donor ECs by recipient-derived ECs in transplanted kidneys is 
contradicting (16-18). However, the majority of studies investigating 
chimerism after acute graft rejection describe replacement of donor 
ECs by recipient-derived cells. Recipient-derived cells with the ability 
to differentiate into ECs are derived from the circulation. These 
endothelial progenitor cell (EPCs) were first described by Asahara et 
al. (19). Since then it has been shown that EPCs can be mobilized 
from the bone marrow into the circulation and home to sites of injury 
(20,21). Lagaaij et al. (18) found a positive correlation between the 
extent of EC chimerism and graft rejection. Their data indicate that 
severe vascular injury might trigger repopulation of severely injured 
graft endothelium by recipient-derived ECs.
The development of TV is thought to be the result of a local 
inflammatory response within the vessel wall, which triggers SMC 
migration and proliferation (22). Until a decade ago, the general dogma 
was that neointimal SMCs in TV are graft-derived, as proposed by the 













Figure 1. The origin of cells in arteries after during chronic transplant 
dysfunction. In a healthy artery, the interior surface is lined with endothelial cells and 
surrounded by the media, which consists of smooth muscle cells. The media is enclosed 
by the internal elastic lamina and the external elastic lamina (dotted black lines). These 
membranes separate the medial smooth muscle cells from the endothelial cells and 
adventitial fibroblasts respectively. During transplantation-related injury, damaged 
endothelial cells can be replaced by either proliferating neighboring endothelial cells (1) 
or by circulating recipient-derived endothelial progenitor cells (2). During continuous 
injury, smooth muscle cells accumulate in the intima, produce and deposit extracellular 
matrix proteins thereby promoting the formation of an occlusive neointima (also called 
transplant vasculopathy, TV). These neointimal smooth muscle cells may be derived 
from proliferating and migrating medial smooth muscle cells (3) and/or adventitial cells 
(4). Neointimal smooth muscle cells can also be derived from circulating smooth muscle 
precursor cells (5). Abbreviations: CTD, chronic transplant dysfunction; TV, transplant 
vasculopathy).
response-to-injury hypothesis for atherosclerosis (23,24). According 
to this hypothesis, graft-derived intimal SMCs originate from the donor 
arterial media, from which they migrate across the internal elastic 
lamina in response to arterial injury (Figure 1). Injured medial SMCs 
can switch their phenotype from a contractile to a synthetic state 
(25). This plasticity of SMCs to modulate their phenotype after injury 
has been the subject of investigation for several years, especially in 
the field of atherosclerosis (26-29). Whether this phenomenon also 
contributes to neointima formation in the development of CTD after 
renal transplantation is not known. Synthetic SMCs have migratory and 
proliferative capacities and secrete ECM molecules which allow them to 
contribute to neointima formation. Synthetic SMCs are characterized 
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by a lower expression of genes encoding smooth muscle-specific 
contractile proteins, such as smooth muscle myosin heavy chain, 
SM22α, calponin, and α-SMA. The transcription of these genes can be 
negatively regulated by Krüppel-like factor 4 (KLF4). KLF4 is a potent 
repressor of contractile genes and can act via several mechanisms, 
such as remodeling the chromatin of CArG box-containing promoters, 
competition with serum response factor (SRF) and reducing myocardin 
expression (30,31). Another possible source for donor-derived 
neointimal cells are migrating adventitial myofibroblasts (Figure 1). 
During the response to vascular injury and inflammation, adventitial 
fibroblasts can be reprogrammed to differentiate into myofibroblasts 
(32). However, the graft origin of neointimal cells, and thus the 
response-to-injury hypothesis, has been challenged since it was 
shown that recipient-derived cells can also contribute to experimental 
neointima formation (Figure 1) (33-36). Recipient-derived neointimal 
SMCs are thought to be derived from circulating progenitor cells that 
are recruited towards sites of vascular injury and differentiate into 
SMCs within the injured vessel. Progenitor cells with SMC-like cell 
outgrowth potential have been shown to exist within human peripheral 
blood (37-39). Data on the mechanisms that attract these progenitor 
cells or on subsets of peripheral blood mononuclear cells that are 
capable of differentiating into SMC-like cells are scarce. Possible SMC 
progenitor candidates are CX3CR1-postive mononuclear cells which 
interact with CX3CL1 (fractalkine), expressed by injured ECs (38). 
Conflicting data have been reported on the origin of neointimal SMCs 
in human CTD, since both kidney graft (donor)-origin and contribution 
of recipient-derived cells have been found. While Grimm et al. (40) 
showed that 34% of neointimal SMCs are recipient-derived, Bittmann 
et al. (41) found no contribution of recipient-derived cells to neointima 
formation after transplantation. Thus definite proof of the contribution 
of recipient-derived cells to neointima formation needs to be provided. 
Also, more research is needed to unravel the phenotype of recipient-
derived SMC progenitor cells and their relation to CTD after renal 
transplantation.
Origin of cells in focal segmental glomerulosclerosis
The glomerulus consists of four different cell types, i.e. ECs, 
mesangial cells, and two types of epithelial cells: podocytes (epithelial 
cell within the glomerular tuft) and parietal epithelial cells (epithelial 
cells that line Bowman’s capsule) (Figure 2).
After renal transplantation, bone marrow-derived cells can home to 
injured glomeruli were they replace injured endothelial and mesangial 
cells (Figure 2), thereby contributing to regeneration as also shown in 
a variety of experimental models of glomerular injury (42-46). Ito et al. 
(47) however, did not find replacement of glomerular endothelial cells 
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1by bone marrow-derived cells. Glomerular endothelial cells may also be replaced by proliferation of adjacent endothelial cells (48) (Figure 2). 
Nevertheless, glomerular capillary repair by either donor or recipient-
derived cells is important since degeneration of glomerular capillaries 














Figure 2. The origin of cells in the glomerulus during chronic transplant 
dysfunction. A healthy glomerulus consists of four cell types; endothelial cells, 
mesangial cells and two types of epithelial cells. The epithelial cells surrounding the 
capillaries (lined with endothelial cells) are podocytes. The epithelial cells that line 
the interior surface of Bowman’s capsule are parietal epithelial cells. Mesangial cells 
are specialized pericytes, localized around capillaries for structural support. During 
transplantation-related injury, damaged endothelial cells in glomerular capillaries can 
be replaced by either proliferating neighboring endothelial cells (1) or by circulating 
(endothelial progenitor) cells (2). Circulating progenitor cells can also replace damaged 
mesangial cells (3). Continuous injury leads to the deposition of extracellular matrix in 
the glomerulus. This will lead to loss of function and scarring (FSGS). Activated cells 
responsible for FSGS can originate from proliferating mesangial cells (4), podocytes 
(5) or parietal epithelial cells (6). Abbreviations: CTD, chronic transplant dysfunction; 
FSGS, focal segmental glomerulosclerosis).
Processes that contribute to the progression of FSGS include 
podocyte injury and mesangial cell proliferation, followed by matrix 
accumulation (Figure 2). Podocytes are highly differentiated cells with 
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a limited capacity to proliferate, which might explain why podocyte 
injury is a key driver of FSGS (50). Also evidence from experimental 
models suggests that there is a certain threshold for loss of podocytes 
after which glomerulosclerosis will develop (50-53).
Conflicting results have been reported about the cellular origin of 
epithelial proliferation in FSGS (podocytes or parietal epithelial cells) 
(Figure 2). Epithelial hyperplasia was considered to be the result of 
proliferation of dedifferentiated podocytes (54,55). However, data from 
animal studies suggest that parietal epithelial cells are the primary 
source of proliferating epithelial cells in FSGS (56-60). FSGS might 
be the consequence of parietal epithelial cells secreting extracellular 
matrix after having failed in their attempt to replace podocytes. The 
most likely scenario is that the pathology of FSGS starts with podocyte 
injury followed by podocyte and/or parietal epithelial cell hyperplasia.
Origin of cells in interstitial fibrosis and tubular repair
As a result of ischemia/reperfusion injury and the alloimmune 
response to the transplanted kidney, tubular epithelial cells are damaged. 
However, surviving tubular epithelial cells can proliferate and replace 
lost epithelial cells (61). However, studies performed in human renal 
transplant biopsies also confirmed the presence of recipient-derived 
tubular epithelial cells (Figure 3) (40,41,45,62-65). Recipient-derived 
cells are thus capable of contributing to tubular regeneration after 
injury. Based on the few studies that are able to correlate chimerism 
with graft outcome and acknowledging the capacity of renal tubular 
cells to regenerate the tubules (61), it is more likely that engraftment 
of recipient-derived tubular cells also depends on the severity of renal 
tubular damage after transplantation, alike EC replacement (66).
The origin of interstitial myofibroblasts in the kidney is controversial. 
Several sources of myofibroblasts have been proposed (Figure 3). These 
include endothelial and tubular epithelial cells (via a process called 
endothelial- or epithelial-to-mesenchymal transition, respectively), 
activation of pericytes, interstitial fibroblasts and the recruitment of 
bone marrow-derived cells (67). 
Endothelial and tubular epithelial cells in the kidney can acquire 
a mesenchymal phenotype. This becomes obvious by de novo 
expression of α-SMA and the production of collagens. Endothelial-
to-mesenchymal transition (EndoMT) and epithelial-to-mesenchymal 
transition (EMT) has been shown to occur after experimental renal 
injury (68-70). Although the presence of EMT has been confirmed in 
human biopsies (71), the contribution of EMT to interstitial fibrosis 
is under debate since others were not able to confirm a role for EMT 
in interstitial fibrosis using epithelial lineage tracing after unilateral 
ureteral obstruction (UUO) in mice (72,73). Also, with the use of 
electron microscopy, no migrating tubular epithelial cells crossing the 
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1tubular basement membrane to the interstitial space were found (74-76). Other potential sources of interstitial myofibroblast are described 
below, since it is likely that other processes than EMT give rise to the 















Figure 3. The origin of cells in the renal tubulointerstitium during chronic 
transplant dysfunction. The normal tubulointerstitium consists of tubular epithelial 
cells and an interstitial space filled with capillaries, which are surrounded by pericytes 
and interstitial fibroblasts. During transplantation-related injury, damaged epithelial 
cells can be replaced by either proliferating neighboring epithelial cells (1) or by 
circulating progenitor cells (2). Ongoing injury leads to the deposition of extra cellular 
matrix in the interstitial space causing interstitial fibrosis and tubular atrophy (IF/TA). 
The myofibroblasts responsible for IF can originate from activation and proliferation of 
pericytes (3) or fibroblasts (4). Myofibroblasts can also be derived from endothelial (5) 
or epithelial (6) cells, via a process called endothelial- or epithelial-to-mesenchymal 
transition, respectively. They can also arise from circulating precursor cells (7). 
Abbreviations: CTD, chronic transplant dysfunction; IF/TA, interstitial fibrosis and 
tubular atrophy).
Bone marrow-derived progenitor cells can also differentiate into 
interstitial myofibroblasts. After experimental ischemia/reperfusion 
injury, 32% of the interstitial myofibroblasts were originated from the 
bone marrow (77). A similar percentage was found in an experimental 
model for kidney transplantation, in which 39% of the interstitial 
myofibroblasts appeared to be recipient-derived (78). The presence of 
recipient-derived myofibroblasts was also confirmed in renal transplant 
patients with CTD (40). Altogether the results of these studies indicate 
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a possible role for recipient-derived myofibroblasts in renal interstitial 
remodeling after transplantation-induced injury.
Pericytes are in close contact with endothelial cells of peritubular 
capillaries in the interstitium. Interstitial pericytes can differentiate 
into myofibroblasts and contribute to interstitial fibrosis after renal 
injury (72). After injury, damage to the endothelium can result in the 
production of growth factors, chemokines and cytokines by damaged 
endothelial cells. As an example, endothelial cell-derived PDGF 
promotes the transition of pericytes into myofibroblasts (79).
Due to the lack of specific markers, resident interstitial fibroblasts 
are difficult to distinguish from other mesenchymal cells. There is 
however, controversy over the question whether resident interstitial 
fibroblasts and pericytes are in fact the same cells (80). Nevertheless, 
identification can be confirmed using electron microscopy, showing 
abundant RER, F-actin filaments and an association with collagen 
fibrils in interstitial fibroblasts (81). Resident interstitial fibroblasts 
perform a scaffolding function by connecting the nephrons and the 
supplying capillaries (81). In addition, they produce the fibrous matrix 
which serves as a common scaffold throughout the renal parenchyma, 
together with the fibroblasts. After injury, resident interstitial fibroblasts 
become activated and transform into myofibroblasts, as evidenced by 
de novo expression of α-SMA. In UUO-induced experimental fibrosis, 
the conversion of a fibroblast into a myofibroblast was seen, starting 
with the appearance of actin microfilaments and abundant RER and 
a gradual increase in expression of α-SMA exclusively in interstitial 
fibroblasts, which were identified by ecto-5′-nucleotidase (82).
ROLE OF THE MICROENVIRONMENT IN THE PATHO-
GENESIS OF CTD
The renal microenvironment, constituting the sum of multiple 
processes taking place in the kidney, plays an important role in the 
development of CTD. All renal compartments i.e. the blood vessels, 
interstitium and glomeruli are continuously in contact with locally 
produced or plasma derived factors. These products, which include 
growth factors, chemokines and cytokines, will not only serve 
the repair processes, but also initiate detrimental processes like 
inflammation and fibrosis. Several of these factors are known to bind to 
proteoglycans, which in addition to their function as a major constituent 
of the extracellular matrix, now also serve as a docking platform for 
substances that play a role regeneration, migration and proliferation 
of endothelial, epithelial and mesenchymal cells in CTD. Proteoglycans 
are glycoconjugates that mediate several biological processes such as 
cell-cell and cell-matrix interactions and cell migration and proliferation 
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1(83,84). Based on the presence of different types of glycosaminoglycan polysaccharide side chains, PGs are mainly classified as heparan 
sulfate PGs (HSPGs), chondroitin sulfate PGs, dermatan sulfate PGs 
and keratan sulfate PGs. Due to their vast structural heterogeneity 
HS are able to bind and interact with a myriad of proteins, such as 
growth factors, chemokines, cytokines and ECM components. The 
length of HS chains varies from ~5 to ~70 kDa (85). Ligand binding 
by proteoglycans depends on the structure of the fine structure of 
HS chains. Several growth factors and chemokines, such as FGFs, 
VEGF and TGF-βs, bind to HS present on cell surface proteoglycans 
(86). The glycosaminoglycan side chains of proteoglycans can be 
modified after injury and are, for example, involved in the regulation 
of leukocyte migration to sites of inflammation (87-89). HSPGs can 
act as co-receptors, as demonstrated for FGFs (90). HS proteoglycans 
are essential for the control of the proliferative response to FGF-2 in 
renal interstitial fibroblasts (91) and the effect of FGF-2 on SMCs is 
only present after modification of proteoglycan bindings sites after 
injury, which allows binding of FGF-2 (92). Syndecan 4, a cell surface 
proteoglycan, has also been shown to regulate SMC proliferation and 
vascular progenitor cell mobilization after injury, thereby ameliorating 
neointima formation after vascular injury (93). Taken together, this 
implies that HSPGs orchestrate tissue plasticity and remodelling and 
as such might be crucial in tissue remodelling associated with CTD in 
transplanted kidneys.
AIM OF THIS THESIS
The general aim of this thesis is uncover the cellular and molecular 
mechanisms involved in the pathogenesis of chronic transplant 
dysfunction (CTD) after renal transplantation with particular emphasis 
on the development of transplant vasculopathy (TV). Knowledge of this 
process is of cardinal importance in order to design novel therapies 
to attenuate or even halt the progressive nature of CTD, thereby 
improving long-term survival of the grafts and quality of life of the 
recipient.
In chapter 2 and chapter 3, we investigated possible cellular 
players critically involved in the pathogenesis of CTD after human 
renal transplantation. To this end in chapter 2, we determined the 
origin (donor vs. recipient) of neointimal smooth muscle cells (SMCs), 
endothelial cells (ECs), glomerular ECs and tubular epithelial cells in 
human explanted transplantectomy samples. We showed that both 
donor- and recipient-derived cells contribute to vascular remodeling 
and tubular repair after human renal transplantation. We reasoned 
that the recipient-derived neointimal SMCs originate from a monocyte 
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population residing within the pool of circulating peripheral blood 
mononuclear cells (PBMNCs). In order to investigate whether SMC 
outgrowth potential was related to the development of CTD, in chapter 
3, we cultured PBMNCs isolated from renal transplant patients (with and 
without CTD) in fibrogenic culture medium to stimulate differentiation 
towards a SMC-like phenotype using α-SMA expression as a specific 
SMC marker. As monocytes are a putative source of circulation-
derived α-SMA expressing cells, the frequency of various circulating 
monocyte (sub)populations was evaluated by flowcytometry in the 
aforementioned patients and related to the in vitro PBMNC culture 
data.
In chapter 4 to chapter 6, we studied possible molecular 
mechanisms underlying the pathogenesis of CTD. To this end, we used 
a rat model for the development of renal CTD that has previously 
been described (94,95). In this model, kidneys from Dark Agouti donor 
rats are transplanted into Wistar Furth recipients. Kidney allograft 
recipients develop CTD as evidenced by characteristic histopathological 
changes within 12 weeks after transplantation. The histopathological 
changes in this model include TV, FGS and IF/TA, thereby resembling 
the characteristics of CTD after human renal transplantation. To verify 
the human data described in chapter 2 regarding the origin of cells 
in transplanted kidneys, we also determined the origin of these cells 
after experimental transplantation. To distinguish between donor 
and recipient-derived cells, we developed and characterized a new 
transplant model using Dark Agouti donors into human placental 
alkaline phosphatase (hPAP)-transgenic Fischer 344 recipient rats. 
hPAP transgene expression allows for the identification of recipient-
derived cells in the transplanted kidney. In chapter 4 we investigated 
the origin of ECs, neointimal SMCs and interstitial myofibroblasts after 
experimental renal transplantation. Since we showed that neointimal 
SMCs are of donor origin, we subsequently hypothesized that these 
graft-derived neointimal SMCs originate from the vascular media. 
Therefore in chapter 5, we explored the medial microenvironment 
in allografts with CTD for the presence of fibrogenic growth factors 
that could eventually lead to subendothelial SMC accumulation and 
neointima formation. SMCs can modulate their phenotype from 
a “normal” contractile to a synthetic SMC. Synthetic SMCs can 
proliferate and migrate to the intima, thereby contributing to the 
development of TV. Therefore, we investigated the expression of 
phenotypic modulators indicative of switching of medial SMCs from a 
contractile to a synthetic phenotype as a result of the altered medial 
microenvironment upon allogeneic transplantation. For this purpose, 
neointimal and medial layers were isolated using laser dissection 
microscopy, followed by low-density array gene expression profiling. 
As phenotypic modulation towards a synthetic phenotype may result 
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1in reduced contractility, we tested the functional consequences of the altered medial microenvironment in an in vitro collagen contraction 
assay using rat aortic SMCs.
Tissue remodeling is modulated by a large array of mediators 
including growth factors. Heparan sulfate proteoglycans (HSPGs) can 
function as docking platforms for growth factors and can thereby 
contribute to tissue remodeling. Therefore in chapter 6, we studied 
the spatial expression of several HSPGs in TV and FSGS in kidney 
allografts with CTD. An in vitro culture assay was performed to study the 
functional role of HSPGs in FGF2-driven proliferation of rat mesangial 
cells. Knowledge of the role of HSPG-growth factor interactions in the 
development of CTD can lead to the development of new therapies that 
can prevent HSPG driven scar formation after renal transplantation.
In chapter 7, we aimed to attenuate the development of CTD 
by blocking activation of graft ECs during the transplant procedure. 
STAT1 is a transcription factor that is involved in the regulation of 
inflammation-related genes such as MCP-1 and E-selectin in a.o. ECs. 
Reducing inflammation after transplantation is expected to attenuate 
tissue remodeling and the development of CTD. To prevent EC activation 
in the peri-operative period, STAT1 decoy oligodeoxynucleotides 
(dODNS) (96,97) were infused in the kidney during organ preparation 
after which they are anticipated to be taken up by ECs. STAT1 dODNS 
can scavenge the transcription factor STAT1 thereby blocking the 
transcription of the various pro-inflammatory target genes located 
downstream STAT1.
In chapter 8, the results from chapter 2-7 are summarized and 
discussed in the context the current knowledge. Furthermore, 
recommendations for future research and for possible novel 
interventional strategies are provided in this final chapter.
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Chronic transplant dysfunction is the leading cause of long-term 
renal allograft loss. One of the histological hallmarks of chronic 
transplant dysfunction is transplant vasculopathy (TV) characterized 
by accumulation of smooth muscle cells (SMCs) in the arterial 
subendothelial space, leading to ischemic graft failure. Currently no 
therapy is available for TV and knowledge of the origin (donor versus 
recipient) of neointimal cells may contribute to develop adequate 
strategies.
Methods
Origin of neointimal SMCs, endothelial and tubular cells was 
determined in four nephrectomy samples from male recipients 
transplanted with a female kidney. Recipient-derived cells were 
detected using X- and Y-chromosome specific fluorescent in situ 
hybridization combined with immunofluorescent staining. Specificity 
and sensitivity of fluorescent in situ hybridization were determined 
with corresponding controls.
Results
No Y-chromosome-positive cells were detected in the female-to-
female graft whereas ~31% of nucleated cells in male-to-male grafts 
had a detectable Y-chromosome. In female-to-male grafts, a recipient-
derived population of neointimal α-smooth muscle actin-positive SMCs 
were detected (6%, range 3 - 11%). Percentages of recipient-derived 
arterial endothelial cells, glomerular endothelial cells and tubular 
epithelial cells were 14% (range 4 - 32%), 19% (range 7 - 31%) and 
3% (range 2 - 5%), respectively.
Conclusions
Both donor- and recipient-derived cells contribute to vascular 
remodeling in clinical renal transplantation. The presence of α-smooth 
muscle actin in donor- as well as recipient-derived cells supports a 
constructive role for these cells in neointimal formation. However, the 
predominance of donor-derived cells in the neointima points to these 
cells as the likely therapeutic target.




Chronic transplant dysfunction (CTD) is a major risk factor for late 
graft loss after kidney transplantation (1). Clinically, CTD after renal 
transplantation is defined as gradual deterioration of graft function, 
manifesting as a slow progressive decline in glomerular filtration rate, 
generally along with proteinuria and hypertension. As these clinical 
variables are not specific, diagnosis is made after histopathogical 
evaluation. Histopathological features of CTD after renal transplantation 
include transplant glomerulopathy, interstitial fibrosis and tubular 
atrophy (IF/TA) (2, 3), at times accompanied by neointimal thickening 
and duplication of the internal elastic lamina (IEL). Although immune 
suppressive therapy has come a long way in reducing acute graft loss, 
it has hardly contributed to reduction of long-term graft loss (4). New 
strategies with different immune suppressive regiments may improve 
the long-term survival of renal allografts (5).
The initiating mechanism of CTD is poorly understood although 
several insults associated with transplantation, such as ischemia-
reperfusion, the alloimmune response, and immunosuppressive 
treatment lead to graft injury (6). This injury triggers vascular 
remodeling (7) and tubular repair (8). Surviving tubular cells have 
the capacity to proliferate and regenerate tubules (8). Vascular 
remodeling is characterized by the accumulation of α-smooth muscle 
actin (α-SMA)-positive smooth muscle cells (SMCs) between the 
endothelial lining and the IEL, forming an occlusive neointima. This 
latter process is referred to as transplant vasculopathy (TV) or chronic 
allograft arteriopathy. Neointimal SMCs secrete extracellular matrix 
leading to arterial stiffness, luminal stenosis and, eventually, ischemic 
graft failure.
Data on the origin of neointimal SMCs in human CTD are contrasting, 
since both kidney graft (donor)-origin and contribution of recipient-
derived cells have been reported. While Grimm et al. reported that 
34% of neointimal SMCs are recipient-derived (9), Bittmann et al. (10) 
found no contribution of recipient-derived cells to neointimal formation 
after transplantation. If recipient-derived SMCs do indeed contribute 
to neointima formation, these cells or their ancestral progenitors 
should be demonstrably present in the circulation. Indeed, circulating 
smooth muscle precursor cells (SMPCs) were identified (11, 12). Deeper 
insight into the origin of neointimal cells may lead to the development 
of new therapeutic approaches that may, for example, target the 
engraftment and function of recipient-derived cells in graft arteries or 
the recruitment, migration and function of donor-derived cells to the 
arterial intimal space.
Since the scarce literature available concerning the origin of 
neointimal SMCs after renal transplantation in human CTD did not 
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reach a consensus (9, 10), the aim of this study was to revisit the origin 
of neointimal cells after renal transplantation. We used nephrectomy 
samples from sex-mismatched renal allograft recipients. As opposed to 
biopsies used previously (9), nephrectomy samples have the advantage 
of containing larger arteries with prominent neointima formation. 
As previous studies demonstrated the plasticity of circulating 
precursors to differentiate into endothelial and epithelial lineages as 
well (13-15), we also determined the contribution of recipient-derived 
cells to endothelial and epithelial regeneration in CTD.
 Chimerism was determined using fluorescent in situ hybridization 
(FISH) for X- and Y-chromosomes, combined with immunofluorescent 
staining on grafts transplanted in a sex-mismatched combination.
MATERIALS & METHODS
Patients
To distinguish between recipient- and donor-derived cells sex-
mismatched nephrectomy samples (n=4) of female kidney grafts 
transplanted into male recipients were investigated (for patient 
characteristics see Table 1). From 1998 until 2007, 31 nephrectomies 
were performed within the University Medical Center Groningen. Of these 
patients, 9 male patients received a female allograft. Four out of these 
nine patients had developed TV and were included in the study for origin 
investigations. As positive and negative controls for fluorescent in situ 
hybridisation (FISH), two male grafts transplanted into male recipients 
and one female graft transplanted into a female recipient were used, 
respectively. All patients had returned to dialysis before nephrectomy. 
Although the immune suppression regimen was tapered after return 
to dialysis in all patients, it was never completely discontinued. None 
of the patients was re-transplanted before nephrectomy. Reasons for 
nephrectomy were chronic renal allograft dysfunction (CTD)/ongoing 
rejection, n= 5, Surgical/infectious complications, n=1 and primary 
non-function/rejection, n=1. All procedures and use of tissue were 
performed according to national ethical guidelines.
Nephrectomy samples
Formalin-fixed, paraffin-embedded renal nephrectomy specimens 
were cut into 1.5 µm sections. A hematoxylin and eosin staining was 
used for morphologic characterization and evaluated by a pathologist 
(MvdH) (2). Classification according to the Banff scheme categorized all 
nephrectomy samples (including controls) as grade IIB, except patient 
4. The nephrectomy sample of patients 4 was categorized as grade III. 
Besides providing sufficient material, nephrectomy samples also 
give the opportunity to investigate neointima formation in larger 
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arteries (Figure 1A), as opposed to biopsy samples which often contain 
few and small arteries. On average, 10 (range 7 – 14) arteries were 
investigated per nephrectomy sample. The degree of obliteration in 
arteries was measured in all patients. Arteries were identified based 
on the presence of an internal elastic lamina using Verhoeff-van Gieson 
stained sections. The total area lying at the luminal side of the IEL, 
including the lumen, was measured and set at 100%. Subsequently, 
the luminal area was subtracted from this total area, to obtain the 
neointimal area. The percentage of the neointimal area from the 
total area was used as a measure for luminal obliteration.  Luminal 
obliteration was expressed as mean percentage ± SD of all arteries 
measured within one patient. Arteries cut diagonally, i.e. compressed 
lumen, were excluded from this measurement.



















1 M  (24) F (24) Anti-GBM GN 72 months 82 months 14 82 ± 17
2 M  (47) F (41) Diabetic Nephropathy 17 months 51 months 12 87 ± 13
3 M  (51) F (43) Hydronephrosis 9 months 10 months 11 58 ± 16
4 M  (65) F (66) Chronic GN Never stopped 3 months 7 89 ± 10
5a M  (57) M (37) Diabetic Nephropathy 5.8 months 6 months 7 91 ± 18
6a M  (47) M (24) IgA-Nephropathy 131 months 150 months 7 92 ± 7
7a F  (52) F  (51) IgA-Nephropathy 48 months 72 months 9 86 ± 5
1Age at time of transplantation. 2Time after transplantation. 3Luminal obliteration of arteries is depicted as a mean 
percentage of different arteries. aFISH controls. Abbreviations: M = Male. F = Female, Tx = Transplantation, GN 
= Glomerulonephritis. 
Fluorescent in Situ Hybridization (FISH)
FISH probes (Kreatech Diagnostics, Amsterdam) were directed 
against repetitive sequences in the centromere of the X chromosome 
(DXZ1) or Y chromosome (DYZ3). The probe directed against DXZ1 
was directly conjugated with PlatinumBright495 (green) and the probe 
directed against DYZ3 was conjugated with PlatinumBright550 (red). 
FISH was performed according to the manufacturer’s instructions, with 
some modifications. After deparaffinization, sections were incubated 
in 0.2M hydrochloric acid (HCL), for 20 minutes. To make the DNA 
accessible for hybridization, sections were incubated in 8% sodium 
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thiocyanate (NaSCN, 80˚C, 30 minutes) followed by 0.025% pepsin in 
0.2M HCL (37˚C, 20 minutes). To reduce autofluorescence, sections 
were incubated in 100mM copper sulfate (CuSO4, 37˚C, 60 minutes) 
followed by 0.2% sodium borohydride (NaBH4, RT, 10 minutes). Probes 
were applied on dehydrated sections and simultaneously denatured 
(80˚C, 10 minutes). Hybridization was performed overnight, in a 
humidified chamber at 37˚C. Sections were then rinsed in 0.4 X Saline-
Sodium Citrate (SSC)/0.3 % Nonidet P-40 (NP-40) (72˚C, 2 minutes) 
followed by 2X SSC/0.1% NP-40 (RT, 1 minute) to remove excess 
unbound probe.
Immunohistochemistry
Immediately after FISH, immunofluorescent stainings were 
performed for either α-SMA to detect smooth muscle cells (SMCs) 
(mouse IgG2a, clone 1A4), CD45 to detect inflammatory cells (mouse 
IgG1, clone 2B11 + PD7/26), or von Willebrand factor to detect 
endothelial cells (ECs) (vWF, rabbit polyclonal, all from DAKO, Heverlee, 
Belgium). Sections were first fixed with 2% paraformaldehyde (PFA) 
(10 minutes). Endogenous biotin was blocked using an avidin/biotin 
blocking kit (DAKO). Sections were blocked with 10% rabbit serum 
and subsequently incubated with the primary antibody (60 minutes) 
followed by a biotinylated rabbit-anti-mouse conjugate (DAKO) for 
the detection of α-SMA and CD45 (30 minutes) or donkey-anti-rabbit 
fragment (ab’)2-Cyanin5 (Cy5) (Jackson Immunoresearch, Soham, UK) 
for the detection of von Willebrand factor. Detection of biotinylated 
antibody complex was done by incubation with a streptavidin-Cy5 
conjugate (Zymed Laboratories inc., CA, USA) diluted in phosphate 
buffer containing 4’,6-diamidino-2-phenylindole (DAPI; Sigma, 20 
minutes). Sections were mounted in Citifluor (Agar scientific, Stansted, 
United Kingdom).
For α-SMA / CD45 / vWF triple stainings without FISH, sections 
were blocked with 10% goat serum followed by incubation with 
primary antibodies diluted in phosphate buffer containing DAPI (60 
minutes). Isotype-specific goat-anti-mouse conjugates (Southern 
Biotechnology, Birmingham, USA) or a donkey-anti-rabbit conjugate 
(Jackson Immunoresearch) were used for detection of bound primary 
antibodies (α-mouse IgG1-fluorescein isothiocyanate for CD45, 
α-mouse IgG2a-rhodamine for α-SMA and α-rabbit fragment (ab’)2-
Cy5 for the detection of von Willebrand factor).
Fluorescence microscopy was performed using a Leica DMLB 
microscope (Leica Microsystems, Rijswijk, the Netherlands) equipped 
with a Leica DC300F camera and Leica QWin 2.8 software. To confirm 
presence of FISH signals inside the nucleus confocal laser scanning 
microscopy (LEICA TCS SP2) was performed. Ten consecutive optical 
sections were scanned at the excitation wavelengths of 488 nm 

























Figure 1. Transplant vasculopathy (TV) in renal nephrectomy samples. Arteries 
displaying TV were identified in HE-stained paraffin sections of renal nephrectomy 
samples (A). The presence of a neointima (NI), and of characteristic morphologic 
features of an artery, i.e. the internal elastic lamina (IEL) and media (M) are indicated 
by arrows. A Verhoeff-van Gieson staining was used to demonstrate ECM deposition by 
neointimal cells (C). The cellular composition of the NI is shown by immunofluorescent 
staining (B&D). Smooth muscle cells (SMC) in the NI were identified by staining 
for α-SMA (red) and endothelial cells by staining for von Willebrand factor (white). 
Inflammatory cells were detected by staining for CD45 (green). Nuclei were identified 
by DAPI staining (blue). Elastic laminae and deposited extracellular matrix are visible 
due to their autofluorescence (green). Arterial components are indicated by arrows, as 
in (A). Tubuli were identified by morphology and inflammatory cells were detected by 
staining for CD45 (green) (E). Original lens magnifications: A,B 20x, C,D 40x. 
Chapter 2
36
(FITC) and 543 nm (TRITC), generating a sequential Z-series of 10 
optical sections. Computerized stacking of these 10 optical sections 
generated a three-dimensional image of cells of interest (Leica confocal 
2.5 software), revealing the presence of two FISH signals within one 
nucleus.
Quantification of neointimal, endothelial and tubular chimerism
Nephrectomy samples of female grafts transplanted into male 
recipients were used to study the origin of cells contributing to kidney 
remodeling after transplantation. In these samples donor-derived 
cells contain two X-chromosomes, while recipient-derived cells contain 
one X- and one Y-chromosome. For chimerism investigations all cells 
containing a Y-chromosome (with or without an X chromosome) were 
included.
Arteries with a clear visible internal elastic lamina were selected 
for counting neointimal Y-chromosome positive cells in sections where 
FISH was combined with staining for α-SMA. Photomicrographs of these 
arteries were taken using a 40x objective. Arteries with a diameter 
smaller than 150 μm were excluded. In the case of large arteries, 
several photomicropgraphs were taken in order to cover the entire 
arterial area. These photomicrographs were electronically assembled 
using Hugin software (http://hugin.sourceforge.net/), to obtain an 
overview of the entire artery. In this process, duplicate photographic 
areas are overlaid, thus ensuring that no cells are counted twice. Using 
these assembled photographs Y-chromosome-positive and α-SMA-
positive cells were counted using Adobe Photoshop software, which 
has a module for keeping track of counted events. First, all α-SMA-
positive cells between the lumen and internal elastic lamina were 
counted. Subsequently all Y+/α-SMA double-positive cells within this 
area were counted. In sporadic cases where a duplication of the elastic 
lamina was observed, recipient-derived cells were never quantified in 
the tissue between the laminae. The percentage of Y+/α-SMA double-
positive cells of the α-SMA-positive cell population was calculated. To 
determine inter-observer variations, multiple arteries were sampled at 
random and recounted by an independent investigator. Percentages 
of recipient-derived α-SMA positive cells of all recounted arteries were 
within the 95% confidence interval, compared to the initial percentages. 
To quantify the number of recipient-derived endothelial cells, FISH was 
combined with a staining for vWF. Recipient-derived (Y-chromosome-
positive) cells co-expressing vWF were quantified and expressed as a 
percentage of the total endothelial (vWF+) cell population, respectively. 
To quantify the number of recipient-derived tubular epithelial cells, 
FISH was combined with a staining for CD45 to exclude inflammatory 
cells. Tubuli and tubular cells were identified based on morphology 
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and localization. Y+/CD45- cells were counted and expressed as a 
percentage of the total number of CD45- tubular cells. 
D


































Figure 2. Specificity of FISH. X (green) and Y (red) chromosome signals are present 
inside the nucleus (blue), Z-plane underneath shows true nuclear localization. This 
demonstrates the presence of sex chromosome inside the nucleus. (A). As a negative 
control for FISH a female graft transplanted into a female recipient was used (B). As 
a positive control, a male transplanted into a male was used (C). Mean (±SD) FISH 




In this study we used nephrectomy samples from 7 patients (4 
female-to-male, 2 male-to-male and 1 female-to-female, Table 1) with 
CTD after renal transplantation. The degree of luminal obliteration 
varied to some extent between arteries within one nephrectomy 
sample (Table 1). Mean luminal obliteration in the 67 arteries analyzed 
in seven nephrectomy samples was 83% ± 17 (mean ± SD). The 
neointima consisted of deposited extracellular matrix (Figure 1C) and 
of α-smooth muscle actin-positive (α-SMA+) cells, intermingled with 
inflammatory CD45+ cells (Figure 1B & D). Cells co-expressing α-SMA 
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and CD45 were never found (Figure 1D). Tubuli were identified by 
morphology. To distinguish between tubular and inflammatory cells 
within tubuli, staining with CD45 was performed (Figure 1E).
FISH efficiency
A punctuate FISH signal was considered a genuine sex chromosome 
if it was located within the nucleus. The location of FISH signals was 
examined by confocal microscopy (Figure 2A). Z-planes were made 
(Figure 2A) and FISH signals were detected within the DAPI signal, 
confirming their presence inside the nucleus.
To determine the efficiency of FISH, the technique was first 
performed on control nephrectomy samples (i.e. male-to-male and 
female-to-female transplants). As an internal control for FISH, a probe 
directed against the X-chromosomes was included, as all nucleated 
cells at least contain one X chromosome. No Y-chromosomes were 
detected in sections of female grafts transplanted into female recipients 
(Figure 2B). The Y-chromosome was clearly visible (with or without an 
identifiable X-chromosome) in 31% (XY=11% ± 4, Y=20% ± 2, mean ± 
SD) of in total 7076 nuclei analyzed in the two male-to-male transplants 
(Figure 2C and D). In 17% ± 1 of the nuclei only the X-chromosome 
was detected whereas in 52% ± 4% of the nuclei no sex-chromosomes 
were detected (Figure 2D). FISH efficiency was similar on serial sections 
of one sample and between the two control samples, demonstrating 
equal detection sensitivity for sex chromosomes within and between 
nephrectomy specimens (not shown).










Mean % (range %) Mean % (range %) Mean % (range %) Mean % (range %)
1 6 (0 – 22) 32 (7 – 60) 31 (0 – 64) 3 (0 – 25)
2 4 (0 - 11) 6 (0 – 24) ND ND 3 (0 – 25)
3 3 (2 – 7) 4 (0 – 11) 7 (0 – 22) 2 (0 – 33)
4 11 (3 – 16) ND ND ND ND 5 (0 – 33)
Abbreviations: ND = Not Determined; SMA = smooth muscle actin; vWF = von Willebrand Factor
Origin of neointimal cells
To discriminate between SMCs and infiltrating, recipient-derived, 
inflammatory cells in the neointima, FISH was combined with an α-SMA 
staining. A neointimal cell was considered a SMC if the nucleus was 
directly surrounded by cytoplasmic α-SMA staining, and was considered 
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recipient-derived if a clear Y-chromosome was visible located within 
the nucleus (Figure 3A). In total, 2906 neointimal α-SMA+ SMCs were 
investigated for chimerism. A mean of 6% (range 3 - 11% between 
patients) of the neointimal α-SMA+/CD45- cells were recipient-derived 
(Table 2). Percentages of chimerism varied between arteries within 
one nephrectomy sample (Table 2). No correlation between artery size 






Figure 3. Recipient-derived 
cells in sex-mismatched renal 
nephrectomy samples. FISH 
was performed on female kidneys 
transplanted into male recipients and 
combined with immunofluorescence 
stainings to investigate recipient-
derived neointimal, endothelial 
and tubular cells (A-D). The origin 
of neointimal cells was examined 
by combining FISH with an α-SMA 
staining (stained white, insert) 
(A). The internal elastic lamina 
(IEL) is indicated with an arrow. 
Endothelial chimerism in arteries 
was investigated with a FISH / 
vWF doublestaining (stained white, 
insert) (B). Endothelial chimerism 
in glomeruli was also investigated 
with a FISH / vWF doublestaining 
(stained white, insert) (C). Tubular 
chimerism was investigated with 
a FISH / CD45 doublestaining to 
exclude inflammatory cells (stained 




Endothelial and tubular chimerism
To investigate EC chimerism, FISH was combined with a vWF 
staining. An EC was considered to be recipient-derived if a punctuate 
Y-chromosome was detected inside the nucleus of a cell that was 
surrounded by cytoplasmic staining for vWF (Figure 3B and C). In 
total, 1404 arterial ECs were investigated for chimerism. A mean of 
14% (range 4-32% between patients) of neointimal ECs were recipient-
derived (Y-chromosome positive) (Table 2). Endothelial chimerism 
could not be investigated in patient 4 since vWF was present in the 
extracellular space, rather than intracellularly. Endothelial cells in 
patient 4 were negative for CD31 and α-SMA (data not shown). In 
total, 660 glomerular ECs were investigated for chimerism. A mean 
of 19% (range 7 - 31% between patients) of glomerular ECs were 
recipient-derived (Y-chromosome positive) (Table 2). Again glomerular 
endothelial chimerism could not be investigated in patients 2 and 4 
due to atypical expression of vWF.
Tubules and tubular epithelial cells were identified based on 
morphology. Furthermore, FISH was combined with CD45 staining 
in order to exclude infiltrating recipient-derived inflammatory cells 
(Figure 3D). In total, 1532 CD45- tubular cells were investigated for 
chimerism. A mean of 3% (range 2 - 5% between patients) of CD45- 
tubular cells were recipient-derived (Y+) (Table 2). 
DISCUSSION
In this study, we report neointimal smooth muscle-, endothelial- 
and tubular epithelial recipient chimerism in nephrectomy samples of 
renal allografts with CTD. We show that chimerism is consistent within 
these different compartments and also between the different patients 
studied.
Information on the origin (donor vs. recipient) of neointimal cells 
may contribute to the development of new therapies to treat or prevent 
TV. The possible contribution of recipient-derived cells to neointima 
formation has received particular attention, since these cells may form 
an easily accessible therapeutic target. However, this contribution 
is still under debate, since currently only two contrasting studies 
regarding the origin of neointimal cells in human renal allografts are 
reported (9, 10). While Grimm et al. reported that approximately a 
third of neointimal cells were of recipient origin (9), Bittmann et al. 
exclusively detected donor-derived neointimal cells (10). The cause 
of these diverging results is difficult to pinpoint and is likely due to 
technical aspects inherent to the complex FISH assay. In agreement 
with the study of Grimm, our current study confirms the presence of 
recipient-derived neointimal cells, albeit at a lower frequency (~6%). 
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Nevertheless, both our study and the study of Grimm et al. probably 
underscore the percentage of recipient-derived neointimal cells, since 
the efficiency of FISH is never 100% (~38% in 4 µm sections in the 
study of Grimm et al., ~31% in 1,5 µm sections in our study). As a 
result, the actual percentage of recipient-derived cells is expected to 
be higher in both studies.
We have previously performed studies on the origin of neointimal 
SMCs in experimental transplant models (aorta and heart) in which 
severe TV develops after allografting (16, 17). In these models, virtually 
all neointimal SMCs were found to be of recipient origin. However, 
in a rat transplant model for long-term renal allograft dysfunction, 
we found that all neointimal SMCs were of donor origin (18). These 
studies suggest that the development of TV with regard to the origin of 
contributing cells is organ-dependent, but also varies between species. 
Since TV can develop to some extent in the absence of alloimmune 
responses (19) most likely any form of vascular injury can initiate, 
or enhance the development of TV. In this respect, the degree of 
injury should be taken into account, since the frequency of recipient-
derived neointimal cells may vary with the severity of vascular injury 
(20, 21). In our present study, it is conceivable that some degree of 
injury may have occurred due to tapering of the immune suppressive 
regimen after graft failure, and thus may have facilitated neointimal 
engraftment of recipient-derived SMCs. However, we previously found 
similar percentages of chimerism in biopsy samples (unpublished 
observations), indicating that recipient cell engraftment precedes graft 
failure.
The most likely source for recipient-derived neointimal cells is the 
pool of recipient peripheral blood mononuclear cells, as corroborated 
by studies that provide evidence for a SMPC subset residing within the 
myeloid lineage (12, 22). The role of recipient-derived neointimal cells 
is unclear. Although their number in the present study is relatively 
limited, these cells may have a constructive role in neointimal formation, 
as suggested by their expression of α-SMA. However, a regulatory role 
for recipient-derived cells cannot be excluded.
A conventionally accepted source of donor neointimal SMCs is the 
arterial media, from which SMCs migrate across the internal elastic 
lamina in response to mechanical arterial injury (the so-called the 
response-to-injury paradigm) (23). Another possible source for donor 
neointimal cells are migrating adventitial myofibroblasts. During the 
response to vascular injury and inflammation, adventitial fibroblasts 
can be reprogrammed to differentiate into myofibroblasts (24). 
These myofibroblasts can be attracted to the subendothelial space 
by chemokines secreted by SMPCs or activated ECs. An alternative 
source for donor-derived neointimal cells may be ECs by a mechanism 
termed endothelial-to-mesenchymal transition (25). In three separate 
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animal models for kidney fibrosis, ECs were shown to differentiate into 
α-SMA positive cells, thereby contributing to interstitial fibrosis (26). 
Whether this mechanism is also applicable to the development of TV 
is not known.
Next to neointimal chimerism, we addressed arterial and glomerular 
endothelial chimerism and tubular chimerism, as well, in order to 
gain insight into the plasticity of recipient-derived cells. Conflicting 
evidence exists on the replacement of donor ECs by recipient-derived 
ECs (10, 14, 27). Most studies find, to a certain extent, replacement 
of donor ECs with recipient-derived cells. Since Asahara et al. (28) 
described circulating EPCs, more research has focused on these cells 
and their therapeutic potential (29). These EPCs are mobilized from 
the bone marrow into the circulation and home to sites of injury (30). 
It is suggested that replacement of donor- by recipient-derived ECs 
may be important for transplantation tolerance in long-term allograft 
survivors (31), a concept that was however challenged by a study from 
Lagaaij et al. who found a positive correlation between the extent of 
EC chimerism and graft rejection (14). Their data indicate that severe 
vascular injury might trigger repopulation of severely injured graft 
endothelium by recipient-derived ECs.
In the present study we found a minor contribution of recipient-
derived cells to tubular regeneration in nephrectomy samples after 
renal transplantation, confirming other studies performed in human 
biopsies (9, 10, 13, 15, 32, 33). Because of the few studies that are 
able to correlate chimerism with graft outcome and acknowledging the 
capacity of renal tubular cells to regenerate the tubules (34), it is more 
likely that engraftment of recipient-derived tubular cells also depends 
on the severity of renal tubular damage after transplantation (8).
We showed that both donor- and recipient-derived cells contribute 
to vascular remodeling and tubular repair after human renal 
transplantation. The presence of α-SMA in donor- as well as recipient-
derived cells supports a constructive role in neointimal formation. 
Since donor-derived SMCs predominated in the neointima, we propose 
that they form an important therapeutic target.
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MUSCLE CELL OUTGROWTH POTENTIAL 







In chronic transplant dysfunction (CTD), persistent inflammation is a 
consequence of the alloresponse to the transplanted kidney eventually 
leading to tissue remodeling. The development of a neointima or 
transplant vasculopathy (TV) is one of the structural characteristics 
of CTD. We previously showed that recipient-derived α-SMA+ cells are 
present in the neointima of human renal allografts with CTD. Although 
peripheral blood mononuclear cells (PBMC) contain cells capable 
of differentiating into α-SMA+ cells in vitro, the phenotype of these 
circulating smooth muscle precursors cells is unclear.
Methods & Results
We hypothesized that recipient-derived α-SMA+ in human renal CTD 
are derived from a specific monocyte subset. We therefore tested the 
association between the frequency of circulating monocyte subsets and 
the presence of renal CTD. To this end, we investigated the potential 
of PBMC from healthy individuals and renal transplant recipients with 
and without CTD to differentiate into α-SMA expressing cells in vitro. 
Outgrowth of α-SMA+ cells was reduced in renal transplant recipients 
(p<0.001 vs. healthy controls) with no difference between non-CTD 
and CTD patients. Since monocytes are the putative source of these 
α-SMA+ cells, healthy control monocyte subsets were sorted based 
on their CD14 and CD16 expression. Expression of α-SMA and SM22α 
was subsequently determined in these sorted subsets. CD14+/CD16++ 
monocytes displayed increased (p < 0.05) α-SMA and SM22α mRNA 
expression compared with CD14++/CD16- monocytes, suggesting that 
CD14+/CD16++ monocytes have increased differentiation potential 
towards smooth muscle-like cells. Compared with non-CTD, renal 
transplant recipients with CTD had reduced circulating CD14+/CD16++ 
cells (p < 0.05) which may reflect an increased recruitment of these 
cells to the kidney. Circulating CD14+/CD16++ monocyte frequency 
correlated with α-SMA+ cell outgrowth potential of PBMC (r=0.62, 
p=0.0002). 
Conclusions
We conclude that CD14+/CD16++ monocytes may have SMC-like 
outgrowth potential and thereby may contribute to the development of 
TV after renal transplantation.




Chronic renal transplant dysfunction (CTD), characterized by a 
gradual decline in kidney function, is histologically characterized by 
glomerulopathy, interstitial fibrosis and tubular atrophy (IF/TA), and 
transplant vasculopathy (TV) (1-3). TV is defined by the development 
of an occluding hyperplastic neointima, which consists of proliferating 
smooth muscle cells (SMCs) between the endothelial cells and the 
internal elastic lamina. Multiple underlying factors contribute to the 
development of TV, including ischemic injury during transplantation, the 
alloresponse to the transplanted kidney as well as non-allo factors such 
as elevated blood pressure and proteinuria. The development of TV is 
the result of ischemic injury during transplantation and the alloresponse 
to the transplanted kidney. SMCs in the neointima secrete ECM and 
cause luminal narrowing of the artery. This will lead to stiffening of the 
arteries and a reduced blood flow through the downstream tissues. We 
have previously shown that recipient-derived α-SMA+ cells are present 
in the neointima in human renal transplantectomy samples with CTD 
(4). These α-SMA+ cells can participate in the progression of fibrotic 
processes. A subset of peripheral blood mononuclear cells (PBMC) 
can differentiate into α-SMA+ cells in vitro, although the phenotype of 
circulating precursors of these cells is still unclear.
It is likely that recipient-derived, α-SMA+ intimal cells originate from 
PBMC which start to express α-SMA after migration into the injured 
artery, where they contribute TV. Previous in vitro studies already 
showed that within the mononuclear cell pool a cell population resides 
which has the ability to differentiate into α-SMA-expressing smooth 
muscle-like cells (5,6). Based on their retained expression of CD68 
and CD14, these cells are most likely of myeloid origin (7). Therefore, 
we postulate that a circulating precursor for smooth-muscle-like cells 
is present within the monocyte pool. Identification of the monocyte 
subset which contributes to fibrosis after renal transplantation can 
aid the development of new therapeutic strategies to attenuate the 
development of CTD, in particular TV.
In humans, peripheral monocytes represent a heterogeneous cell 
population which can be divided into different subsets based on the 
expression of the lipopolysaccharide receptor CD14 and co-expression 
of the FcγIII receptor CD16. The majority (~85%) of monocytes 
express high levels of CD14 without CD16 co-expression (i.e. CD14++/
CD16− classical monocytes). In addition, a minor monocyte subset 
(~10%) expresses lower levels of CD14 but high levels of CD16 (i.e. 
CD14+/CD16++ non-classical monocytes) (8). Transcriptional profiling 
of CD16 positive and CD16 negative circulating monocytes confirmed 
that these monocyte populations originate from a common myeloid 
precursor (9). However, a number of genes are differentially expressed 
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in these cells, which suggests different biological functions in vivo (9). 
Compared to the major subset of CD14++/CD16− classical monocytes, 
the non-classical CD14+/CD16++ have lower phagocytic activity and 
produce higher levels of TNF-α and IL-1ß (10,11). In addition to the 
classical and non-classical monocytes, a small population (~5%) of 
CD14++/CD16+ intermediate monocytes can be identified in the human 
peripheral blood (12,13). Classical, intermediate and non-classical 
monocytes exhibit different features and present different biologic 
properties in vivo (14). As yet it is unknown whether these various 
monocyte subsets also differ in expression of mesenchymal markers 
which would favor for the enrichment of circulating smooth muscle 
precursor cells within (one of) these monocyte subpopulations. 
We hypothesize that recipient-derived α-SMA+ neointimal smooth 
muscle cells in human renal CTD are derived from a specific monocyte 
subset. We therefore tested the association between the frequency 
of monocyte subsets and PBMC α-SMA+ cell outgrowth potential in 




In this cross-sectional study, 13 renal transplant patients with CTD 
were recruited from the renal transplantation outpatient clinic of the 
University Medical Center Groningen. Relevant transplant characteristics 
such as age, gender, and date of transplantation were extracted from 
the Groningen Renal Transplant Database, which contains information 
on all renal transplantations performed at our center since 1968 (15). 
Current medication was taken from the medical record.  Inclusion 
criteria for CTD were urine protein excretion of >1.0 gram/24 hrs, 
accompanied by increasing plasma creatinine concentrations. as 
measured during the previous visit to the outpatient clinic. For 
comparison, matched renal transplant recipients without CTD (i.e. 
protein excretion <1.0 gram/24 hrs; n=14) were recruited. Matching 
was performed based on age, gender and time since transplantation. 
Healthy subjects (n=12) which were matched for age and gender 
where used as controls. Study participant characteristics are shown in 
Table 1. Patients maintained their regular medication. No differences 
were present with regard to the immunosuppressive regimen between 
renal transplant recipients with or without CTD (Table 2). The number 
of WBCs/ml blood was determined using a Coulter Counter (Beckman 
Coulter, Mijdrecht, the Netherlands). Plasma glucose and creatinine 
were determined by standard diagnostic techniques. All participants 
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provided informed consent, and the study was conducted according to 
the principles of the Declaration of Helsinki.
Table 1. Characteristics of healthy controls and renal transplant recipients with 








Age, years(mean ± SD) 45.3 ± 17.6 42.2 ± 17.2 0.731
Female (%) 9 (69) 3 (25) 0.027
Transplant characteristics
Cold ischemia time (h) 12 ± 10 14 ± 11 0.710
1e warm ischemia time (min) 5 ± 9 4 ± 7 0.701
2e warm ischemia time (min) 39 ± 10 36 ± 9 0.361
No. of HLA mismatches 3 ± 1 2 ± 1 0.777
Characteristics of subjects 
Age, years(mean ± SD) 43.6 ± 11.4 50.1 ± 11.4 46.5 ± 13.0 0.400
Female (%) 4 (33) 4 (29) 4 (31) 0.966
Time since TX, years 
(mean ± SD) 6.1 ± 4.6 7.1 ± 7.1 0.686
Creatinine (µmol/l) 141 ± 35 199 ± 92 0.043
Urea (mmol/l) 10.2 ± 3.2 16.9 ± 9.3 0.023
Proteinuria (gr/24 hours) 0.3 ± 0.4 2.5 ± 2.5 0.009
Mean blood pressure 
(mmHg) (mean ± SD)
112 ± 10 112 ± 14 0.960
Culture of PBMC for outgrowth of smooth muscle precursor 
cells
Chamberslides (Sanbio B.V., Uden, the Netherlands) were coated 
with fibronectin (1 μg/cm2; Harbor Bio-Products, Norwood, MA) for 1 h 
at 37°C in a humidified incubator with 5% CO2. PBMCs were cultured 
on these precoated chamberslides in low glucose DMEM (Lonza 
Benelux BV, Breda, the Netherlands) supplemented with 20% FCS 
(BioWhittaker, Verviers, Belgium), 2 mM L-glutamine, 1% penicillin/
streptomycin (both Sigma, St. Louis, MO), at a density of 6000 cells/
mm2. After 3 days of culture, medium was replenished and TGF-β1 
(10 ng/ml, Preprotech, Rocky Hill, NJ, USA) was added. Hereafter, 
medium was refreshed every 3 days with medium containing TGF-β1. 
After 14 days cells were gently washed with PBS and fixed with 2% 
paraformaldehyde for 20 minutes at room temperature.
Immunofluorescent staining
After 14 days of culture, PBMC were stained for α-SMA in 
chamberslides. Slides were first incubated for 1 h with mouse-anti-
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human α-SMA (IgG2a, clone 1A4, DAKO, Heverlee, Belgium) followed 
by a biotinylated rabbit-anti-mouse Ig secondary antibody. Binding of 
the biotinylated antibody complex was visualized by incubation with 
streptavidin-alexa 555 (Life Technologies Europe BV, Bleiswijk, The 
Netherlands) diluted in PBS containing 4’,6-diamidino-2-phenylindole 
(DAPI; Sigma-Aldrich Chemie B.V., Zwijndrecht, the Netherlands, for 
30 min). Slides were mounted in Citifluor (Agar scientific, Stansted, 
United Kingdom).
Examination of α-SMA staining was performed using a Leica DMRXA 
microscope and Leica software (Leica Microsystems). Quantification of 
adherent cells (using DAPI) and α-SMA expression was performed by 
TissueFAXS analysis using a Zeiss AxioObserver.Z1 microscope and 
TissueQuest cell analysis software (TissueGnostics, TissueGnostics 
GmbH, Vienna, Austria).
Flow cytometry of monocyte subsets
PBMC were isolated from 10 ml anticoagulated (EDTA) venous blood 
by density-gradient centrifugation on Lymphoprep gradient (Axis-
Shield, Oslo, Norway), as previously described (16). PBMC (1×106) were 
incubated with FITC-conjugated anti-CD14 (IQ Products, Groningen, 
The Netherlands) and APC-conjugated anti-CD16 (Miltenyi Biotec, 
Utrecht, The Netherlands) monoclonal antibodies. Data were acquired 
on a FACSCalibur and analyzed using CellQuest software (both from 
Becton and Dickinson, San Jose, CA, USA).
Isolation of CD14++/CD16- and CD14+/CD16++ monocyte subsets
To sort monocyte subsets, PBMC were isolated from anticoagulated 
(EDTA) venous blood from 7 healthy controls as described above. 
Monocyte subsets were isolated from healthy control subjects as in 
our study it was not possible to sort sufficient cell numbers from renal 
transplant recipients. All isolated PBMC were incubated with FITC-
conjugated anti-CD14 and APC-conjugated anti-CD16 after which 
CD14++/CD16- and CD14+/CD16++ monocyte subpopulations were 
sorted using a MoFlo high speed cell sorter (DakoCytomation, CA, 
USA). Sorted monocyte subsets were than further processed for gene 
expression analysis.
RNA isolation and quantitative PCR
For gene expression analysis of sorted monocyte subsets, total 
RNA was isolated using the RNeasy Micro Kit (Qiagen Inc., CA, USA). 
Subsequently, 200 ng of total RNA was reverse transcribed using the 
FirstStrand cDNA synthesis kit (Fermentas UAB, Lithuania). Quantitative 
RT-PCR analysis was performed in a final reaction volume of 10 μl, 
consisting of 4.5 μl SYBR Green Supermix (Bio-Rad, Veenendaal, The 
Netherlands), 0.5 μl primer-mix (0.5 mm/l), and 5μl cDNA (2 ng/μl) 
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using the ViiA™ 7 Real-Time PCR System (Applied Biosystems, the 
Netherlands). Gene expression of GAPDH, α-SMA and SM22α was 
assessed using the following primer sets; 
GAPDH  sense 5’-CTGCCGTCTAGAAAAACCTG-3’; 
   antisense 5’-GTCCAGGGGTCTTACTCCTT-3’ 
α-SMA  sense 5’-CTGTTCCAGCCATCCTTCAT-3’ 
   antisense 5’-TCATGATGCTGTTGTAGGTGGT-3’ 
SM22α  sense 5’-GGCCAAGGCTCTACTGTCTG-3’
   antisense 5’-CCCTTGTTGGCCATGTCT-3’
Reactions were performed at 95°C for 15s, 60°C for 30s, and 72°C 
for 30s, for 40 cycles. Relative mRNA levels were calculated as 2−
ΔCT, in which ΔCT is CTgene of interest – CTGAPDH. Relative mRNA level of 
CD14+CD16++ was subsequently related to mRNA level of CD14++CD16- 
for either α-SMA or SM22α.







Cyclosporin 5 4 0.785
Tacrolimus 3 6 0.173
No calcineurin inhibitor 6 4 0.516
Azathioprine 1 2 0.496
MMF 7 6 0.842
Prednisolon 14 13
mTOR inhibitor 3 0 0.077
Other medication
Calcium channel blocker 6 2 0.118
Beta blocker 8 6 0.568
Diuretics 6 9 0.168
ACE inhibitor 8 6 0.568
Angiotensin receptor blocker 0 2 0.127
Statins 6 7 0.568
Statistics
Data are expressed as mean ± standard error of the mean (SEM). 
Statistic outliers detected by SPSS were excluded from analyses. In 
healthy controls, differences in gene expression levels of mesenchymal 
markers between monocyte subsets were analyzed using a paired 
t-test. Differences between healthy controls and renal transplant 
recipients without and with CTD were analyzed using a one-way 
ANOVA with Tukey’s posthoc test or a chi-square test for categorical 
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variables. p < 0.05 was considered statistically significant. Statistical 
analyses were performed using SPSS (version 16.0.2; IBM Nederland 

























































































Figure 1. Number of WBC and culture of PBMC from healthy controls and 
renal transplant recipients. (A) Number of WBC/ml blood in healthy controls and 
renal transplant recipients without and with CTD. (B) Photomicrographs of PBMC from 
healthy controls and renal transplant recipients without and with CTD after 14 days 
of culture. Nuclei are stained with DAPI (white). Graphs show the quantification of 
the total number of nuclei, which corresponds to the number of cells, present after 
14 days of PBMC culture. (C) Photomicrographs of PBMC culture of healthy controls 
and renal transplant recipients without and with CTD after 7 and 14 days of culture. 
(D) Photomicrographs of α-SMA staining (red) after 14 days of PBMC culture from 
healthy controls and renal transplant recipients without and with CTD. Graphs show 
the quantification of the number of α-SMA positive cells/mm2 after 14 days of PBMC 
culture Data are presented as mean ± SEM. * p<0.05, *** p<0.001. Original lens 
magnifications: 20x. Abbreviations: WBC, white blood cell; PBMC, peripheral blood 
mononuclear cell; CTD, chronic transplant dysfunction.




Culture of PBMC in the presence of TGF-β1 stimulates out-
growth of α-SMA+ cells
Patients with CTD had higher serum creatinine and blood urea levels 
as well as proteinuria compared with non-CTD patients (Table 1). 
Next, we determined whether the number of white blood cells (WBC) 
differs among renal transplant recipients (with or without CTD) and 
healthy controls. Figure 1A shows that despite the immunosuppressive 
treatment the total WBC count was higher (p < 0.05) in renal transplant 
recipients (with or without CTD) compared with healthy control 
subjects. 
To study the capacity of PBMC to differentiate into α-SMA expressing 
cells, total PBMC were isolated and cultured for 14 days. TGF-β1 was 
added after the first three days. After seeding a fixed number of cells, 
the number of viable PBMC (i.e. number of nuclei) present after 14 
days of culture was lower in renal transplant recipients than in healthy 
controls (p < 0.05, Figure 1B). No difference between renal transplant 
recipients with or without CTD was observed (Figure 1B). At the start of 
culture, most of the adherent cells had a spindle-shaped morphology. 
After 14 days of culturing, the majority of these spindle-shaped cells 
had disappeared and the remaining cells revealed a rounded shape 
as shown in (Figure 1C). Remaining spindle-shaped and round cells 
were α-SMA+ after 14 days of culture (Figure 1D). The numbers of 
α-SMA+ cells cultured from PBMC from renal transplant recipients with 
and without CTD were significantly reduced (p < 0.001) compared to 
healthy controls (3.8- and 5.1-fold reduction, respectively) (Figure 1D). 
No differences in numbers of α-SMA+ cells were observed between 
renal transplant recipients with and without CTD (Figure 1D). 
Monocyte subsets in healthy controls and renal transplant re-
cipients
To study the frequency of CD14++/CD16-, CD14++/CD16+, and CD14+/
CD16++ monocyte subsets in healthy controls and renal transplant 
recipients, PBMC obtained from these groups were analyzed by flow 
cytometry. A representative example of the forward scatter (FSC)/
side scatter (SSC) plot is shown in Figure 2A. Monocytes were gated 
based on their increased FSC/SSC profile (region 2) as opposed to 
lymphocytes (region 3). The number of CD14+ monocytes (expressed 
as percentage CD14+ cells within the live cell gate [region 1, Figure 2A] 
was determined in all three study groups. As shown in Figure 2B, the 
frequency of CD14+ monocytes did not differ between healthy controls 
and renal transplant recipients. To determine the frequency of CD14++/
CD16-, CD14++/CD16+, and CD14+/CD16++ monocyte subsets in renal 






















































































































































Figure 2. Monocyte subset characteristics in renal transplant recipients 
and healthy controls. (A) Representative example of a forward scatter/sideward 
scatter flow cytometry plot. Numbers designate cell populations: 1. total living cells, 
2. monocytes 3. lymphocytes. (B) Frequency of CD14 positive monocytes from total 
living cells in healthy controls and renal transplant recipients without and with CTD. (C) 
Representative example of CD14 and CD16 expression patterns in PBMC. (D) Frequency 
of monocyte subsets in healthy controls and renal transplant recipients. Data are 
presented as mean ± SEM. * p<0.05, *** p<0.001. Abbreviations: PBMC, peripheral 
blood mononuclear cell; CTD, chronic transplant dysfunction.
analyzed by flow cytometry as shown in Figure 2C. Frequencies of 
CD14++/CD16- classical monocytes within the monocyte gate (region 
2, Figure 2A) were comparable between healthy controls and renal 
transplant recipients (Figure 2D, left panel). However, the percentages 
of CD14++/CD16+ intermediate monocytes were significantly reduced 
in transplant recipients with CTD (compared with non-CTD, Figure 2D, 
middle panel). No differences were observed between healthy control 
subjects and transplant recipients without CTD (Figure 2D, middle 
panel). In the CD14+/CD16++ non-classical monocyte subset, the 
reduction of monocytes was even more pronounced (p < 0.001 and p 
< 0.05 vs. healthy controls and non-CTD patients, respectively; Figure 
2D, right panel). Also renal transplant recipients without CTD had lower 
numbers of CD14+/CD16++ monocytes compared with healthy controls 
(p < 0.001, Figure 2D, right panel). 























































































Figure 3. Gene expression of mesenchymal markers in CD16 positive 
monocytes. (A) Representative example of CD14 and CD16 expression patterns in 
PBMC. Numbers designate cell populations used for cell sorting: 1. CD14++/CD16- 
monocytes, 2. CD14+/CD16++ monocytes. (B) Gene expression of α-SMA and SM22α in 
monocyte subsets. CD14 positive monocytes were set to 1. CD14+/CD16++ monocytes in 
healthy controls are depicted as a fold change in gene expression compared to CD14++/
CD16- monocytes. (C) Correlation of the number of α-SMA positive cells/mm2 after 14 
days of culturing of PBMC, with the frequency of CD14+/CD16++ monocytes in healthy 
controls and renal transplant recipients. Data are presented as mean ± SEM. * p<0.05. 
Abbreviation: PBMC, peripheral blood mononuclear cell.
CD14+/CD16++ monocytes express increased levels of α-SMA 
and SM22α
Previous studies suggested that myeloid cells are the most likely 
source of PBMC-derived α-SMA+ cells (7). We wondered whether the 
differences in reduced outgrowth potential of α-SMA expressing cells 
as observed in renal transplant recipients was related to the numbers 
of a specific monocyte subset. We first analyzed whether CD14++/CD16- 
and CD14+/CD16++ monocyte subsets displayed differential α-SMA and 
SM22α mRNA expression. To this end we sorted these monocyte subsets 
from healthy control subjects as in our study it was not possible to 
sort sufficient cell numbers from renal transplant recipients. Figure 3A 
shows the gates used for cell sorting. Cell numbers obtained were too 
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low for additional in vitro cell culture. As shown in Figure 3B, CD14+/
CD16++ monocytes had increased α-SMA (4 fold) and SM22α (50 fold) 
gene expression levels compared to CD14++/CD16- monocytes. These 
results suggest that CD14+/CD16++ monocytes are enriched for cells 
with smooth muscle-like cell outgrowth potential. This was supported 
by the observation that in healthy control subjects the number of 
CD14+/CD16++ monocytes is positively correlated with the number of 
α-SMA+ cells cultured in vitro (r=0.6, p=0.02). When combining the flow 
cytometry and in vitro data from all three study groups this correlation 
became more evident (r=0.62, p=0.0002) (Figure 3C).
DISCUSSION
In the current study we found that PBMC from healthy control 
subjects as well as renal transplant recipients have the potential to 
differentiate into α-SMA+ cells in vitro. Since we observed that CD14+/
CD16++ non-classical monocytes in healthy control subjects display 
high gene expression levels of the mesenchymal markers α-SMA and 
SM22α, we postulate that this monocyte subpopulation is capable of 
differentiating into α-SMA+ cells. In line with this, the frequency of 
circulating CD14+/CD16++ monocytes positively correlated with the 
number of α-SMA+ cells present after in vitro PBMC culture. This positive 
correlation was observed in both healthy control subjects and renal 
transplant recipients. Characterization of monocyte subsets in renal 
transplant recipients revealed that patients with CTD tended to have 
lower numbers of CD14+/CD16++ non-classical monocytes compared to 
patients without CTD. This difference might reflect the recruitment of 
CD14+/CD16++ monocytes into the kidney followed by differentiation 
into α-SMA+ cells.
Previous studies reporting on functional differences between CD16 
negative and CD16 positive monocytes showed that CD16 negative 
monocytes express the chemokine receptor CCR2 resulting in migration 
in response to CCL2. CCL2 is a chemokine known to initiate monocyte 
migration from bone marrow and recruitment to sites of inflammation. 
In contrast to CD16 negative monocytes, CD16 positive monocytes 
express the chemokine receptor CX3CR1 and migrate in response to 
CX3CL1 (fractalkine), a membrane-bound chemokine expressed by 
inflamed endothelial cells (13). CD16 positive monocytes produce IL-6, 
CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-
expressing endothelial cells (17). Ancuta et al. found that in particular 
CD14+/CD16++ monocytes express high levels of CX3CR1 (13). In our 
study, the CD14+/CD16++ monocyte subset in renal transplant recipients 
was also characterized by high CX3CR1 expression levels when 
compared to CD14++/CD16- monocytes (data not shown). Interestingly, 
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the expression of CX3CR1 is also found on smooth muscle-like cells 
cultured from PBMC (7), suggesting that  α-SMA+ cells in TV are, at 
least in part, derived from CD16+/CX3CR1+ monocytes. 
Even though there is evidence that circulating PBMC can 
differentiate into α-SMA+ cells in vitro, the function of these cells 
in vivo is still unclear. In vivo studies in mice subjected to arterial 
injury suggest that α-SMA+ cells derived from the circulation reflect 
rather macrophages with smooth muscle-like characteristics than true 
smooth muscle cells (18,19). In these studies, the recipient-derived 
α-SMA+ cells did not fully differentiate into smooth muscle cells since 
they never expressed smooth muscle-specific markers such as myosin 
heavy chain and calponin. Nevertheless, macrophages with smooth 
muscle-like characteristics had an important paracrine function and 
contributed to inflammatory processes by an increased expression of 
matrix metalloproteinases and inflammatory cytokines (18,19). It is 
therefore of interest to study whether CD16 positive monocytes have 
a similar role in the development of TV. CD16 positive monocytes may 
also differentiate into macrophages with smooth muscle-like properties 
and a proinflammatory paracrine function, thereby contributing to 
the development of TV. In patients with chronic liver disease it was 
already shown that CD14+/CD16++ non-classical monocytes were the 
main producers of pro-inflammatory cytokines and chemokines. Also, 
CD14+/CD16++ non-classical monocytes, but not CD14++/CD16- classical 
monocytes could directly activate collagen-producing hepatic stellate 
cells in vitro (20).
In patients with chronic kidney disease on dialysis the numbers of 
CD14++/CD16+ monocytes were increased and independently predicted 
cardiovascular events (21). Also numbers of CD14+/CD16++ non-
classical monocytes were increased in patients on dialysis, compared 
to aged matched controls without chronic kidney disease (21). In 
contrast to dialysis patients, renal transplant recipients in our study 
were characterized by reduced numbers of CD14+/CD16++ non-classical 
monocytes compared to healthy control subjects. A previous study 
found reduced numbers of these cells in renal transplant recipients 
compared with patients on dialysis (22). In this study the numbers 
of CD14+/CD16++ also independently correlated with subclinical 
atherosclerosis. A possible role of these cells in the development of 
CTD after renal transplantation was not investigated (22). The decrease 
in CD14+/CD16++ monocytes in renal transplant recipients, instead of 
an increase as seen in patients with chronic kidney disease, may be 
explained by the immune suppressive therapy usied in renal transplant 
patients. Immunosuppressive therapy can induce a shift between the 
different monocyte subpopulations. In vitro and in vivo data suggest 
that glucocorticoids selectively deplete CD16 positive monocytes by 
inducing apoptosis (23,24). Since there was no difference in the use 
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of glucocorticoids between renal transplant recipients with or without 
CTD, we propose that the decrease in CD14+/CD16++ monocytes as 
observed most pronounced in transplant patients with CTD may reflect 
their preferential recruitment to damaged endothelium. 
In conclusion, in this study we provide data supporting the presence 
of smooth muscle-precursor cells with the CD14+/CD16++ non-
classical monocyte subset. This subset is reduced in renal transplant 
recipients with CTD suggesting a possible causal role of CD14+/CD16++ 
monocytes to TV development. Future studies should reveal whether 
such a causality exist. If so, modulation of monocyte subsets after 
renal transplantation may be a new therapeutic strategy to attenuate 
or prevent TV after renal transplantation. 
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Chronic transplant dysfunction (CTD) is the leading cause for limited 
kidney graft survival. Renal CTD is characterized by interstitial and 
vascular remodeling leading to interstitial fibrosis, tubular atrophy 
and transplant vasculopathy. The origin of cells and pathogenesis of 
interstitial and vascular remodeling are still unknown. 
Methods 
To study graft versus recipient origin of interstitial myo-fibroblasts, 
vascular smooth muscle cells (SMCs) and endothelial cells (ECs), we 
here describe a new rat model for renal CTD using Dark Agouti kidney 
donors and R26-human Placental Alkaline Phosphatase-transgenic 
Fischer344 recipients. 
Results
This model showed development of CTD within 12 weeks after 
transplantation. In interstitial remodeling, both graft- and recipient-
derived cells contributed to a similar extent to the accumulation of 
myofibroblasts. In arteries with transplant vasculopathy, we observed 
graft origin of neointimal SMCs and ECs, whereas in peritubular and 
glomerular capillaries we detected recipient EC-chimerism. 
Conclusion
These data indicate that within the interstitial and vascular 
compartments of the transplanted kidney, myofibroblasts, SMCs, and 
ECs involved in chronic remodeling are derived from different sources 
and suggest distinct pathogenetic mechanisms within the renal 
compartments.




Chronic transplant dysfunction (CTD) is the leading cause of 
long-term loss of transplanted organs (1). Although considerable 
improvement has been made in overall graft survival due to improved 
prevention and treatment of acute rejection, the rate of long-term 
graft loss remained unchanged. CTD is characterized by organ specific 
lesions coinciding with vascular remodeling resulting in transplant 
vasculopathy (TV), which is a central feature in most transplanted solid 
organs (1). TV is characterized by the formation of a neointima in the 
lumen of intragraft arteries. The neointima consists of smooth muscle 
cells (SMCs), extracellular matrix and inflammatory cells (2). Vascular 
remodeling is believed to be incited by endothelial activation and/or 
loss induced by ischemia/reperfusion and rejection episodes resulting 
in SMC proliferation, migration, and synthesis of extracellular matrix 
(3). In rat models of aorta and cardiac transplantation, we previously 
described the origin of neointimal SMCs and endothelial cells (ECs) 
(4-6). Interestingly, in aortic allografts, both neointimal SMCs and ECs 
were of recipient origin (4,5), whereas in cardiac allografts, neointimal 
SMCs were of recipient origin and the ECs of graft origin (4-6). These 
data demonstrate organ-dependent pathogenesis of TV and prompts 
for organ-specific studies.
In renal CTD, TV results from chronic rejection (7). The most 
significant lesions of renal CTD are interstitial fibrosis and tubular 
atrophy (IF/TA) and beside TV also de novo glomerulosclerosis can be 
present (7-10). Interstitial fibrosis is the result of interstitial remodeling 
induced by accumulated interstitial myofibroblasts. The lesions of CTD 
contribute to graft failure and to date no effective therapy is available 
to prevent or treat CTD. Direct targeting of cells contributing to these 
lesions is the aim in development of specific therapies in the future. To 
this end, it is important to identify the origin of these cells.
In this study, we identified the origin of neointimal SMCs, vascular 
ECs, and interstitial myofibroblasts in vascular and interstitial 
remodeling in CTD in rats. For this purpose, we present a new rat 
kidney transplant model for CTD using Dark Agouti (DA) and R26 
human-Placental-Alkaline-Phosphatase-transgenic Fischer344 (R26) 
rats in the DA-to-R26 combination.
MATERIALS & METHODS 
Rats
Inbred female (170-210 gram) and male (200-250 gram) Dark 
Agouti (DA) rats were obtained from Harlan (Horst, The Netherlands) 
and inbred male Wistar Furth (WF) rats (245-280 gram) from Charles 
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River Laboratories Inc. (l’Arbresle, Cedex, France). Male R26 human-
Placental-Alkaline-Phosphatase-transgenic Fischer344 (R26) rats (225-
390 gram) were derived from our breeding nucleus (kindly provided by 
Dr. E. Sandgren, School of Veterinary Medicine, University of Wisconsin-
Madison, Madison, WI). All animals received humane care in compliance 
with the Principles of Laboratory Animal Care (NIH Publication No.86-
23, revised 1985) and the Dutch Law on Experimental Animal Care.
Kidney transplantation and experimental groups
Female DA kidneys were orthotopically transplanted into male 
recipients as described previously (11). Cold ischemic time ranged from 
7 to 38 minutes. Warm ischemic time was consistently 25 minutes. 
Recipients received cyclosporine A (CsA; 2.5 or 5 mg/kg bodyweight) 
(Sandimmune, Novartis, Arnhem, The Netherlands) subcutaneously 
for 10 days posttransplantation. The native kidney was removed after 
8 to 11 days. In total 38 renal transplantations were performed. Nine 
animals were excluded from the study because of technical failure. The 
following experimental groups were included: 1) DA-to-DA isografts, 
5 mg/kg BW CsA (n=5); 2) DA-to-DA, 2.5 mg/kg BW CsA (n=3); 3) 
DA-to-WF, 5 mg/kg BW CsA, (n=9); 4) DA-to-R26(5), 5 mg/kg BW CsA 
(n=5) and 5) DA-to-R26(2.5), 2.5 mg/kg BW CsA (n=7). Follow-up was 
12 weeks or shorter in case of graft failure.
Graft function
Blood plasma and 24h urine were collected before, 4, 8 and 12 
weeks after transplantation. Plasma and urine creatinine levels were 
determined using the enzymatic colorimetric assay CREA plus (Roche 
Diagnostics GmbH, Mannheim, Germany) (12). Total urinary protein 
excretion was determined using the Roche Diagnostics Urinary/CSF 
Protein assay (Roche Diagnostics GmbH, Mannheim, Germany) (13, 
14). Pre-transplantation data from the excluded animals with technical 
failure are included in the pre-transplantation analyses. 
Immunohistochemistry and immunofluorescence
Two-micron paraffin sections were stained for PAS, methenamine 
silver and mouse anti-human α-smooth muscle actin (α-SMA; clone 
1A4, DAKO, Glostrup, Denmark). For α-SMA staining, overnight antigen 
retrieval was performed in 0.1 M Tris/HCl buffer, pH 9.0, at 80°C. After 
blocking endogeneous peroxidase activity sections were incubated with 
mouse anti-human α-SMA for 1h and secondary horseradish peroxidase 
(HRP)-conjugated rabbit anti-mouse polyclonal antibody (DAKO) for 30 
min. Color development was performed with 3,3’-diaminobenzidine in 
PBS with 0.03% H2O2.
For immunofluorescence staining, 3-micron aceton-fixed frozen 
sections were blocked for endogenous peroxidase activity with 0.03% 
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H2O2 and endogenous biotin and avidin with biotin blocking system 
(DAKO) if appropriate. Sections were incubated for 1h with the following 
primary antibodies: α-SMA, mouse anti-rat endothelium (RECA-
1) (15), mouse-anti-rat MHC class I RT1Aa (DA MHC class I, clone 
MN4-91-6, AbD Serotec, Oxford, UK), rabbit anti-human Placental 
Alkaline Phosphatase polyclonal antibody (AbD Serotec, Oxford, UK), 
and goat anti-procollagen I (Santa Cruz Biotechnology, Santa Cruz, 
USA). α-SMA was detected using goat anti-mouse IgG2a-HRP. RECA-
1 and DA MHC class I were detected using goat anti-mouse IgG1-
Cy5, goat anti-mouse IgG1-FITC goat or anti-mouse IgG1-TRITC. hPAP 
was detected using goat anti-rabbit-FITC (aforementioned all from 
Southern Biotechnology, Birmingham, AL, USA), swine anti-rabbit IgG-
HRP (DAKO), or donkey anti-rabbit Cy5 (Jackson ImmunoResearch, 
Newmarket, Suffolk, UK). Procollagen I was detected with biotin-
labeled donkey anti-goat IgG (Abcam, Cambridge, UK) and FITC-
labeled streptavidin (DAKO). HRP activity was visualized using the 
TSATM Tetramethylrhodamine System (PerkinElmer LAS, Inc., Boston, 
MA, USA). Nuclei were stained with DAPI. Fluorescence microscopy 
was performed using a Leica DMLB microscope (Leica Microsystems, 
Rijswijk, The Netherlands) equipped with a Leica DC300F camera and 
LeicaQWin 2.8 software, an Olympus AX70 fluorescence microscope, 
or a Leica TCS SP2 confocal laser scanning microscope equipped with 
the Leica Confocal Software package (version 2.61). Colocalization of 
hPAP and RECA-1 in a z-resolution was demonstrated by 20 consecutive 
optical sections that were scanned and stacked.
Analysis of interstitial fibrosis, interstitial myofibroblast accu-
mulation, focal glomerulosclerosis, and transplant vasculopa-
thy
IF was semi-quantitatively scored after PAS staining. The interstitial 
area involved in IF was determined in 20 fields (magnification 200x) 
and expressed on a scale from 0-5. If 0-  10% of the interstitium was 
involved, it was scored as 1; 10 - 25% as 2; 25 - 50% as 3, 50 - 75% as 
4, and 75 - 100% as 5. The total IF score was calculated by multiplying 
the score by the percentage of fields with the same IF score. The sum 
of these scores gives the total IF score from 0-to-500.
Accumulation of interstitial myofibroblasts was quantified by 
measuring the level α-SMA staining using computerized morphometry 
(Leica Qwin 2.8 software). Twentyfive randomly selected fields 
in the cortex (magnification 200x) were quantified for α-SMA 
staining, excluding vascular expression. Accumulation of interstitial 
myofibroblasts was expressed as the percentage α-SMA-positive 
surface area of total surface area measured.
FGS was semi-quantitatively scored after PAS staining by determining 
the level of mesangial expansion and focal adhesion in each quadrant 
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in a glomerulus and expressed on a scale from 0 - 4. If 25% of the 
glomerulus was affected, it was scored as 1; 50% as 2; 75% as 3, and 
100% as 4. In total, 50 glomeruli per graft were analyzed and the total 
FGS score was calculated by multiplying the score by the percentage 
of glomeruli with the same FGS-score. The sum of these scores gives 
the total FGS score from 0-to-400.
TV was expressed as the percentage occlusion of the lumen of 
intragraft arteries, with an identifiable internal elastic lamina and a 
luminal diameter of >15 μm. We considered TV present if >5% luminal 
occlusion was observed.


















DA-to-DA 8 5 mg/kg CsA (n=5) 2.5 mg/kg CsA (n=3) 88 39 [34-50] 1.0 ± 0.6 
DA-to-WF 9 5 mg/kg CsA 44 184 [43-615] 14.3 ± 4.6*
DA-to-R26(5) 5 5 mg/kg CsA 60 204 [64-477]* 2.3 ± 1.4 
DA-to-R26(2.5) 7 2.5 mg/kg CsA 43 176 [66-331]** 28.4 ± 11.2 *
* p<0.05, **p<0.01 versus DA-to-DA. CsA: Cyclosporin A
Statistical analyses
Data are expressed as mean ± standard error of the mean (SEM). 
Differences between groups were analyzed using an unpaired t-test. 
Differences in graft survival were analyzed using a Kaplan-Meier log 
rank test. p < 0.05 was considered statistically significant. Statistical 
analyses were performed using GraphPad Prism (Version 4.00, 
GraphPad Software, Inc., San Diego, CA, USA).
RESULTS
Survival
Since the outcome of functional and histological analyses of the 
DA-to-DA isografts were similar irrespective of CsA treatment, data 
of both isograft groups (2.5 and 5 mg/kg CsA) were pooled. Of the 
29 transplanted animals, 2 allografted animals were lost because of 
premature death. In the isograft group 1 out of 8 of the recipients 
was sacrificed at 10 weeks. In the different allograft groups, about 
50% of the recipients were prematurely sacrificed varying from 4 to 
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9 weeks after transplantation. Earlier sacrificed animals presented 
poor condition and elevated plasma creatinine levels (allografts >4 
times, isograft >2 times preTx levels). Graft survival rates and plasma 



































































































Figure 1. Allograft recipients showed reduced creatinine clearance and 
increased urinary protein excretion. (A) Before transplantation, creatinine 
clearance was similar in all combinations (white bars). Eight weeks after transplantation, 
the allograft recipients showed reduced creatinine clearance (black bars) compared 
with pre-transplantation levels and isograft recipients at 8 weeks. (B) Eight weeks 
after transplantation, urinary protein excretion was significantly increased in allograft 
recipients (black bars) compared to pre-transplantation levels (white bars) and 
isograft recipients at 8 weeks. Data are presented as mean+SEM. *p<0.05, **p<0.01, 
***p<0.001 versus DA-to-DA at 8 weeks and preTx.
Renal function
Before transplantation, creatinine clearance and urinary protein 
excretion (Figures 1A and 1B, respectively) was similar in the DA, 
WF and R26 recipient rat strains. Four weeks after transplantation, 
creatinine clearance was significantly reduced by 35%-75% in all 
experimental groups compared to their preTx levels (DA-to-DA: 1.8  ± 
0.2 ml/min (p < 0.0001), DA-to-WF: 1.2 ± 0.2 ml/min (p < 0.0001), 
DA-to-R26(5): 1.4 ± 0.3 ml/min (p < 0.05), DA-to-R26 (2.5): 0.7 ± 
0.2 ml/min (p < 0.0001)). In the DA-to-R26(2.5) group, creatinine 
clearance at 4 weeks was significantly reduced compared with the 
isograft group (p<0.001). At 8 weeks, creatinine clearance in the 
isograft recipients was restored to pre-transplantation levels (Figure 
1A) and remained at these levels until the end of the experiment at 
12 wks (2.2 ± 0.2 ml/min). In contrast to isograft recipients, in all 
allograft recipients creatinine clearance remained significantly reduced 
at 8 weeks after transplantation (Figure 1A), which persisted till the 
end of the experiment (DA-to-WF: 1.1 ± 0.4 ml/min, DA-to-R26(5): 0.6 














































































































Figure 2. Allografts are characterized by significant development of IF/TA, 
accumulation of interstitial myofibroblasts, and FGS. (A) Isograft showed minimal 
development of IF/TA (score 1, sacrificed at 10 weeks) (B) Allografts presented with 
severe IF/TA characterized by expansion of the interstitial space and atrophic tubules 
(arrow) (score 5, DA-to-R26(5) sacrificed at 4 weeks). Magnification 200x. (C) Allografts 
showed significant development of IF compared to isografts. Maximum score is 500 
(100% of the interstitial area involved) (D) Representative cortical region of an isograft 
after α-SMA staining (sacrificed at 10 weeks). (E) Representative cortical region of 
a DA-to-R26(5) allograft after α-SMA staining (sacrificed at 4 weeks). Magnification 
200x. (F) The renal cortex of allografts (white bars) showed substantial accumulation 
of α-SMA+ myofibroblasts compared to isografts (black bar). (G) Representative 
glomerulus without FGS in a DA-to-DA isograft (score 0, sacrificed at 10 weeks). (H) 
Representative glomerulus with severe FGS in a DA-to-R26(5) allograft characterized 
by matrix expansion and adhesion to Bowman’s capsule (score 3, sacrificed at 12 
weeks). PAS staining, magnification 400x. (I) Allografts showed marked FGS compared 
to isografts. Data are presented as mean+SEM. *p<0.05, **p<0.01, ***p<0.001 versus 
DA-to-DA.
In contrast to creatinine clearance, 4 weeks after transplantation, 
urinary protein excretion was not changed significantly in any 
experimental group (DA-to-DA: 8.3 ± 1.1 mg/24h, DA-to-WF: 32.7 ± 
19.0 mg/24h, DA-to-R26(5): 6.2 ± 2.2 mg/24h, DA-to-R26(2.5): 10.3 
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± 1.6 mg/24h). While isograft recipients did not develop proteinuria 
throughout follow-up, all allograft recipients developed severe 
proteinuria at 8 weeks (Figure 1B), which tended to increase further 
at 12 wks after transplantation (DA-to-DA: 16.0 ± 4.8 mg/24h, DA-to-
WF: 193.1 ± 24.0 mg/24h, DA-to-R26(5): 120.8 ± 24.1 mg/24h, DA-
to-R26(2.5): 140.0 ± 27.8 mg/24h).
Development of interstitial fibrosis, myofibroblast accumula-
tion, and focal glomerulosclerosis 
IF/TA was minimally present in the isografts (Figure 2A and C), while 
the allografts presented with severe IF/TA and significantly higher IF 
scores (Figure 2B and C). 
α-SMA-positive myofibroblasts were virtually absent in isografts 
(Figure 2D and F), while they were abundantly present in the allograft 
groups (Figure 2E and F).
In isografts, FGS was virtually absent (Figure 2G and I), whereas in 
the allograft groups marked FGS was present (Figure 2H and I). Grafts 
from the DA-to-R26(5) group had more pronounced FGS than grafts 
from the DA-to-R26 (2.5) group (p<0.05).
Development of transplant vasculopathy
In non-transplanted DA kidneys, no neointimal lesions were present 
(Figure 3A). The isografts developed minimal occlusion, whereas DA-
to-R26(2.5) allografts developed the most severe neointimal lesions 
(Figures 3B and C). TV was detected in all types of intrarenal arteries. 
In isografts and DA-to-R26(5) allografts, moderate to severe occlusion 
(>50%) was hardly present, whereas in DA-to-WF and DA-to-R26(2.5) 
allografts it was detected in a substantial number of arteries (Table 1 
and Figure 3D). Compared to DA-to-R26(2.5) allografts, DA-to-R26(5) 
presented with reduced numbers of arteries with moderate to severe 
occlusion, however, without reaching the level of statistical significance 
(p=0.12).
To determine whether the severity of TV was positively correlated 
with graft loss and renal graft dysfunction, allografts (from all three 
groups) were subdivided in grafts with mild TV (≤10% of arteries >50% 
occluded) and severe TV (>10% of arteries >50% occluded). Allografts 
with severe TV had significantly reduced survival rates compared with 
allografts with mild TV and isograft controls (Figure 3E). Moreover, 
plasma creatinine levels at sacrifice in allograft recipients with severe 
TV were significantly increased compared with isograft controls (Figure 
3E). Although plasma creatinine levels in allograft recipients with severe 
TV were clearly elevated compared with allograft recipients with mild 
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Figure 3. DA-to-WF and DA-to-R26(2.5) allografts developed severe TV. 
(A) Normal artery in DA kidney before transplantation. (B) Representative artery 
in an isograft at 12 weeks after transplantation. (C) Representative artery in a DA-
to-R26(2.5) allograft at 7 weeks after transplantation with severe neointima formation. 
Abbreviations: M; media, IEL; internal elastic lamina, NI; neointima. Methenamine silver 
staining. Magnification 400x. (D) Percentage of intragraft arteries with moderate (51-
75%) and severe (76-100%) luminal occlusion. DA-to-WF and DA-to-R26(2.5) allografts 
show a significantly increased number of arteries with >50% occlusion compared 
with isografts. *p<0.05 versus DA-to-DA. (E) Recipients with severe TV (≥10% of the 
arteries >50% occlusion) showed reduced survival compared with isograft recipients 
as well as allograft recipients with mild TV (≤10% of the arteries >50% occlusion). 
Plasma creatinine level in recipients with severe TV was significantly higher compared 
with isograft recipients. Plasma creatinine levels at time of sacrifice are represented 
as mean+SEM between brackets (pCr: plasma creatinine). *p<0.01 versus isograft 
recipients, †p<0.05 versus allograft recipients with mild TV.
Graft origin of neointimal smooth muscle cells and endothelial 
cells
Immunolabeling for α-SMA confirmed that the neointima primarily 
consisted of SMCs (Figure 4A). Co-labeling for hPAP revealed that only few 
recipient-derived cells were present in the neointima (Figure 4B). Staining 
for CD45 indicated that the recipient-derived hPAP+ neointimal cells were 
infiltrating leukocytes (not shown). Double-labeling for α-SMA and DA 
MHC class I showed graft origin of neointimal SMCs (Figure 4C and D).
In R26 kidneys, vascular ECs expressed hPAP (Figure 4E) but not 
DA MHC class I (Figure 4F). In non-transplanted DA kidneys, hPAP 
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Figure 4. Graft origin of neointimal SMC and ECs. (A-D) Graft origin of neointimal 
SMCs in a DA-to-R26(2.5) allograft. Sections were stained for α-SMA (red, A), hPAP 
(green, B) and DA MHC class I (blue, C). (D) The merged image shows graft-derived 
neointimal SMCs that express DA MHC class I but not hPAP. Magnification 3150x. (E-H) 
Graft origin of ECs in arteries. (E) Co-expression of hPAP (red) and RECA-1 (EC, green) 
on arterial ECs in a R26 kidney. (F) Serial section of E after double-labeling for hPAP 
(red) and DA MHC class I (green). Magnification 1260x. (G) Artery with neointima in a 
DA-to-R26(2.5) allograft showing neointimal ECs negative for hPAP. (H) Serial section 
of G showing that the ECs are positive for DA MHC class I. Magnification 2520x. Dotted 
line in A-D, G & H indicates the internal elastic lamina (IEL).
was absent in arterial ECs (not shown). These results indicate that the 
hPAP and DA MHC class I staining is sensitive and specific allowing 
discrimination between DA- and R26-derived ECs. Neointimal ECs in 
DA-to-R26 allografts (2.5 and 5 mg/kg CsA) did not express hPAP, 
suggesting graft origin (Figure 4G). Graft origin was confirmed on 
serial sections after double-labeling for hPAP and DA MHC class I in 
which only DA MHC class I was positive (Figure 4H). No differences 
in EC origin were observed between arteries with or without TV (not 
shown).
Recipient-chimerism in glomerular endothelium
hPAP expression was detected in glomerular ECs in R26 kidneys 
(Figure 5A), but not in non-transplanted DA kidneys (Figure 5B). In 
contrast to our findings in the arteries, RECA-1+/hPAP+ double positive 
ECs were detected in the glomerular capillaries indicating recipient-EC 
chimerism (Figure 5C). Stacked confocal consecutive z planes confirmed 
true colocalization of RECA-1 and hPAP (Figure 5D). More in-depth 
quantitative analysis of allografts at 12 weeks (n=4) and one allograft 









Figure 5. Recipient EC-chimerism in glomerular capillaries. (A) Glomerulus 
in a non-transplanted R26 kidney double-labeled for hPAP (green) and RECA-1 (EC, 
red). (B) Glomerulus in a DA kidney double-labeled for hPAP (green) and RECA-1 (EC, 
red). Magnification 2520x. (C) Glomerulus in a DA-to-R26(5) allograft with recipient-
derived ECs identified by co-expression of both hPAP (red) and RECA-1 (EC, green). 
Magnification 1260x. (D) Higher power magnification of the framed area shown in C. 
The x/z plane underneath and y/z plane on the right demonstrate colocalization of hPAP 
and RECA-1. Magnification 4410x.
section contained recipient-derived ECs with an average of 2 recipient-
derived ECs per chimeric glomerulus. Results on EC chimerism in the 
allograft at 30 days did not differ from the results obtained in grafts 
that survived until the end of the experiment. Recipient-EC chimerism 
was furthermore detected in peritubular capillaries albeit at low levels 
(not shown). These observations were not rat strain-specific since 
qualitative analyses in DA-to-WF allografts also revealed recipient-EC 
chimerism in glomerular and peritubular capillaries (not shown).
Graft and recipient origin of interstitial myofibroblasts
Triple-labeling for α-SMA, hPAP and DA MHC class I within fibrotic 
lesions revealed a graft-derived (Figure 6A and B) as well as a recipient-
derived (Figure 6C and D) population of myofibroblasts. More in-depth 
quantitative analysis of allografts at 12 weeks (n=4) and one allograft 
retrieved at 30 days, revealed that 53% [range 43 to 66%] of the 
interstitial α-SMA+ myofibroblasts originated from the recipient. 







Figure 6. Graft and recipient origin of interstitial myofibroblasts. (A) 
Representative photomicrograph of cortical interstitium in a DA-to-R26(5) allograft 
stained for α-SMA (red), hPAP (green) and DA MHC class I (blue) showing α-SMA+/
DA MHC class I+ graft-derived myofibroblasts. Magnification 1260x. (B) Higher power 
magnification (3150x) of the framed area shown in A. Arrow indicates an α-SMA+/DA 
MHC class I+ graft-derived myofibroblast. (C) Identical section and staining as shown in 
A now depicting α-SMA+/hPAP+ recipient-derived myofibroblasts. Magnification 1260x. 
(D) Higher power magnification (3150x) of the framed area shown in C. Arrows indicate 
α-SMA+/hPAP+ recipient-derived myofibroblasts.
Results on myofibroblast origin in the allograft at 30 days did not differ 
from the results obtained in grafts that survived until the end of the 
experiment. Additional immunofluorescence triple stainings for hPAP, 
α-smooth muscle actin, and procollagen I revealed that (part of) the 
recipient-derived interstitial myofibroblasts express procollagen I, 
suggesting that these cells are actively involved in the development of 
IF (Figure 7).
DISCUSSION
Our data demonstrate the diversity of the vascular and interstitial 
compartments with regard to the pathogenesis of renal chronic 
transplant dysfunction (CTD). We showed graft origin of both the 







Figure 7. Procollagen I expression in recipient-derived myofibroblast. Sections 
were stained for α-SMA (red, A), procollagen I (green, B), and hPAP (blue, C). Figure D 
shows the merged image of A-C. Arrows indicate a procollagen I-expressing recipient-
derived interstitial myofibroblast in a DA-to-R26(5) allograft. Magnification 640x.
the other hand, we showed recipient-EC chimerism in glomerular 
and peritubular capillaries at very low levels. In the interstitium, we 
demonstrated both graft- as well as recipient-derived myofibroblasts. 
We obtained these results by introducing a new rat model for CTD 
with TV using R26 hPAP-transgenic Fischer344 recipient rats and DA 
donors.
An elegant renal transplantation model for CTD has been described 
in the Dark Agouti (DA) to Wistar Furth (WF) rat combination which 
develops CTD including TV within 3 months after transplantation (16, 
17). Using this model as positive control for the development of CTD, 
we transplanted DA kidneys into R26-hPAP transgenic F344 rats. 
These rats show constitutive and ubiquitous expression of hPAP (18). 
hPAP expression can be detected by immunostaining and can be easily 
combined with antibodies for e.g. SMCs and ECs, which makes the model 
attractive for graft versus recipient origin studies as described in this 
study. Like DA-to-WF allografts, allografts in the DA-to-R26 combination 
developed CTD within 12 weeks after transplantation characterized by 
interstitial fibrosis and tubular atrophy (IF/TA), moderate to severe TV, 
and focal glomerulosclerosis (FGS). Development of severe TV was 
associated with reduced survival underscoring its contribution to graft 
deterioration. Whereas all histological components of human CTD are 
present, the severity of FGS in our model is relatively high and may be 
a specific feature of the rat model used.
In the DA-to-R26 combination, we used two doses of CsA in the first 
10 days after transplantation; 5 and 2.5 mg/kg. Development of TV 
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has been shown before in the DA-to-WF combination with a dose of 5 
mg/kg for 10 days (17). However, in comparison to WF recipients, F344 
rats turned out to be “low TV responders” as indicated by slower and 
less severe TV development in an aortic transplantation model (19). In 
addition, TV development can be prevented by continuous treatment 
with CsA in experimental aorta allografts in rats (4). Based on these 
results, we hypothesized that TV development in R26 transgenic F344 
recipients treated with 5 mg/kg might be limited. Here, we indeed 
show that the DA-to-R26 combination with 2.5 mg/kg CsA treatment 
developed more prominent TV compared with 5 mg/kg CsA treatment.
The results from human studies on cell origin are inconclusive 
about the origin of SMCs, myofibroblasts and ECs in the different renal 
compartments after renal transplantation. For TV, only two (clinical) 
studies have reported on the origin of neointimal SMCs (20, 21). In line 
with our results, Bittmann et al. (20)  presented graft-derived neointimal 
ECs and SMCs in renal TV. They analyzed human renal allografts 
transplanted in a sex-mismatched combination for the presence of 
neointimal cells containing the Y chromosome by in situ hybridization. 
However, using a similar experimental approach, Grimm et al. (21) 
reported that neointimal SMCs were both graft- and recipient-derived. 
A similar discrepancy was described for interstitial cells as Bittmann 
et al. (20) showed graft origin of interstitial myofibroblasts, whereas 
Grimm et al. (21) demonstrated, like us, graft and recipient origin of 
interstitial myofibroblasts.
In this study, we used a rat model for CTD to analyze arterial, 
capillary and interstitial remodeling at the same time. Although some 
discrepancies between the human and experimental setting in the 
pathogenesis of CTD cannot be excluded, our results indicate that 
different compartments in de renal graft use different sources of 
endothelial and mesenchymal cells during chronic remodeling. This 
sheds new light on the pathogenesis of CTD. Our results indicate 
that there is compartmentalization within the kidney, i.e. intragraft 
arteries, capillaries and the interstitium undergo chronic remodeling via 
different pathogenetic pathways. In addition to pathogenetic pathways 
depending on the compartment within the kidney, we also suggest 
that the pathogenetic pathway of TV depends on the organ studied. In 
rats, the origin of SMCs and ECs in TV in renal allografts differs from 
the origin of these cells in aorta and cardiac allografts (4-6). In aorta 
allografts both neointimal SMCs and ECs in TV were of recipient origin, 
whereas in cardiac allografts we showed recipient origin of neointimal 
SMCs but graft origin of ECs. The finding that pathogenetic pathways 
in CTD depend on the specific renal compartment and organ studied, 
is of potential relevance for the development of new therapeutic 
approaches to target CTD. 
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Although we showed graft origin of neointimal SMCs, their 
anatomical source is unknown. We hypothesize that the neointimal 
SMCs are derived from the media of the affected artery which is in 
line with the response-to-injury hypothesis proposed by Ross et al. (3) 
for the development of atherosclerosis. According to this hypothesis, 
activation and damage of ECs induces pro-inflammatory and pro-
fibrotic processes ultimately leading to migration of medial SMCs into 
the subendothelial space followed by proliferation and synthesis of 
extracellular matrix components (3). Although direct experimental 
proof for proliferation and migration of medial SMCs into the neointima 
is still lacking, in rat carotid arteries with balloon angioplasty, medial 
SMC proliferation and neointimal hyperplasia were prevented by 
in vivo adenoviral delivery of anti-proliferative A20 to medial SMCs 
(22). Alternatively, vascular progenitor cells residing in the adventitia 
of arterial vascular walls and vein grafts have also been shown to 
be a source of neointimal SMCs (23, 24). In addition to vascular wall 
progenitor cells, other (non-vascular) sources of renal progenitor cells 
might play a role in TV development. Renal progenitor cells have been 
recently identified and have been implicated in primarily tubular repair 
(25-28). So far, however, these cells have not been related to renal 
vascular repair in general or neointima formation in particular.
In this study, we only observed EC chimerism in capillaries 
(glomerular and peritubular) but not in arterioles and arteries. Vascular 
EC chimerism in renal transplantation has been shown mainly in human 
biopsies obtained from patients with suspected acute rejection (29-
31). Recipient-derived ECs were predominantly observed in peritubular 
capillaries (29, 32, 33) and the level of EC chimerism has been linked to 
the severity of vascular rejection (29, 32) or duration of ischemia (30, 
31). According to these studies, one might suggest that the presence 
of EC chimerism appears to be a resultant of the severity of endothelial 
damage (34). Possibly, it reflects a functional repair process mediated 
by recipient-derived (progenitor) cells to maintain endothelial integrity. 
Differences in origin of vascular ECs might be explained by different 
phenotypical characteristics of intrarenal ECs (35). Specifically, ECs in the 
renal vasculature might differ in their susceptibility to transplantation-
related damage and/or in their capacity to maintain endothelial 
integrity by reendothelialization. Possibly, arterial ECs could possess 
the capacity to maintain endothelial integrity by reendothelialization 
mediated by neighbouring ECs, whereas capillary ECs do not have this 
capacity. Alternatively, differences in microenvironmental factors, like 
hemodynamics and inflammatory responses, might play a role in the 
observed diversity in vascular remodeling.
We showed that interstitial myofibroblasts in CTD are both derived 
from sources within the graft as well as from sources located within 
the recipient but outside the graft. Potential endogenous sources 
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are resident fibroblasts, which upon activation proliferate and 
obtain mesenchymal characteristics, or epithelial-to-mesenchymal 
transdifferentiation (EMT) (36, 37). The putative external sources are 
recipient-derived circulating fibrocytes and BM-derived myofibroblast 
progenitor cells (36, 38, 39). In our model, we were not able to reveal 
the exact source of recipient-derived myofibroblasts. However, it is 
most likely that these are, at least in part, BM-derived since in an 
ischemia/reperfusion injury model in R26 hPAP BM chimeric F344 
rats it was shown that 32% of the interstitial myofibroblasts were 
derived from the bone marrow (39). Recruitment of recipient-derived 
myofibroblasts appears to begin in the early acute phase after renal 
transplantation since it was recently demonstrated that at 14 days after 
renal transplantation of DA allografts in R26 F344 recipients, already 
39% of the interstitial myofibroblasts are recipient-derived (40), which 
further increases to 53% at later timepoints as demonstrated in our 
study. We furthermore showed that recipient-derived myofibroblasts 
express procollagen I, suggesting that these cells are actively involved 
in the development of IF. From a therapeutic point of view, recipient-
derived myofibroblasts form a potential target for intervention which 
should, however, start already in the early phase after transplantation.
In conclusion, we have shown that different compartments within the 
vasculature and interstitium use different sources of endothelial and 
mesenchymal cells for chronic remodeling after renal transplantation. 
To prevent development of CTD, multiple cell populations should be 
targeted simultaneously. On the one hand, graft-derived cells may be 
inhibited in their local activation, whereas on the other hand, recipient-
derived cells may be targeted by inhibiting their recruitment. Future 
studies should elucidate the exact source and mechanism of activation 
and recruitment of cells involved in chronic remodeling after renal 
transplantation.
REFERENCES
1. Kouwenhoven EA, IJzermans JN, de Bruin RW. Etiology and pathophysiology of 
chronic transplant dysfunction. Transpl Int 2000; 13(6):385-401.
2. Hillebrands JL, Klatter FA, Rozing J. Origin of vascular smooth muscle cells and 
the role of circulating stem cells in transplant arteriosclerosis. Arterioscler Thromb 
Vasc Biol 2003; 23380-387.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 
1993; 362(6423):801-809.
4. Hillebrands JL, Klatter FA, van den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J. 
Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in 
transplant arteriosclerosis. J Clin Invest 2001; 107(11):1411-1422.
5. Hillebrands JL, Klatter FA, van Dijk WD, Rozing J. Bone marrow does not contrib-
ute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat 
Med 2002; 8(3):194-195.
6. Hillebrands J, van den Hurk BM, Klatter FA, Popa ER, Nieuwenhuis P, Rozing J. Re-
Chapter 4
80
cipient origin of neointimal vascular smooth muscle cells in cardiac allografts with 
transplant arteriosclerosis. J Heart Lung Transplant 2000; 19(12):1183-1192.
7. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE et al. Banff ‘05 Meeting 
Report: differential diagnosis of chronic allograft injury and elimination of chronic 
allograft nephropathy (‘CAN’). Am J Transplant 2007; 7(3):518-526.
8. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M et al. Banff 07 classifica-
tion of renal allograft pathology: updates and future directions. Am J Transplant 
2008; 8(4):753-760.
9. Colvin RB, Nickeleit V. Renal transplant pathology. In: Jennette JC, Olson JL, 
Schwartz MM, Silva FG (eds). Pathology of the kidney. 5th ed., Philadelphia, PA: 
Lippincott Williams & Wilkins, 2007:1347-1490.
10. Chapman JR, O’Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am 
Soc Nephrol 2005; 16(10):3015-3026.
11. Smit-van Oosten A, Navis G, Stegeman CA, Joles JA, Klok PA, Kuipers F et al. 
Chronic blockade of angiotensin II action prevents glomerulosclerosis, but in-
duces graft vasculopathy in experimental kidney transplantation. J Pathol 2001; 
194(1):122-129.
12. Mazzachi BC, Peake MJ, Ehrhardt V. Reference range and method comparison 
studies for enzymatic and Jaffe creatinine assays in plasma and serum and early 
morning urine. Clin Lab 2000; 46(1-2):53-55.
13. Iwata J, Nishikaze O. New micro-turbidimetric method for determination of protein 
in cerebrospinal fluid and urine. Clin Chem 1979; 25(7):1317-1319.
14. Luxton RW, Patel P, Keir G, Thompson EJ. A micro-method for measuring total pro-
tein in cerebrospinal fluid by using benzethonium chloride in microtiter plate wells. 
Clin Chem 1989; 35(8):1731-1734.
15. Duijvestijn AM, van GH, Klatter F, Majoor GD, van BE, van B, V. Antibodies defining 
rat endothelial cells: RECA-1, a pan-endothelial cell-specific monoclonal antibody. 
Lab Invest 1992; 66(4):459-466.
16. Yilmaz S, Taskinen E, Paavonen T, Mennander A, Hayry P. Chronic rejection of rat 
renal allograft. I. Histological differentiation between chronic rejection and cyclo-
sporin nephrotoxicity. Transpl Int 1992; 5(2):85-95.
17. Kunter U, Floege J, von Jurgensonn AS, Stojanovic T, Merkel S, Grone HJ et al. Ex-
pression of A20 in the vessel wall of rat-kidney allografts correlates with protection 
from transplant arteriosclerosis. Transplantation 2003; 75(1):3-9.
18. Kisseberth WC, Brettingen NT, Lohse JK, Sandgren EP. Ubiquitous expression of 
marker transgenes in mice and rats. Dev Biol 1999; 214(1):128-138.
19. Hillebrands JL, Klatter FA, Bruggeman CA, Rozing J. Development of transplant 
arteriosclerosis after allogeneic aorta transplantation in the rat: influence of recipi-
ent genotype. Transplant Proc 2001; 33(1-2):324-325.
20. Bittmann I, Baretton GB, Schneeberger H. [Chronic transplant reaction of the 
kidney. A interphase cytogenetic and immunohistologic characterization of the in-
volved cells in relation to donor and recipient origin]. Pathologe 1998; 19(2):129-
133.
21. Grimm PC, Nickerson P, Jeffery J, Savani RC, Gough J, McKenna RM et al. Neo-
intimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic 
renal-allograft rejection. N Engl J Med 2001; 345(2):93-97.
22. Patel VI, Daniel S, Longo CR, Shrikhande GV, Scali ST, Czismadia E et al. A20, a 
modulator of smooth muscle cell proliferation and apoptosis, prevents and induces 
regression of neointimal hyperplasia. FASEB J 2006; 20(9):1418-1430.
23. Zengin E, Chalajour F, Gehling UM, Ito WD, Treede H, Lauke H et al. Vascular 
wall resident progenitor cells: a source for postnatal vasculogenesis. Development 
2006; 133(8):1543-1551.
24. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B et al. Abundant pro-
genitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-
Cell origin in renal allograft remodeling
81
4
deficient mice. J Clin Invest 2004; 113(9):1258-1265.
25. Oliver JA, Maarouf O, Cheema FH, Martens TP, Al Awqati Q. The renal papilla is a 
niche for adult kidney stem cells. J Clin Invest 2004; 114(6):795-804.
26. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D et al. 
Isolation of renal progenitor cells from adult human kidney. Am J Pathol 2005; 
166(2):545-555.
27. Gupta S, Verfaillie C, Chmielewski D, Kren S, Eidman K, Connaire J et al. Isola-
tion and characterization of kidney-derived stem cells. J Am Soc Nephrol 2006; 
17(11):3028-3040.
28. Dekel B, Zangi L, Shezen E, Reich-Zeliger S, Eventov-Friedman S, Katchman H 
et al. Isolation and characterization of nontubular sca-1+lin- multipotent stem/
progenitor cells from adult mouse kidney. J Am Soc Nephrol 2006; 17(12):3300-
3314.
29. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, van Es LA, Bruijn JA, van 
Krieken JH. Endothelial cell chimerism after renal transplantation and vascular 
rejection. Lancet 2001; 357(9249):33-37.
30. Bai HW, Shi BY, Qian YY, Na YQ, Cai M, Zeng X et al. Does endothelial chimerism 
correlate with renal allograft rejection? Transplant Proc 2006; 38(10):3430-3433.
31. Bai HW, Shi BY, Qian YY, Na YQ, Zeng X, Zhong DR et al. Endothelial cell chimerism 
by fluorescence in situ hybridization in gender mismatched renal allograft biopsies. 
Chin Med J (Engl ) 2007; 120(10):859-862.
32. Sinclair RA. Origin of endothelium in human renal allografts. Br Med J 1972; 
4(5831):15-16.
33. van Poelgeest EP, Baelde HJ, Lagaaij EL, Sijpkens YW, de HE, Bruijn JA et al. 
Endothelial cell chimerism occurs more often and earlier in female than in male 
recipients of kidney transplants. Kidney Int 2005; 68(2):847-853.
34. Xu W, Baelde HJ, Lagaaij EL, De Heer E, Paul LC, Bruijn JA. Endothelial cell chime-
rism after renal transplantation in a rat model. Transplantation 2002; 74(9):1316-
1320.
35. Segal MS, Baylis C, Johnson RJ. Endothelial health and diversity in the kidney. J 
Am Soc Nephrol 2006; 17(2):323-324.
36. Okada H, Kalluri R. Cellular and molecular pathways that lead to progression and 
regression of renal fibrogenesis. Curr Mol Med 2005; 5(5):467-474.
37. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for 
fibrosis. J Clin Invest 2003; 112(12):1776-1784.
38. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differ-
entiation pathway and migration to wound sites. J Immunol 2001; 166(12):7556-
7562.
39. Broekema M, Harmsen MC, van Luyn MJ, Koerts JA, Petersen AH, van Kooten TG 
et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myo-
fibroblast population and produce procollagen I after ischemia/reperfusion in rats. 
J Am Soc Nephrol 2007; 18(1):165-175.
40. Broekema M, Harmsen MC, Koerts JA, van Kooten TG, Navis G, van Luyn MJ et al. 
Tubular engraftment and myofibroblast differentiation of recipient-derived cells af-
ter experimental kidney transplantation. Transplantation 2007; 84(8):1003-1011.

CHAPTER












LOCAL MEDIAL MICROENVIRONMENT DIRECTS 
PHENOTYPIC MODULATION OF SMOOTH 







Smooth muscle cells (SMCs) play a key role in the pathogenesis 
of occlusive vascular diseases, including transplant vasculopathy. 
Neointimal SMCs in experimental renal transplant vasculopathy are 
graft-derived. We propose that neointimal SMCs in renal allografts 
are derived from the vascular media resulting from a transplantation-
induced phenotypic switch. 
We examined the molecular changes in the medial microenvironment 
that lead to phenotypic modulation of SMCs in rat renal allograft 
arteries with neointimal lesions. 
Methods
Dark Agouti donor kidneys were transplanted into Wistar Furth 
recipients and harvested at day 56. Neointimal and medial layers were 
isolated using laser-microdissection. Gene expression was analyzed 
using low-density arrays and confirmed by immunostaining. 
Results
In allografts, neointimal SMCs expressed increased levels of Tgfβ1 
and Pdgfb. In medial allograft SMCs, gene expression of Ctgf, Tgfβ1 and 
Pdgfrb was upregulated. Gene expression of Klf4 was upregulated as 
well, while expression of Sm22α was downregulated. Finally, PDGF-BB-
stimulated phenotypically modulated SMCs as evidenced by reduced 
contractile function in vitro which was accompanied by increased Klf4 
and Col1α1, and reduced α-Sma and Sm22α expression.
Conclusion
In transplant vasculopathy, neointimal PDGF-BB induces phenotypic 
modulation of medial SMCs, through upregulation of KLF4 in the media 
to contribute to (further) expansion of the neointima.




Vascular remodeling comprises of structural changes of the arterial 
wall in response to various stimuli including shear stress, hypoxia, and 
immunological or mechanical injury. The structural changes of the 
arterial wall lead to changes in vessel size and luminal width (1). Vascular 
remodeling has various clinical and pathological manifestations, 
including transplant vasculopathy (TV), (in-stent) restenosis and 
spontaneous (native) atherosclerosis. Hallmark of these obliterative 
vascular pathologies is neointima formation resulting from both an 
increase in the number of cells in the subendothelial intima as well as 
deposition extracellular matrix (ECM) (2). Narrowing, thickening and 
stiffening of the vessel wall by neointima formation results in reduced 
blood flow and subsequent ischemia in downstream tissues.
TV in renal allografts is a histopathologic feature observed in 
addition to transplant glomerulopathy, interstitial fibrosis and tubular 
atrophy (IF/TA) in patients with chronic renal transplant dysfunction 
(CTD). Development of CTD is a major cause of renal allograft loss, only 
second to patient death with a functioning graft (3). Development of TV 
in transplanted kidneys presumably contributes to graft deterioration. 
In support of this, we recently demonstrated that TV severity is indeed 
associated with premature graft loss in a renal transplant model in rats 
(4). As yet, no adequate preventive or curative therapies for TV are 
available.
Neointima formation in TV is the accumulation of α-smooth 
muscle actin (α-SMA)-positive smooth muscle cells (SMCs) between 
the endothelial lining and the internal elastic lamina (IEL), forming 
an occlusive neointima (5). Neointimal SMCs secrete ECM leading 
to arterial stiffness, luminal stenosis and, eventually, ischemic graft 
failure. The overall concept of neointima formation in general and in 
TV in particular, is that local inflammatory responses of the vessel wall 
trigger SMC migration and proliferation (6). Until a decade ago, the 
general dogma was that neointimal SMCs in TV are graft-derived as 
proposed in the response-to-injury hypothesis for atherosclerosis (7). 
However, this response-to-injury hypothesis has been challenged as 
various research groups, including our own, showed recipient-origin of 
neointimal SMCs in TV in predominantly experimental arterial-segment 
and cardiac transplant models in rodents (5,8,9). Until recently the 
anatomical origin of neointimal SMCs in TV in renal allografts was 
largely unknown. Knowing the anatomical origin of neointimal SMCs 
is key to the development of new therapeutic modalities to attenuate 
TV development that should lead to prolonged graft survival. We 
therefore determined host vs. graft origin of neointimal SMCs in both 
an experimental renal transplant model in rats as well as in human 
renal allografts with TV. In both experimental renal transplantation in 
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rats as well as in human renal transplantectomy samples neointimal 
SMCs turned out to be of graft origin with only a relatively small 
proportion of host-derived SMCs being detected in human renal 
allografts (4,10). Graft origin of neointimal SMCs fits with the response-
to-injury hypothesis which states that medial SMCs migrate across 
the internal elastic lamina in response to arterial injury (7). However, 
formal proof for medial origin (rather than recruitment of adventitial 
or interstitial (myo)fibroblasts or SMC precursor cells) still needs to be 
delivered. Based on our previous results on graft origin of neointimal 
SMCs in renal allografts we hypothesize that these cells are indeed 
derived from the vascular media. Due to the lack of markers specific 
for medial-derived SMCs, it is however not possible to track medial 
SMCs during neointima development using lineage tracing.
Medial SMCs can only contribute to neointima formation after 
undergoing a phenotypic switch from a contractile to a synthetic 
state (11). Synthetic SMCs have migratory and proliferative capacities 
and secrete ECM molecules. We hypothesize that the combination of 
ischemia/reperfusion injury and ongoing alloreactivity towards the 
allograft induces medial SMCs to switch to synthetic SMCs. Synthetic 
SMCs can migrate to the subendothelial space which will eventually 
lead to neointima formation. To test this hypothesis, we investigated 
the spatiotemporal expression of factors in the neointimal and medial 
microenvironment known to influence phenotypic modulation of 
SMCs. Furthermore, we investigated genes indicative of phenotypic 
modulation of medial SMCs in rat renal allografts with TV as well as 
in isografts and non-transplanted control kidneys without TV. To not 
disturb the location nor the status of the cellular content, neointimal 
and medial layers were isolated using laser dissection microscopy after 
which gene expression was analyzed in these different compartments 
with a low density array. Results were confirmed at protein level in 
tissue sections and functionally analyzed in an in vitro SMC function 
assay.
 METHODS
Kidney Transplantation and Experimental Groups
Animals were handled in compliance with the Principles of Laboratory 
Animal Care (NIH Publication No. 86-23, revised 1985), the University 
of Groningen guidelines for animal husbandry (University of Groningen, 
the Netherlands), and the Dutch Law on Experimental Animal Care. 
Female Dark Agouti (DA) kidneys were orthotopically transplanted 
into male DA or Wistar Furth (WF) recipients as described previously 
(4). The following experimental groups were included: control (non-
transplanted) DA kidneys (n = 5), DA-to-DA isografts (n = 5), and 




















































































































































Figure 1. CTD development after renal allograft transplantation. (A) Creatinine 
clearance in allografts (n=3) and isografts (n=5) before and 8 weeks after transplantation. 
(B) Protein excretion in allografts (n=3) and isografts (n=5) before and 8 weeks after 
transplantation. (C) Renal allografts developed IF, glomerulosclerosis and TV (Masson’s 
trichrome staining [collagen: blue]). Scale bar represents 50 μm. (D) Gene expression 
analysis of fibrosis-related genes Tgfβ1 and Col1α1 in total kidney samples from renal 
allografts, isografts and non-transplanted control kidneys (n=5). Data are presented as 
mean ± SEM. *p < 0.05, **p < 0.01. Abbreviation: TX; transplantation
DA-to-WF allografts (n = 5). Isograft recipients were sacrificed at day 
81 (range 70 – 84 days) and allograft recipients at day 65 (range 54 – 
84 days) after transplantation.
Laser Dissection Microscopy and Gene Expression Analysis
The neointima and media were separately laser microdissected from 
nine serial kidney sections per animal. Per renal allograft, an average 
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of 75 (range 25 – 117) arteries was dissected (Supplemental Table 1). 
An average of 46 (range 37 – 52) arteries was dissected from renal 
isografts and an average of 69 (range 47 – 100) was dissected from 
arteries of non-transplanted kidneys (Supplemental Table 1).
Total RNA was isolated from microdissected vascular structures 
and gene expression of genes known to influence fibrosis and SMC 
phenotype were analyzed with a custom made micro fluidic card-based 
low density array (Supplemental Table 2). Relative mRNA levels were 
calculated as 2−ΔCT, in which ΔCT is CTgene of interest – CTβ-actin. CT values 
that were below detection level were set at 50.
For gene expression analysis of cultured rat aortic SMCs, total 
RNA was isolated after 24 hours of stimulation with PDGF-BB or 
TGF-β1 (PreproTech EC LTD. London, UK). Relative mRNA levels were 
normalized against β-actin expression as described above.
Immunohistochemistry
Sections were stained for Masson’s trichrome, Verhoeff-van Gieson, 
TGF-β1, CTGF, PDGF-B and smooth muscle myosin heavy chain 11 
(MYH11). The degree TV (i.e. obliteration in arteries) was measured 
in all arteries with a clearly visible IEL (Verhoeff-van Gieson staining) 
within a section. 
Collagen gel contraction assay
Gel contraction assay of 3D collagen gels were performed using a 
solution of rat tail collagen I (BD Bioscience, Breda, the Netherlands). 
Aliquots of 50 μl (containing 50,000 rat aortic SMCs and 0.25 mg Collagen 
type I) were added to a 96 wells plate that had been preincubated with 
0.1% BSA. After solidification, collagen gels were further cultured with 
or without additional PDGF-BB or TGF-β1 (PreproTech EC LTD. London, 
UK). Collagen gels were imaged using a common flatbed-scanner 
(ScanJet 5370C; HP, CA, USA) and gel contraction was measured after 
24 hours (12).
Statistics
Data are expressed as mean ± standard error of the mean (SEM). 
Differences between contralateral kidneys, isografts and allografts 
were analyzed using a one-way ANOVA with Tukey’s posthoc test. 
Differences between unstimulated SMCs and TGF-β1- or PDGF-BB-
stimulated SMCs were analyzed using a one-way ANOVA with Dunnett’s 
posthoc test. p < 0.05 was considered statistically significant. Statistical 
analyses were performed using SPSS (version 16.0.2; IBM Nederland 
B.V., Nieuwegein, the Netherlands).





















































































Figure 2. Characteristics of transplant vasculopathy in renal allografts. (A) 
Artery with neointima in a renal allograft (Verhoeff staining [elastin: black; collagen: 
red]). Scale bar represents 50 μm. (B) Luminal obliteration due to neointima formation 
in renal allografts, isografts and non-transplanted control kidneys. (C) Smooth muscle 
cells (MYH11, red staining) in the neointima of renal allografts. Scale bar represents 
20 μm. (D) Laser microdissected neointima (upper photo) and medial (lower photo) 
layers. (E) Gene expression of Tgfβ1, Ctgf and Pdgfb in laser microdissected neointimal 
tissue normalized to their expression in medial tissue of non-transplanted control 
kidneys. Detection of (F) TGF-β1, (G) CTGF and (H) PDGF-B protein in the neointima. 
Scale bar represents 20 μm. IEL = internal elastic lamina; M = media; NI = neointima. 





Chronic transplant dysfunction after experimental renal trans-
plantation
We first confirmed the development of CTD in allograft recipients 
by renal function analysis and histological evaluation of the graft. 
Creatinine clearance was similar in allograft and isograft recipients 
before transplantation (2.7 ml/min [2.1 – 3.1 mL\l/min] (mean [range]) 
vs. 2.7 ml/min [2.3 – 2.8 ml/min], respectively) (Figure 1A). Eight 
weeks after transplantation, creatinine clearance in isograft recipients 
did not differ from pre-transplantation levels (2.1 ml/min [1.4 - 2.8 ml/
min]), whereas allograft recipients had significantly lower creatinine 
clearance rates compared with pre-transplantation levels and isograft 
recipients 8 weeks after transplantation (1.1 ml/min [0.9 - 1.6 ml/min]) 
(Figure 1A). In addition, allograft but not isograft recipients developed 
proteinuria as determined 8 weeks after transplantation (150 mg/
day [90 – 237 mg/day] vs. 18 mg/day [9 – 26 mg/day], respectively) 
(Figure 1B). 
Functional deterioration observed in allografts was accompanied 
by histopathological changes indicative of CTD, including interstitial 
fibrosis, glomerulosclerosis and TV (Figure 1C). Isografts developed 
some interstitial fibrosis as well, however, to a significantly lesser 
extent than allografts (Figure 1C), corroborating our previous 
observations (4). These histological changes were associated with 
significantly upregulated mRNA expression levels of fibrosis-related 
genes Tgfβ1 and Col1α1 in renal allografts compared to isografts and 
non-transplanted contralateral kidneys (Figure 1D).
Neointimal Tgfβ1, Ctgf and Pdgfb mRNA expression
TV in rat renal allografts developed neointima formation (Figure 
2A). Luminal occlusion of measured arteries in renal allografts was 
37% [range 7 - 88%], whereas luminal occlusion in isografts and 
non-transplanted kidneys was 15% [1 - 28%]) and 6% [0 - 11%], 
respectively. Luminal occlusion detected in non-transplanted control 
kidneys was comprised of endothelial cells covering the IEL and was 
considered as the basal surface intima (not shown). The neointima 
consisted predominantly of SMCs, as shown by expression of smooth 
muscle myosin heavy chain (MYH11, (13)) (Figure 2C). Staining for 
CD45 revealed only a few infiltrating leukocytes in the neointima (data 
not shown).
Since we previously showed donor origin of neointimal SMCs in this 
model we hypothesized that neointimal SMCs are derived from the media 
by migration and proliferation. To test whether the microenvironment 
within the arterial neointima and media in allografts support this 
hypothesis, we determined gene expression levels in the vascular 




































































































































































Figure 3. Microenvironment of laser microdissected medial tissues. The medial 
microenvironment was assessed by low-density arrays in laser microdissected media 
from allografts, isografts and non-transplanted control kidneys. (A-D) Gene expression 
of (A) Tgfβ1, (B) Ctgf, (C) Pdgfb and (D) Pdgfrb in laser-dissected medial tissue of 
allografts and isografts normalized to non-transplanted control medial tissue. (E-G) 
Protein expression of (E) TGF-β1, (F) CTGF and (G) PDGF B in arteries from a non-
transplanted control kidney, an isograft and an allograft. Scale bar represents 100 μm. 
IEL = internal elastic lamina; M = media; NI = neointima. Dotted line indicates the IEL. 




media and neointima using a low density array. Genes included in this 
array were associated with SMC phenotype, growth factors and their 
receptors and ECM molecules as summarized in Supplemental table 2. 
Medial and neointimal tissues were isolated using laser microdissection 
(Figure 2D) and processed for gene expression analysis. Per allograft, 
a mean of 74 (range 25 - 117) neointimae were microdissected (Table 
1). Medial tissue from a non-transplanted kidney (i.e., control medial 
tissue) contained fully differentiated contractile SMCs and was used 
for comparison. When compared with control medial tissue, SMCs in 
the allograft neointima displayed increased Tgf-β1 (~7 fold) and Ctgf 
(~2 fold) gene expression levels (Figure 2E). Both genes are known for 
their profibrotic actions (reviewed in (14)) which would stimulate SMC 
accumulation in the neointima. Furthermore, expression of Pdgfb was 
~27 fold upregulated in the neointima compared with control medial 
tissue (Figure 2E), suggesting that the neointimal microenvironment 
is capable of attracting SMCs to the neointima. PDGF-BB is known to 
act as a mitogen and chemoattractant for SMCs in intimal thickening 
(15). Due to a relatively high variation in neointimal gene expression 
levels between the different allografts, differences in gene expression 
levels between the neointima and control media were not statistically 
significant although marked differences were observed. Presence of 
Tgfβ1, Ctgf and Pdgfb mRNA transcripts in the neointima was confirmed 
at the protein level by immunohistochemistry (Figure 2F, 2G and 2H). 
TGF-β1 protein was mainly associated with neointimal SMCs close to 
the internal elastica lamina (Figure 2F), whereas CTGF and PDGF-B 
protein was distributed across the entire neointima (Figure 2G and 
2H). 
Increased medial Tgf-β1, Ctgf and Pdgfrb mRNA expression
In a healthy artery, medial SMCs are fully differentiated and have a 
contractile phenotype. In contrast, synthetic SMCs have a decreased 
expression of contractile proteins and show a high degree of proliferation 
and the ability to migrate, which can potentially lead to neointima 
formation (11). Since we found increased expression of profibrotic 
growth factors in the neointima (Figure 2E-G), we subsequently 
investigated whether the medial microenvironment is characterized by 
increased expression of profibrotic growth factors and growth factors 
known to induce phenotypic modulation of SMCs.
To this end we analyzed gene expression of Tgfβ1, Ctgf and Pdgfb 
in laser-microdissected medial tissue from iso- and allografts. Gene 
expression of Tgfβ1 and Ctgf was increased in medial SMCs in allografts 
compared to isografts and non-transplanted control kidneys (~7 fold 
(p < 0.01) and ~8 fold (p < 0.05), respectively) (Figure 3A and 3B). 
No differential expression of Pdgfb was observed in medial tissue from 
all groups (Figure 3C). However, gene expression of Pdgfrb was ~4 
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fold (p < 0.05) increased in the media of allografts when compared 
to isografts and non-transplanted control kidneys (Figure 3D). The 
increased mRNA expression of Tgfβ1 and Ctgf in the media of allografts 
was confirmed at the protein level (Figure 3E and 3F, respectively). 
TGF-β1 and CTGF protein expression were not detected in the media 
of non-transplanted kidneys and isografts (upper and middle panels, 
respectively in Figure 3E and 3F). In allografts, TGF-β1 expression 
was associated with SMCs at sites in the media adjacent to neointima 
formation. Protein expression of PDGF-B was similar in the media of 





















































































































































































Figure 4. Allograft medial SMCs are phenotypically modulated. Medial SMCs were 
characterized by low-density arrays in laser-dissected medial tissue from allografts, 
isografts and non-transplanted control kidneys. (A-F) Gene expression of (A) Sm22α, 
(B) Klf4, (C) Srf, (D) Myocardin, (E) Col1α1 and (F) Col4α1 in laser-dissected media of 
allografts and isografts normalized to laser-dissected non-transplanted control kidneys. 
Data are presented as mean ± SEM (n=5). *p < 0.05, **p < 0.01. Abbreviation: TX; 
transplantation.
Allograft medial SMCs are phenotypically modulated
Next, we investigated whether medial SMCs indeed switch to 
a synthetic phenotype after allogeneic transplantation. In non-
transplanted donor-type (DA) kidneys, medial SMCs had a relatively 
high gene expression of Sm22α (Figure 4A). Since the expression 
of Sm22α is required for modulation of vessel contractility (16), this 
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marker is indicative of a contractile SMC phenotype. In medial SMCs 
from isografts, Sm22α gene expression was reduced (~1.5 fold) but 
not significantly different compared with medial tissue from non-
transplanted control kidneys (Figure 4A). When compared to medial 
SMCs from non-transplanted control kidneys, expression of Sm22α 
was significantly reduced in allograft medial SMCs (~3 fold, p < 0.001) 
(Figure 4A). In line with the downregulation of Sm22α expression 
in the allograft media, Klf4, which is a transcription factor known 
to downregulate mRNA transcription of SMC genes such as Sm22α 
(17), was significantly increased (~8 fold, p < 0.05) in allograft medial 
SMCs compared to medial SMCs from isografts and non-transplanted 
kidneys (Figure 4B). We also investigated the expression of myocardin, 
a transcriptional co-activator for serum response factor (Srf), and Srf 
which regulate the expression of SMC differentiation genes (18). Gene 
expression of Srf and Myocardin was not altered in allograft medial 
SMCs compared to medial SMCs in isografts and non-transplanted 
control kidneys (Figure 4C and 4D). A hallmark of synthetic SMCs is 
the production of extracellular matrix components. In allograft medial 
SMCs the expression of the ECM molecules Col1α1 and Col4α1 was 
significantly increased (~8 fold and ~18 fold, respectively, both p < 0.05) 
compared with medial SMCs in isografts and non-transplanted control 
kidneys (Figure 4E and 4F). The question remains what the source is of 
PDGF-BB when there is no neointima formed yet. Therefore, a staining 
was performed for PDGF-B on isografts and allografts harvested 16 
days after transplantation. PDGF-B protein was found in the arterial 
media of allografts whereas the arterial media of isografts only showed 
relatively low expression of PDGF-B protein (Supplemental Figure S1).
PDGF-BB-induced synthetic rat aortic SMCs display reduced 
contractility in vitro 
To investigate whether synthetic SMCs display less contractility 
in vitro, we performed a collagen type 1 gel contraction assay. To 
induce phenotypic modulation, SMCs were stimulated with PDGF-BB 
and TGF-β1, growth factors of which the expression was increased 
within the neointima (Figure 3E). Rat aortic SMCs were prestimulated 
with PDGF-BB (20 ng/ml or 60 ng/ml) or TGF-β1 (5 ng/ml or 15 ng/ml) 
for 24 hours to induce phenotypic modulation followed by subsequent 
culture in a collagen gel allowing contractile function measurements. 
After one hour of stimulation with PDGF-BB (both 20 and 60 ng/ml), 
expression of Klf4 was increased ~2-3 fold (p < 0.001) compared with 
unstimulated and TGF-β1-stimulated SMCs (Figure 5A). Stimulation of 
SMCs with TGF-β1 did not upregulate gene expression of Klf4 (Figure 
5A). Stimulation of SMCs for 1 hour with either PDGF-BB or TGF-β1 did 
not affect gene expression levels of Srf and Myocardin (Figure 5B and 
5C). After 24 hours of stimulation with PDGF-BB, a significant decrease 
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Figure 5. PDGF-BB-induced phenotypically modulated rat aortic SMCs display 
reduced contractility in vitro. Rat aortic SMCs were stimulated with TGFβ1 and 
PDGF-BB. Unstimulated SMCs were used as control. (A-C) Gene expression of (A) Klf4, 
(B) Srf and (C) Myocardin after stimulation for 1 hour with TGF-β1 (5 ng/ml or 15 ng/
ml) or PDGF-BB (20 ng/ml or 60 ng/ml), normalized to unstimulated SMCs. (D-F) Gene 
expression of (D) α-Sma, (E) Sm22α and (F) Col1α1 after stimulation for 24 hours 
with TGF-β1 (5 ng/ml or 15 ng/ml) or PDGF-BB (20 ng/ml or 60 ng/ml), normalized to 
unstimulated SMCs. To investigate functional consequences of phenotypic modulation of 
SMCs, rat aortic SMCs were stimulated with PDGF-BB (20 ng/ml) after which SMCs and 
collagen I gels were admixed. (G) Collagen I gel contraction assay with unstimulated 
SMCs or SMCs prestimulated with PDGF-BB (20 ng/ml) or TFG-β1 (5 ng/ml). SMCs 
were allowed to contract for 24 hours in the presence of TGF-β1 or PDGF-BB. Data are 
presented as mean ± SEM (n=3). *p < 0.05, **p < 0.01, ***p < 0.001
Chapter 5
96
in gene expression of α-Sma and Sm22α was detected compared 
with unstimulated and TGF-β1-stimulated SMCs (Figure 5D and 5E). 
Stimulation with 60 ng/mL PDGF-BB resulted in a ~2 fold (p < 0.001) 
decrease in α-Sma gene expression compared with unstimulated and 
TGF-β1-stimulated SMCs. Stimulation with 20 ng/mL PDGF-BB resulted 
in a ~1.5 fold decrease (p < 0.01) in Sm22α gene expression, which was 
further reduced (~2 fold (p < 0.001) following stimulation with 60 ng/
mL PDGF-BB. Gene expression of α-Sma and Sm22α after stimulation 
with TGF-β1 (5 ng/ml and 15 ng/ml) was similar to unstimulated SMCs. 
Furthermore, stimulation of SMCs with PDGF-BB (both concentrations) 
led to increased gene expression of Col1α1 (~2 fold, p < 0.001), 
whereas stimulation with TGF-β1 did not have an effect (Figure 5F).
After stimulation for 24 hours, SMCs and collagen type 1 gels were 
admixed and cultured for an additional 24 hours in the presence of 
PDGF-BB (20 ng/ml) or TGF-β1 (5 ng/ml). Reduction of collagen gel 
size by contraction of unstimulated SMCs was 38 ± 4% (Figure 5G). 
Contraction of collagen gels by SMCs prestimulated with PDGF-BB 
was 30 ± 2%, which was significantly less compared to unstimulated 
SMCs (p < 0.05) (Figure 5G). SMCs prestimulated with TGF-β1 were 
able to contract the collagen gels by 53 ± 1% (Figure 5G), which 
was significantly more compared to either unstimulated or PDGF-BB-
stimulated SMCs (p < 0.001).
DISCUSSION
Neointima formation plays an important role in the pathogenesis of 
TV, restenosis and atherosclerosis. Neointima formation is the luminal 
narrowing of arteries by SMC accumulation which leads to downstream 
ischemic injury. For the development of new treatment modalities to 
attenuate TV, it is important to know the anatomical origin of neointimal 
SMCs and the molecular mechanisms that lead to the formation of 
TV. We recently showed in a rat kidney transplantation model that all 
neointimal SMCs were of graft origin (4). The results of the present 
study indicate that medial SMCs are phenotypically modulated during 
neointima formation after rat renal transplantation, and are the most 
likely source for neointimal SMCs in TV.
According to the response-to-injury hypothesis (7), medial SMCs 
migrate to the subendothelial intimal space in response to transplantation-
induced vascular injury, culminating in the formation of an occlusive 
neointima. Due to the lack of markers specific for differentiated medial 
SMCs, it is not (yet) feasible to investigate if medial SMCs are truly 
the anatomical origin of neointimal cells using lineage tracing. Medial 
SMCs can only contribute to neointima formation after a phenotypic 
switch from a contractile to a synthetic phenotype which is induced by 
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growth factors and cytokines produced in response to vascular injury 
(11). To investigate the neointimal microenvironment and presence 
of factors indicative of medial phenotypic modulation of SMCs after 
allogeneic kidney transplantation, we analyzed the gene expression 
profile in laser microdissected neointimal and medial tissue. Within the 
allograft neointima we observed enhanced gene expression of Pdgfb 
when compared with the normal (non-transplanted) vascular media. 
Enhanced expression of Pdgfb in the neointima was accompanied by 
increased expression of Pdgfrb in the allograft media. This raises the 
question what the source is of PDGF-BB when a neointima has not yet 
been formed. Protein expression analysis of PDGF-B in arteries without a 
neointima 16 days after transplantation showed the presence of PDGF-B 
in the media of allografts. This suggests that injury to medial SMCs 
shortly after transplantation induces the expression of endogenous 
PDGF-B which might contribute to initiation of SMC phenotypic 
modulation. PDGF-BB is well documented to act as a potent mitogen 
and chemoattractant for SMCs, leading to intimal thickening (19,20). 
PDGF-BB is also a known mediator of SMC phenotypic modulation (21). 
Our observations support a role of PDGF-BB in phenotype switching of 
medial SMCs after allogeneic transplantation resulting in subsequent 
chemoattraction to the developing neointima.
Phenotypically modulated SMCs are characterized by a decreased 
expression of SMC-specific proteins and show a high degree of 
proliferation and the ability to migrate. We found reduced expression 
of the SMC-specific gene Sm22α and increased expression of ECM 
molecules in medial SMCs from arteries with a neointima. Consistent 
with the downregulation of Sm22α, Klf4, a transcription factor known 
to downregulate mRNA transcription of SMC genes, was increased in 
allograft medial SMCs. To study whether this in vivo observation might 
be PDGF-BB driven, as PDGF-BB was highly expressed in the developing 
neointima, in vitro experiments using rat SMCs were performed. 
PDGF-BB indeed reduced the expression of Sm22α and α-Sma which 
was accompanied by increased Klf4 and Col1α1 expression indicating 
phenotypic modulation of SMCs. Stimulation with TGF-β1 did not induce 
phenotypic modulation of SMCs. KLF4 can repress myocardin-induced 
activation of SMC genes by selectively decreasing binding of SRF to 
DNA within intact chromatin (22). It is well established that virtually all 
SMC differentiation genes characterized to date are SRF/myocardin-
dependent (23). Our observations are in line with data reported by Yu 
et al. (24) who showed that stimulation of SMCs with PDGF-BB resulted 
in a downregulation of SM22α expression which was mediated via KLF4. 
Also KLF5 has been suggested to have a role in phenotype modulation 
of SMCs. However, we did not find any differences in Klf5 expression 
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Figure 6. Scheme illustrating the molecular mechanisms of NI formation after 
renal transplantation. (A) One of the histopathologic features of CTD after renal 
transplantation is the development of TV. (B) Luminal narrowing of TV by neointima 
formation is the result of SMC accumulation between the endothelial cells and the IEL. 
Profibrotic growth factors CTGF and TGF-β1 stimulate matrix production and are found 
in the neointima and media of arteries with TV. PDGF-BB is present in the neointima 
and may act as a chemoattractant for medial SMCs that express PDGFrβ. (C) Medial 
SMCs modulate their phenotype after transplantation-related injury and switch from 
a contractile to a synthetic phenotype, characterized by a lower expression of SMC 
genes. (D) In synthetic SMCs, KLF4 abrogates myocardin-induced expression of SMC 
genes such as SM22α.
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We thus demonstrate for the first time a potential role for KLF4 in 
phenotype switching of medial SMCs after transplantation-related injury. 
To further study whether PDGF-BB induced phenotypic modulation 
of SMCs resulted in reduced contractile function, in vitro collagen 
1 contraction assays with rat aortic SMCs were performed. SMCs 
stimulated with PDGF-BB showed indeed impaired contractile function 
when compared with unstimulated SMCs, whereas stimulation with 
TGF-β1 enhanced contractile function. The stimulating effect of TGF-β1 
on SMC contractility is probably unrelated to SMC phenotype as 
TGF-β1 is shown to induce activation of Rho-GTPase and subsequent 
contraction of SMCs without interfering with the phenotype of SMCs 
(25,26).
This is the first study showing an upregulation of Klf4 and a 
downregulation of Sm22α in medial SMCs after renal transplantation 
thereby indicating phenotypic modulation of medial SMCs during 
neointima formation. One of the questions that can be raised is at what 
time-point after allogeneic transplantation phenotypic modulation SMC 
is initiated. This knowledge will provide valuable information required 
for the design of interventional strategies to attenuate neointima 
formation using phenotypic modulation of SMC as a target. In addition, 
we need to know whether phenotypic modulation of medial SMCs in 
vivo is associated with the enhanced proliferation rather than migration 
or vice versa. To address this issue Ki67 stainings were performed, 
revealing only few proliferating neointimal and medial SMCs 12 
weeks after transplantation (data not shown). Neointima formation 
after transplantation-related injury seems to be more dependent 
on migration than enhanced proliferation of synthetic SMCs. The 
pathways involved in increasing Klf4 expression in our model needs to 
be determined but we propose an important role for PDGF-BB-induced 
signaling on medial SMCs. miRNAs might be involved as well as it has 
been shown that specific miRNAs (in particular miR-145) influence SMC 
phenotype by targeting KLF4 (27,28). Local perfusion with miR-145 
was indeed shown to reduce neointima formation after balloon injury 
(29). The potential role of miR-145 in the development of TV needs to 
be determined.
Based on the data described in this study we propose the following 
cascade of events leading to the development of TV in renal allografts 
(illustrated in Figure 6). Medial SMCs in renal allografts have increased 
expression of growth factors leading to ECM deposition and subsequently 
fibrosis. Furthermore, medial SMCs modulate their phenotype after 
transplantation-related injury and switch from a contractile to a 
synthetic phenotype, which is characterized by a reduced SM22α and 
increased KLF4 and ECM expression. PDGF-BB, which is expressed in 
the developing neointima, may act as a chemoattractant for medial 
SMCs that express PDGFrβ. Phenotypically modulated medial SMCs will 
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migrate into the subendothelial intimal space followed by proliferation, 
culminating in the formation of an occlusive neointima.
In conclusion, our results indicate that in a rat model for CTD after 
renal transplantation, medial SMCs phenotypically modulated and are 
the most likely source for neointimal cells. Prevention of phenotypic 
modulation of medial SMCs may provide a novel strategy to reduce 
occlusive neointima formation, including transplant vasculopathy.
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Inbred female (175 – 210 gram) and male (200 – 225 gram) Dark 
Agouti (DA) rats were obtained from Harlan (Horst, the Netherlands) 
and inbred male Wistar Furth (WF) rats (240 – 295 gram) from 
Charles River Laboratories Inc. (l’Arbresle, Cedex, France). Animals 
were handled in compliance with the Principles of Laboratory Animal 
Care (NIH Publication No. 86-23, revised 1985), the University of 
Groningen guidelines for animal husbandry (University of Groningen, 
the Netherlands), and the Dutch Law on Experimental Animal Care.
Kidney Transplantation
Female DA kidneys were orthotopically transplanted into male DA 
or WF recipients. Donor rats were anesthetized with isoflurane/O2, and 
left kidneys were flushed in situ with saline and removed. The donor 
rats were then killed by exsanguination, warm ischemia time varied 
between 0 to 15 min. Kidneys were preserved in ice-cold saline (range 
16-38 min) and then transplanted into the recipient from which the left 
kidney was removed under isoflurane/O2 anesthesia. The graft renal 
vein, artery, and ureter were anastomosed end-to-end to the recipients’ 
left renal vein, artery, and ureter, respectively, using 10-0 prolene 
sutures. Vascular clamps were released after a warm ischemia time of 
25 to 30 min. Both adrenal glands of the recipient remained in situ. All 
transplanted rats were given buprenorphine (Temgesic; 0.01 mg/kg) 
subcutaneously directly after transplantation and for 8–10 h and 24 h 
after transplantation for pain relief. Recipients received cyclosporine 
A (5 mg/kg bodyweight) (Sandimmune, Novartis, the Netherlands) 
subcutaneously during the first 10 days after transplantation. The 
recipients contralateral kidney was removed 8 to 14 days after 
transplantation. Total follow-up was time 12 weeks unless animals had 
to be sacrificed earlier due to graft failure. 
Laser Dissection Microscopy and Gene Expression Analysis
Frozen kidneys were sectioned at 9 µm and mounted on UV-
pretreated slides (PALM Micro Laser Technology, Bernried, Germany). 
Sections were fixed in acetone and air-dried. Sections were 
subsequently stained with Mayer’s hemalum (Merck, Darmstadt, 
Germany) and rinsed in diethyl pyrocarbonate (DEPC)-treated tap 
water. Slides were then used for laser dissection microscopy using a 
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Leica Microdissection System (Leica Microsystems). The neointima and 
media were separately dissected from nine serial sections per kidney. 
Total RNA was isolated from microdissected vascular structures using 
the RNeasy Micro Kit (Qiagen, Hilden, Germany). Reverse transcription 
was carried out using Superscript III reverse transcriptase (Invitrogen, 
Breda, the Netherlands) and random hexamer primers (Promega, 
Leiden, the Netherlands). Gene expression was analyzed with a 
custom made microfluidic card-based low density array (Table 2, full 
manuscript) using the ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands). Micro 
fluidic cards consists of 384 wells pre-loaded with oligos including 3 
endogenous controls, for high-throughput, low reaction volume, real-
time PCR. For each micro fluidic card, 10 μl cDNA was diluted in 40 μl 
of double distilled water and mixed with 50 μl of Taqman PCR master 
mix (Applied Biosystems). Standard recommended PCR protocols were 
performed (50°C for 2 minutes, 94.5°C for 10 min, 97°C for 30 s, 
59.7°C for 1 min, with steps 3 and 4 repeated for 50 cycles). Relative 
mRNA levels were calculated as 2−ΔCT, in which ΔCT is CTgene of interest – CTβ-
actin. CT values that were below detection level were set at 50.
For gene expression analysis of cultured rat aortic SMCs, total RNA 
was isolated after 24 hours of stimulation with PDGF-BB or TGF-β1 
(PreproTech EC LTD. London, UK) using the RNeasy Micro Kit (Qiagen 
Inc., CA, USA). Subsequently, 1 μg of total RNA was reverse transcribed 
using the FirstStrand cDNA synthesis kit (Fermentas UAB, Lithuania). 
Real time RT-PCR analysis was performed in a final reaction volume of 
10 μl, consisting of 4.5 μl SYBR Green Supermix (Bio-Rad, Veenendaal, 
The Netherlands), 0.5 μl primer-mix (Table 3, 0.5 mmol/l), and 5 μl 
cDNA (1 ng/μl) using the ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems, the Netherlands). Reactions were performed at 
95°C for 15s, 60°C for 30s, and 72°C for 30s, for 40 cycles. Relative 
mRNA levels were normalized against β-actin expression as described 
above.
Immunohistochemistry
Immunohistochemistry was performed on 2 µm paraffin sections. 
Sections were stained for Masson’s trichrome, Verhoeff-van Gieson, 
TGF-β1, CTGF , PDGFB and MYH11. Sections were dewaxed and 
antigen retrieval was performed for TGF-β1 and PDGFB staining by 
incubation in 0.1 M citric acid buffer for 8 minutes in a microwave. 
Endogenous peroxidase was blocked with 0.1% H2O2 for 10 min at room 
temperature. Sections were incubated for 1 h with primary antibodies 
i.e. rabbit anti TGF-β1 (Santa Cruz, Heidelberg, Germany), rabbit anti 
CTGF (Santa Cruz, Germany), rabbit anti PDGFB (Abcam, Cambridge, 
UK) or rat anti MYH11 (Abnova, Heidelberg, Germany). Goat anti 
rabbit-horseradish peroxidase (HRP), rabbit anti goat-HRP, Goat anti 
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rabbit-biotin, rabbit anti goat-biotin and rabbit anti rat-HRP conjugates 
were used as secondary antibodies. Detection of biotinylated antibody 
complex was done by incubation with a streptavidin-HRP conjugate. 
Color development was performed with 3-amino-9-ethylcarbazole 
substrate dissolved in N,N-dimethylformamide and 0.5 M acetate 
buffer (pH 4.9) or with 3,3′-diaminobenzidine tetrachloride. Sections 
were counterstained with Mayer’s hemalum (Merck) and mounted in 
Kaiser’s glycerol gelatin (Merck).
The degree TV (i.e. obliteration in arteries) was measured in all 
arteries within a section with a clearly visible internal elastic lamina 
(IEL) in the Verhoeff-van Gieson stained sections. The total surface 
area lying at the luminal side of the IEL (lumen + neointima), was 
measured and set at 100%. Subsequently, the luminal area was 
subtracted from this total area, to obtain the neointimal area. Luminal 
occlusion was expressed as mean percentage ± SEM. Arteries cut 
diagonally, i.e. arteries with a compressed lumen, were excluded from 
this measurement.
Collagen gel contraction assay
Gel contraction assay of 3D collagen gels were performed using a 
solution of rat tail collagen I (BD Bioscience, Breda, the Netherlands). 
Rat aortic SMCs(passage 3) were cultured for 24 hours in medium 
containing 2% FCS (Lonza Benelux BV, Breda, The Netherlands) and 
subsequently stimulated for another 24 hours with PDGF-BB or TGF-β1 
in the presence of 2% FCS. Prestimulated SMCs were resuspended 
in a mixture of collagen I, 10X DMEM, 1.5 mg/ml NaHCO3 and 25 
mmol/l HEPES at a concentration of 3.0 × 106 cells/ml. Aliquots of 50 
μl (containing 50,000 cells and 0.25 mg collagen type I) were added 
to a 96 wells plate, that had been preincubated with 0.1% BSA, and 
allowed to solidify at 37°C in a humidified incubator with 5% CO2 for 1 
hour. After solidification, collagen gels were further cultured in DMEM/
F12 (Lonza) containing 2% FCS with or without additionally added 
PDGF-BB or TGF-β1 (PreproTech EC LTD. London, UK). SMCs and 
SMCs embedded in collagen gels were cultured in the presence of 2% 
FCS since we needed to have a basal condition in which spontaneous 
contraction still is present, as in the absence of FCS no spontaneous 
SMC-mediated collagen gel contraction occurs. Collagen gels were 
imaged using a common flatbed-scanner (ScanJet 5370C; HP, CA, 
USA) and gel contraction was measured after 24 hours. The degree of 
gel contraction was determined by dividing the total gel area before 
contraction (i.e. surface area of a 96 well) by the gel area after 24 
hours of contraction.




Table 1. Characteristics of arteries collected by laser dissection microscopy
Number of arteries 
collected per animal 
(n=5)
NI surface area (μm2) 
mean [range]
Media surface area 
(μm2) mean [range]
Allograft kidneys 74 [25–117] 1,092,834 [136,748-3,961,874]
1,064,410 
[239,821-3,607,250]
Isograft kidneys 46 [37-52] NP 596,368 [338,924-913,221]
Contralateral 





Table 2. Composition of low-density array
Gene name General name Gene symbol Assay ID
Smooth muscle phenotype
calponin 1, basic, smooth muscle Calponin 1 Cnn1 Rn00582058_m1
krüppel-like factor 4 KLF4 Klf4 Rn00821506_g1
krüppel-like factor 5 KLF5 Klf5 Rn00821442_g1
myocardin Myocardin Mycd Rn01786178_m1
serum response factor Srf Srf Rn01757240_m1
transgelin SM22α Tagln Rn00580659_m1
Growth factors and receptors
connective tissue growth factor CTGF Ctgf Rn00573960_g1
platelet-derived growth factor beta 
polypeptide PDGFB Pdgfb Rn01502596_m1
platelet derived growth factor receptor, 
beta polypeptide PDGFRb Pdgfrb Rn00709573_m1
transforming growth factor, beta 1 Tgf-b1 Tgfb1 Rn01475963_m1
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Table 2. Composition of low-density array
Matrix molecules
collagen, type I, alpha 1 Collagen I Col1a1 Rn01463848_m1
collagen, type IV, alpha 1 Collagen IV Col4a1 Rn01482925_m1
Reference genes
ß-actin Beta-actin Actb Rn00667869_m1
ß2-microglobulin B2m B2m Rn00560865_m1
Eukaryotic 18S rRNA 18S 18s Hs99999901_s1
cadherin 5 VE-cadherin Cdh5 Rn01536708_m1
Table 3. Primer sequences used for real-time RT-PCR






























Supplemental Figure 1. Expression of PDGF-B in the media of isografts and 
allografts 16 days after transplantation. Protein expression of PDGF-B was 
assessed in the media from allografts and isografts 16 days after transplantation. 
Polyclonal rabbit IgG replaced the PDGF-B antibody and was used as a negative control. 
Scale bar represents 100 μm. M = media. 
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RENAL HEPARAN SULFATE PROTEOGLYCANS 







Depending on the glycan structure, proteoglycans can act as co-
receptors for growth factors thereby contributing to cell survival, 
proliferation and fibrosis. Chronic transplant dysfunction is characterized 
by extensive fibrotic tissue remodeling including glomerulosclerosis and 
neointima formation in arteries. We hypothesize that proteoglycans 
and their growth factor ligands orchestrate tissue remodeling in chronic 
transplant dysfunction. 
Methods
Therefore, in a rat renal transplantation model, we studied 
proteoglycan and growth factor expression in glomeruli, arterial 
mediae and neointimae by qRT-PCR and immunofluorescence. To this 
end, laser microdissection of glomeruli, arterial mediae and neointimae 
followed by low density qRT-PCR was performed.
Results
Uniform upregulation of collagen I, IV, and Tgf-β1 in the allografted 
kidneys was observed. However, spatial differences in proteoglycan 
expression and ligand binding properties were detected. In glomeruli 
and neointimae of allografts we found induction of the matrix heparan 
sulfate proteoglycan perlecan along with massive accumulation of 
FGF2. Profiling the heparan sulfate polysaccharide side chains of renal 
heparan sulfate proteoglycans revealed conversion from a non-FGF2-
binding heparan sulfate phenotype in control and isografted kidneys 
towards a FGF2-binding phenotype in allografts. Both perlecan and 
FGF2 could be demonstrated in human allografts as well. The functional 
significance of these findings was evidenced by in vitro experiments 
with perlecan-positive rat mesangial cells showing that FGF2-induced 
proliferation is dependent on sulfation and can be inhibited by 
exogenously added heparan sulfate.
Conclusion
These data indicate that heparan sulfate proteoglycans such 
as perlecan serve as docking platforms for FGF2 in various renal 
compartments in chronic transplant dysfunction. We speculate that 
heparin-like glycomimetica could be a promising intervention to retard 
development of chronic transplant dysfunction.




Renal chronic transplant dysfunction (CTD) is the leading cause of 
long-term loss of transplanted kidneys (1,2). CTD is the result of tissue 
remodeling in the intrarenal arteries, glomeruli and tubulointerstitium 
leading to transplant vasculopathy, focal glomerulosclerosis (FGS), 
interstitial fibrosis and tubular atrophy (2-4). These lesions are 
characterized by accumulation of extracellular matrix, activation of 
mesangial cells, interstitial myofibroblasts and tubular epithelial cells, 
and chronic inflammation. To date, due to the lack of knowledge on 
the pathogenetic mechanisms leading to the development of these 
lesions, no effective therapies are available to prevent or treat renal 
CTD. Progressive loss can only be retarded by anti-hypertensive and 
anti-proteinuric treatment in combination with lipid lowering drugs.
Recently, we showed accumulation of the heparan sulfate 
proteoglycans (HSPGs) collagen type XVIII and perlecan during tissue 
remodeling in CTD in rats (5). However, whether and how these 
proteoglycans mediate tissue remodeling in CTD is as yet unknown. In 
native kidney diseases and ischemia-reperfusion injury we have already 
shown that HSPGs are involved in leukocyte influx and proteinuria-
mediated renal injury (6-8).
The carbohydrate side chains (i.e. the glycosaminoglycans) 
are attached to proteoglycan core proteins and can bind a variety 
of ligands depending on their highly variable composition, mainly 
variations in N- and O-sulfation patterns (9). Along with chondroitin 
sulfate- and dermatan sulfate proteoglycans, HSPGs form the large 
majority of the proteoglycan family. Potential ligands are chemokines 
(9) and growth factors such as basic fibroblast growth factor (bFGF/
FGF2; 10,11). Proteoglycans are highly involved in morphogenesis and 
tissue remodeling processes (12-17).
Studies in non-transplantation models of renal and vascular disease 
have shown potential roles of FGF2 in FGS and neointima formation 
(18-22). These data led us to hypothesize that interaction of FGF2 
with proteoglycans also affects tissue remodeling processes in CTD. 
To test this hypothesis we used an experimental rat CTD model, from 
which we microdissected glomeruli, the arterial media as well as the 
neointima followed by low density qRT-PCR analysis for matrix and cell 
surface proteoglycans and FGF2. In addition, we profiled the heparan 
sulfate (HS) polysaccharide side chains by anti-HS mAbs and their 
binding capacity for FGF2 and L-selectin. Functionally, we investigated 
the HSPG involvement of FGF2-driven mesangial proliferation. In a 
translational approach we evaluated HSPG and FGF2 expression in 
human CTD kidneys. Our data indeed indicate spatial proteoglycan 




MATERIALS AND METHODS 
Rats 
Inbred female (175-210 gram) Dark Agouti (DA) rats were obtained 
from Harlan (Horst, The Netherlands) and inbred male Wistar Furth 
(WF) rats (240-295 gram) from Charles River Laboratories Inc. 
(l’Arbresle, Cedex, France). All animals received care in compliance 
with the Principles of Laboratory Animal Care (NIH Publication No.86-
23, revised 1985), the University of Groningen guidelines for animal 
husbandry and the Dutch Law on Experimental Animal Care. 
Kidney transplantation and experimental groups
Female DA kidney allografts were orthotopically transplanted into 
male Wistar Furth recipients as described previously (5,23). Cold 
ischemic time ranged from 16 to 38 minutes. Warm ischemic time 
ranged from 19 to 32 minutes. Recipients received cyclosporine A (5 
mg/kg bodyweight) (Sandimmune, Novartis, Arnhem, the Netherlands) 
subcutaneously for 10 days posttransplantation. The native kidney was 
removed after 8 to 14 days. Total follow-up was 12 weeks or shorter in 
case animals had to be sacrificed due to renal failure. Allografts used 
in this study had developed severe CTD (n=5). Further characteristics 
of the model are described elsewhere (5,18). Non-transplanted DA 
kidneys (n=5) and DA to DA isografted kidneys (n=5) served as 
controls.
Human renal CTD and control tissue
Four human CTD explants were selected based on graft survival 
time (mean three years), and histologically proven interstitial fibrosis / 
tubular atrophy (IFTA) eventually with some interstitial inflammation. 
Mean donor age at time of donation was 49 years, recipients being 
2 males and 2 females on regular immunosuppressive medication. 
Control renal tissue was from patients with a kidney tumor. Healthy 
parts of these explanted kidneys (IFTA and interstitial inflammation 
<5%) were used. Mean age of these patients was 40 years, one male, 
two females.
Laser Microdissection and Gene Expression Analysis
Laser microdissection, RNA isolation and qRT-PCR were performed 
essentially according to Asgeirsdottir et al. (39). Briefly, frozen kidneys 
were sectioned at 9 µm and mounted on UV pretreated slides (PALM 
Micro Laser Technology, Bernried, Germany). Sections were quickly 
fixed in acetone and air-dried for 3 min. Sections were subsequently 
stained with Mayer’s hematoxylin (Merck, Darmstadt, Germany) for 
1 min and rinsed in diethyl pyrocarbonate (DEPC) treated tap water 
for 20 s. Slides were then used for microdissection using the Leica 
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Microdissection microscope (Leica Microsystems, Houston, Texas). 
Glomeruli and various layers (including media and neointima) of larger 
arteries were separately dissected from 9 serial sections per kidney. 
An average of 194 [range 71 - 308 ] glomeruli and 63 [range 25 - 117] 






























































































































50 µm 50 µm 50 µm
50 µm 50 µm 50 µm
Figure 1. Chronic transplant dysfunction in renal allografts. A: Representative 
photomicrographs showing development of glomerulosclerosis in alA: Representative 
photomicrographs showing development of glomerulosclerosis in allografted kidneys, 
in contrast to isografted and control kidneys (upper row; PAS staining). Neointima 
formation was observed in allografts but not in isografts and controls (lower row, 
Verhoeff staining). Scale bar represents 50 µm. B: qRT-PCR analysis performed on 
RNA isolated from microdissected glomeruli from non-transplanted control tissue, 
isografts and allografts (n=5/group). Expression levels of ColIVα1, ColIIα1 and Tgf-β1 
are expressed relative to the expression level of β-actin. ** p<0.01 vs. isografts and 
non-transplanted control tissue. Abbreviations:: IEL: internal elastic lamina, M: media, 
A: adventitia, NI: neointima
Total RNA was isolated from microdissected structures by using the 
RNeasy Micro Kit (Qiagen, Hilden, Germany). Reverse transcription 
was carried out using Superscript III reverse transcriptase (Invitrogen, 
Breda, the Netherlands) and random hexamer primers (Promega, 
Leiden, the Netherlands). Gene expression was analyzed with a custom 
made microfluidic card-based low density array (Applied Biosystems, 
Nieuwerkerk a/d IJssel, the Netherlands) using the ABI Prism 7900HT 
Sequence Detection System (Applied Biosystems, Nieuwerkerk a/d 
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IJssel, the Netherlands). Composition of the low density array is 
indicated in Supplemental Table 1. Relative mRNA levels were calculated 
as 2−ΔCT, in which ΔCT is CTgene of interest – CTβ-actin. CT-values that were 
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Figure 2. Upregulation of perlecan in glomeruli and neointimae of renal 
allografts with CTD. A-C. Perlecan expression measured by qRT-PCR in glomeruli 
(n=5/group) (A), arteries (n=5/group) (B), and whole kidney tissue (n=3/group) (C). 
Expression levels of perlecan are expressed relative to the expression level of β-actin. 
** p<0.01 vs. isografts and non-transplanted control tissue. D: Immunofluorescence 
demonstrating perlecan accumulation in glomeruli (left column) and neointimae (right 
column) of allografts with CTD. In isografted kidneys a minor increase of perlecan was 
seen in glomeruli and arterial media compared to control tissue. Dotted line represents 
the internal elastic lamina. Scale bar represents 50 µm.
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Immunofluorescence on rat kidney sections 
Four µm frozen sections were fixed in acetone or 4% formaldehyde 
and were blocked for endogenous peroxidase activity with 0.03% H2O2 
if appropriate. Sections were blocked with normal goat or rabbit serum. 
Sections were incubated for 1h with the following primary antibodies: 
mouse anti-human FGF2 (Peprotech, London, UK), mouse anti-HS 
mAb JM-403, which recognizes low sulfated heparan sulfate domains 
with N-unsubstituted glucosamine residues (25), mouse anti-HS stub 
mAb 3G10 (epitope becomes expressed after heparitinase I digestion 
of HS; Seikagaku, Tokyo, Japan; ref. 26) and mouse anti-rat perlecan 
(clone10B2 kindly provided by Prof. dr. J.R. Couchman, Copenhagen, 
Denmark). Binding of primary antibodies was detected by incubating 
the sections for 30 min with secondary antibodies diluted in PBS with 
5% normal rat serum: goat anti-mouse IgG1 HRP (Southern Biotech, 
Birmingham, AL, USA), rabbit anti-mouse IgM HRP (DAKO, Heverlee, 
Belgium,), or goat anti-mouse IgG1 Alexa488 (Invitrogen-Molecular 
Probes, Breda, the Netherlands). HRP-activity was visualized using 
the TSATM Tetramethylrhodamine System (PerkinElmer LAS Inc.). All 
fluorescence microscopy was performed using a Leica DMLB microscope 
(Leica Microsystems, Rijswijk, the Netherlands) equipped with a Leica 
DC300F camera and Leica QWin 2.8 software.
Ligand binding assays on rat kidney sections 
To detect capacity of renal proteoglycans to bind FGF2, formalin-
fixed rat renal sections were incubated with recombinant human FGF2 
(Peprotech) for 60 min. After washing, the staining was continued 
according to the FGF2 staining protocol described above. Formalin 
fixation essentially avoids recognition of endogenous renal FGF2 by 
anti-FGF2 antibodies. To confirm that the observed binding pattern 
was mediated by HS proteoglycans, the sections were pretreated 
with 0.05 U/ml heparitinase I (Flavobacterium heparinum, EC 4.2.2.8; 
Seikagaku, Tokyo, Japan) for 1h at 37°C in a humidified chamber.
FGF2 binding assays in ELISA
In an ELISA approach we evaluated the capability of fluid phase 
HS-like polysaccharides to compete for the interaction of recFGF2 
with immobilized perlecan. To this end maxisorp 96-wells plates (U96 
from VWR International, Amsterdam, The Netherlands) were coated 
overnight in PBS with 5 µg/ml perlecan (Sigma). After washing in PBS 
with 0.05% Tween 20, wells were blocked with 5% skimmed milk 
powder in Tris buffered saline (TBS) for 1 h. In a separate microtiter 
plate, recFGF2 (0.5 µg/ml) was incubated for 30 min with a dilution 
range of different HS-like polysaccharides (see below) and transferred 
to the ELISA plate after the wells were washed again. Incubation in the 
wells took 1 h. The wells were washed again and monoclonal mouse 
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anti-FGF2 antibodies were added to the wells (0.5 µg/ml TBS-Tween 
20). Secondary antibody was added after a washing step (HRP-labeled 
rabbit anti-mouse IgG, 1:5000; DAKO, Glostrup, Denmark). Secondary 
antibody was detected with 3,3’,5,5’-tetramethylbenzidine substrate 
(Sigma) for 15 min in the dark, and the reaction was stopped by adding 
1.5 N H2SO4. Absorbance was measured at 450 nm in a microplate 
reader. All incubations were done in a volume of 100 µl/well at RT. 
Polysaccharides used in the FGF2 competition ELISA were: heparin 
from porcine intestinal mucosa (Sigma), HS from bovine kidney 
(Seikagaku, Tokyo, Japan), N-sulfation of HS from bovine kidney was 
done as described before (8), N- and O-desulfation of heparin from 
porcine intestine was done as described before (8). HS from human 
aorta was isolated essentially accoriding to Iverius (41). HS from EHS 
sarcoma was from Seikagaku (Tokyo, Japan).
In order to evaluate FGF2 binding by perlecan from renal lysates a 
different ELISA approach was followed. Maxisorp 96-wells plates were 
coated overnight with monoclonal mouse anti-rat perlecan antibody 
(mAb 10B2 from John Couchman, Copenhagen, Denmark; 1:1000 in 
PBS). Wells were washed with TBS and blocked with 5% skimmed milk 
powder in TBS for 1 h. After washing the wells were incubated by a 
2-step dilution range of rat renal lysates containing perlecan (100 mg 
tissue/ml RIPA-buffer, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM 
Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM 
sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 μg/
ml leupeptin  ), starting in a 1:20 dilution in TBS + 1% skimmed milk 
powder. After appropriate washing with TBS-T, wells were incubated 
with recFGF2 (0.5 µg/ml) in 1% skimmed milk powder TBS buffer for 1 
h. After washing, wells were now incubated with biotinylated anti-FGF2 
mAb (clone JKFb-2 from Novus Biologicals, Cambridge, UK.; 1 µg/ml 
TBS-T), followed by HRP-conjugated streptavidin, 1:5000 in TBS-T. 
Substrate reaction and plate reading was as described above.
FGF2 stimulation assay on rat mesangial cells 
Rat mesangial cells (Thy 1.1 and α-smooth muscle actin positive, 
passage 11-15) were cultured in 24 well plates in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 25 mM HEPES, 4.5 mg/ml 
glucose, pyridoxine, 1 mM pyruvate, 50 ng/ml insulin, and 10% fetal 
bovine serum. Before stimulation with FGF2 cells were grown until 
confluency, serum deprived (0.5% serum) for 24 h and subsequently 
incubated with different concentrations (0.031 – 8 ng/ml) of FGF2 for 
24 h. Proliferation was measured by adding 0.5 µCi/ml 3H-thymidine 
(Amersham, Buckinghamshire, UK) for 24 h to the cultures. After 24 
h, 5% trichloric acid precipitable material was dissolved in 0.1% SDS, 
Optiphase “HiSafe 3” was added and radioactivity was counted in a 
1214 Rackbeta liquid scintillation counter. To study whether FGF2-




































































































































































































































































































































































































































































































Figure 3. Proteoglycan mRNA expression profiles in microdissected glomeruli 
(A.1-E.1), arteries (A.2-E.2) and total kidney lysates (A.3-E.3) of non-
transplanted control tissue, isografts and allografts with CTD. Expression of 
syndecan-1 (A), syndecan-4 (B), agrin (C), biglycan (D) and versican (E) was analyzed 
using qRT-PCR (glomeruli and arteries: n=5/group; whole kidney, n=3/group). 
Expression levels of the respective genes are expressed relative to the expression level 
of β-actin. Transcripts for the various proteoglycans were adjusted for the expression 
of β-actin. * p<0.05 vs. isografts and non-transplanted control tissue.
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induced proliferation of mesangial cells was reduced in the presence of 
exogenous HS, mesangial cells were stimulated with 0.5 ng/ml FGF2 
for 24 hours in the presence of various concentrations (0, 8, 32 and 
128 µg/ml) exogenous HS from bovine kidney [HSBK] (Seikagaku, 
Tokyo, Japan). Proliferation was measured as described above. To 
study whether proteoglycan sulfation was reduced by chlorate, 
mesangial cells were cultured for 24 h in the presence of various 
concentrations (5-25 mM) Na-chlorate (Sigma) and 35S-sulfate (2 µCi/
ml; Amersham, Buckinghamshire, UK). Incorporation of 35S-sulfate 
into proteoglycans was quantified similarly as described above for 
3H-thymidine incorporation. Finally, to analyze whether chlorate impairs 
FGF2-induced proliferation of mesangial cells, cells were stimulated 
with FGF2 (0.5 ng/ml) for fixed times (0, 0.5, 1, 2, 4 and 24 h) in the 
presence or absence of 25 mM Na-chlorate and in the presence of 0.5 
µCi/ml 3H-thymidine. Total culture time was 24 h. Proliferation was 
determined as described above.
Statistics 
mRNA expression levels were analyzed using a one-way ANOVA with 
Turkey’s posthoc test. P values of < 0.05 were considered statistically 
significant (SPSS® software package). Mesangial cell culture data 
were expressed as mean ± standard error of the mean (SEM) and 
analyzed by one-way ANOVA. If overall p < 0.05, Bonferroni’s Multiple 
Comparison Test was performed (GraphPad Prism 5.0, GraphPad 
Software, Inc.).
RESULTS
Development of chronic transplant dysfunction in renal al-
lografts
Progressive renal function loss was evidenced in the allografted 
kidneys by a ~50% loss in creatinine clearance and a ~15-fold rise 
in urinary protein excretion at 8 weeks after transplantation, both of 
which were not observed in isografted kidneys, as we showed before 
in this model (5,23). The rat renal allografts showed development of 
severe CTD with FGS and arterial neointima formation (Figure 1A). 
In isografts, development of FGS was minimal and no neointima 
formation was observed (5,23). The development of FGS coincided with 
significantly increased expression of the pro-fibrotic factors Col1α1, 
ColIVα1 and TGF-β1 as determined by qRT-PCR on microdissected 
glomeruli (Figure 1B). These molecular responses were also observed 
in RNA isolated from microdissected arterial medial and neointimal 
tissue as well as in whole kidney material (not shown). These data 
confirm development of CTD in our rat transplantation model.
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Figure 4. Modification of glomerular HS structure in allografts with CTD. 
Glomerular expression of HS was evaluated by two anti-HS mAbs (JM-403 [A] and 3G10 
[B]) as well as by the binding of FGF2 (C) and L-selectin (D). In allografts, glomerular 
JM-403 staining is partly lost in sclerotic areas (A.3 arrows). This is evidenced by loss 
of JM-403 staining in PAS-positive sclerotic area (A.5). On the contrary HS expression 
as evidenced by 3G10 (B.3) and FGF2 binding capacity (C.3) was increased in glomeruli 
in allografts. L-selectin did not bind to glomerular HS of control (D.1), isografted (D.2) 
or allografted (D.3) kidneys, although HS in Bowman’s capsule and tubular basement 
membranes did bound L-selectin. Blanks represent staining of allograft renal tissue 
without anti-HS mAb (A.4 and B.4) or ligand binding assay without incubation with FGF2 
(C.4) or L-selectin (D.4). Blanks are shown in a double staining with DAPI to visualize 
the nuclei of renal material. Dotted line represents Bowmans capsule. Arrows indicate 
sclerotic area. Scale bars represent 50 or 100 µm (indicated in the photo’s).
Induction of glomerular and neointimal perlecan expression in 
CTD
Proteoglycans can modulate growth factor responses by virtue 
of their glycosaminoglycan side chains. Therefore, we profiled the 
matrix HS proteoglycans agrin and perlecan, the matrix chondroitin 
sulfate- and dermatan sulfate proteoglycans versican and biglycan, 
and the major epithelial cell surface proteoglycans syndecan-1 and 
-4 by qRT-PCR. PCR analysis showed the expression of the basement 
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membrane HSPG perlecan to be upregulated mainly in the glomeruli 
(Figure 2A), and mediae and neointimae (Figure 2B) of the allografts. 
This spatial upregulation of perlecan by qRT-PCR in glomeruli, mediae 
and neointimae was however not observed when performing qRT-PCR 
analysis on whole kidney RNA isolates (Figure 2C), which clearly stresses 
the power, and need, of using microdissection of specific structures 
to demonstrate differential proteoglycan expression in specific renal 
compartments. Using immunofluorescence, expression of perlecan 
was virtually absent in the glomerular basement membranes of non-
transplanted control kidneys. In the glomerular basement membranes 
of isografts, perlecan expression was increased compared with control 
kidneys, but to a far lesser extent than the increase observed in 
allografts (Figure 2D, left column). In glomeruli with FGS in allografts a 
strong expression of perlecan was observed in the glomerular basement 
membranes and mesangial areas (Figure 2D, left column). In control 
tissue, isografts and allografts the Bowmans capsule was positive for 
perlecan. Immunofluorescence also showed perlecan expression in the 
mediae and the newly-formed neointimae present in allografts (Figure 
2D, right column). No significant differences in expression levels were 
found for syndecan-1 and -4, agrin, and biglycan, although these 
proteoglycans were expressed in the neointimae based on qRT-PCR 
data (Figure 3A-E). Versican expression was significantly upregulated 
in the media of the allografted kidneys (Figure 3E.2), which is in line 
with a pro-migratory phenotype of the vascular smooth muscle cells. 
This proteoglycan profiling led us to conclude that glomerular and 
neointimal perlecan is upregulated in renal allografts at both the mRNA 
and protein level.
3G10 allograft
50 µmA B 50 µm C 50 µm
Perlecan allograft Merge
Figure 5. Perlecan and 3G10 HS co-localize in glomeruli of allografted kidneys. 
In a double immunofluorescent staining protocol, perlecan (A) and HS (B; evidenced by 
mAb 3G10) stained identical structures in the glomerulus, namely Bowman’s capsule, 
the thickened glomerular basement membranes and enlarged mesangial matrix (see C 
for merged photo’s). MAb 3G10 also stained some tubular basement membranes which 
were barely perlecan positive, and most likely recognized HS bound to agrin and/or 
collagen XVIII. Scale bars represent 50 µm.




Since HS proteoglycans are involved in morphogenesis and tissue 
remodeling mainly by their HS glycosaminoglycan side chains, we 
profiled HS polysaccharide structures in renal sections. To this end 
we visualized HS epitopes by anti-HS mAbs JM-403 and 3G10, and 
by a ligand binding assay using the HS-binding growth factor FGF2 
and HS-binding adhesion molecule L-selectin. Characteristics of the 
corresponding HS-epitopes are detailed in Supplemental Table 2.
Anti-HS mAb JM-403 demonstrated a clear staining of the 
glomerular basement membranes in control (Figure 4A.1) and 
isografted (Figure 4A.2) kidneys. Mesangial staining was weak for 
mAb JM-403. In allografts however, glomerular JM-403 HS staining is 
partly or completely lost in sclerotic areas (Figure 4A.3), likely due to 
increased HS sulfation. Figure 4A.5 represents JM-403 staining (brown) 
combined with PAS histochemistry. PAS-positive sclerotic tissue indeed 
being negative for anti-HS mAb JM-403. The 3G10 HS epitope, which 
becomes available after heparitinase cleavage of HS, is absent in the 
glomerular basement membranes of control kidneys (Figure 4B.1), 
becomes weakly expressed in the isografted kidneys (Figure 4B.2), 
and is strongly upregulated in glomerular basement membranes and 
sclerotic areas in the allografts (Figure 4B.3). The 3G10 staining  exactly 
colocalized with perlecan (see Figure 5), indicating this HS epitope to be 
expressed by perlecan. FGF-2 binding is completely HS-dependent as 
evidenced by control experiments on heparitinase pretreated sections, 
where all binding of FGF-2 was lost (not shown). In glomeruli of control 
kidneys (Figure 4C.1) and isografts (Figure 4C.2) FGF-2 binding to HS 
was absent or only weakly present. In allografts, increased binding of 
FGF-2 was observed (Figure 4C.3). Although L-selectin clearly bound 
to HS in Bowmans capsule and to HS in a number of tubular basement 
membranes, no glomerular staining was observed in either control, 
isografted or allografted kidneys (Figure 4D.1-D.3 ). These data indicate 
changes in glomerular HS composition in CTD as evidenced by loss of 
low-sulfated JM-403 HS epitope, an increase in FGF2 binding capacity 
to N- and 2-O sulfated HS epitopes, without binding of L-selectin to 
N- and 6-O sulfated HS epitopes. Altogether this HS profiling shows 
increase in HS sulfation in the glomeruli of allografted kidneys, most 
likely by increased N- and 2-O sulfation. 
In the arterial media of control and isografted kidneys moderate 
staining for anti-HS mAbs JM-403 (Figure 6A.1,2) and 3G10 (Figure 
6B.1,2) was observed, however binding capacity for FGF2 (Figure 6C.1,2) 
and L-selectin (Figure 6D.1,2) was absent. Compared to the mediae of 
control and isografted kidneys, in allografts JM-403 staining was lost in 
the media (Figure 6A.3), whereas 3G10 staining was increased (Figure 
6B.3). Moreover, FGF2 binding capacity was increased in the allograft 
media (Figure 6C.3). In the neointimae strong binding of anti-HS mAbs 
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JM-403 (Figure 6A.3) and 3G10 (Figure 6B.3) as well as binding of 
FGF2 (Figure 6C.3) was observed. L-selectin did not bind to arterial HS 
of control, isografted, and allografted kidneys, despite recognition of 
HS isoforms in other renal structures such as Bowman’s capsule and 
tubular basement membranes (see Figure 4). 
Collectively, these data show changes in arterial HS composition in 
allografts with CTD very similar to the changes observed within the 
glomeruli, with loss of JM-403 staining and increased FGF2 binding 
capacity, without L-selectin binding capacity, which can be explained 

















































Figure 6. Modification of arterial HS structure in allografts with CTD. Medial and 
neointimal expression of HS was evaluated by two anti-HS mAbs (JM-403 [A] and 3G10 
[B]) as well as by the binding of FGF2 (C) and L-selectin (D). In the media of allografted 
kidneys, JM-403 staining was largely lost, whereas in the neointima this epitope was 
clearly expressed (A.3). Both the media and neointima of the allografts expressed the 
3G10 HS epitope (B.3). The media and  neointima bound FGF2 (C.3), but no L-selectin 
(D.3). Negative controls are shown in Figure 4. Although L-selectin did not bound to 
arteries, HS-dependent binding was seen in Bowman’s capsule and tubular basement 
membranes (see Figure 4). Scale bars represent 50 or 100 µm, as indicated in the 
Figure.
































































Figure 7. FGF2 binding to perlecan. Inhibition of the binding of recFGF2 to 
immobilized perlecan by fluid phase GAGs was measured in ELISA (A and B). Heparin 
dose-dependently inhibited FGF2 from binding to immobilized perlecan. N-desulfated 
heparin largely lost inhibitory capacity and O-desulfated heparin completely lost 
binding to FGF2 (A). HS from bovine kidney dose-dependently inhibited FGF2 binding to 
perlecan (B). N-sulfated HS from bovine kidney increased binding capacity to FGF2. On 
the contrary, two lower sulfated HS preparations (from EHS sarcoma and from human 
aorta) bound poorly with FGF2. FGF2 binding to antibody-captured perlecan from renal 
lysates show increased FGF2 binding to perlecan from allografted kidneys compared to 
perlecan from control kidneys.
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FGF2 binding to perlecan-HS requires specific sulfation motifs
In an ELISA approach we evaluated the interaction of recFGF2 
with immobilized perlecan and studied competition of FGF2-perlecan 
interaction by fluid phase glycosaminoglycans. As expected heparin 
dose-dependently inhibited the interaction of FGF2 with the HS side 
chains of perlecan. N-desulfation of heparin largely reduced the 
inhibitory capacity of heparin, and O-desulfation completely prevented 
interaction with FGF2 (Figure 7A). Dose-dependent inhibition was 
also achieved by HS isolated from bovine kidney, although to a lesser 
extent than heparin. N-deacetylation followed by N-resulfation of HS 
from bovine kidney increased the inhibitory capacity clearly (Figure 
7B), whereas low sulfated HS from mouse EHS tumor or from human 
aorta inhibited FGF2-perlecan interaction to some extent or not at 
all. These data convincingly show that the degree of sulfation of HS/
heparin polysaccharides determines interaction with FGF2.
In a next experiment we evaluated the FGF2 binding capacity 
of perlecan selectively adsorbed from renal lysates by immobilized 
anti-rat perlecan mAb in ELISA plates. We thus found that perlecan 
from allografted kidneys bound substantially more FGF2 compared to 
perlecan from control kidneys (p < 0.01; Figure 7C), which is due 
to increased sulfation and/or content of perlecan from allografted 
kidneys.
Endogenous expression of FGF-2 in allografts with CTD
After showing an upregulation of glomerular and neointimal perlecan 
expression accompanied by increased FGF2 binding capacity by perlecan 
in renal allografts, we next evaluated endogenous expression levels 
of FGF2. In control kidneys, we only observed weak segmental FGF2 
expression in the glomeruli (Figure 8A.1), the tubulointerstitium (Figure 
8A.1) and arteries (Figure 8B.1) being devoid of any FGF2 expression. 
In isografts, a slight upregulation of FGF2 expression in glomeruli was 
observed (Figure 8A.2), with the arteries remaining devoid of any FGF2 
expression (Figure 8B.2). However, in the allografts, FGF2 was strongly 
and homogeneously accumulated throughout the glomeruli, and 
present mainly in the glomerular capillary wall and mesangium (Figure 
8A.3). PCR analysis showed no significant differences in glomerular 
FGF2 expression, although a tendency towards higher expression was 
observed in the allografts (Figure 8C). We suggest that this discrepancy 
may be explained by plasma-derived FGF2 being trapped in the glomeruli 
by perlecan endowed with HS chains able to bind FGF2 (as shown in 
Figure 4) during ultrafiltration. This would cause local accumulation 
of FGF2 protein in the absence of an increase in mRNA expression. 
In addition, in the neointimae of allografts increased FGF2 expression 
was observed both at the protein and mRNA level (Figures 8B.3 and 
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8D, respectively). FGF2 expression in glomeruli largely colocalized 




































































































Figure 8. Glomerular and arterial expression of FGF2 in allografts with CTD. 
Endogenous expression of FGF2 was evaluated by immunofluorescence (A-B) and qRT-
PCR (C-D). In allografts with CTD, a strong expression of FGF2 was exclusively found 
in glomeruli (A.3) and neointimae (B.3). In glomeruli of isografts a slight increase in 
FGF2 expression was found   (A.2). The dotted line represents the internal elastic 
lamina. qRT-PCR analysis revealed an increase in FGF2 expression in the glomeruli in 
allografts, which did however reach the level of statistical significance when compared 
with isografts and non-transplanted control tissue  (C). Neointimal expression of FGF2 
was clearly present (D) (n=5/group). Scale bars represent 50 or 100 µm as indicated in 
the Figure. Blank represents the staining without incubation by anti-FGF2 mAb, in the 
presence of DAPI to show the nuclei of renal allograft tissue. Glomerular expression of 
FGF2 in allografts largely colocalized with perlecan as evidence by immunofluorescence 











































































































































Figure 9. FGF2-induced proliferation of mesangial cells depends on sulfated 
proteoglycans. A: Rat mesangial cells were stained for alpha-smooth muscle actin 
and perlecan in order to show perlecan expression in proliferating mesangial cells. B: 
Rat primary mesangial cells were stimulated with various concentrations of FGF2 for 24 
h. Proliferation was measured by 3H-thymidine incorporation. Data are expressed as the 
stimulation index, i.e. fold increase in proliferation + FGF2 / proliferation – FGF2 (n=4; 
*p<0.05, **p<0.01 vs. no FGF2 added). C: Exogenous HS from bovine kidney (HSBK) 
hampers FGF2-induced mesangial cell proliferation in a dose-dependent manner (n=2). 
D: Proteoglycan sulfation of mesangial cells is reduced by chlorate in a dose-dependent 
manner (**p<0.01, ***p<0.001 vs. no chlorate added). E: Chlorate impairs FGF2-
induced proliferation of mesangial cells which is dependent on the duration of FGF2 
stimulation (***p<0.001 vs. no chlorate at the respective duration of FGF2 stimulation).
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Involvement of proteoglycans in FGF2-driven proliferation of 
mesangial cells
As described above, we showed an upregulation of the HS 
proteoglycan perlecan in the glomeruli of allografts, which coincided 
with increased FGF2 binding capacity and FGF2 expression. We next 
hypothesized that the upregulation of perlecan and FGF2 may be 
involved in mesangial expansion and formation of FGS. To explore a 
possible mechanistic relation between mesangial HSPGs and FGF2 in 
more detail, we conducted a number of in vitro experiments. Primary 
rat mesangial cells were cultured and stained for alpha-smooth muscle 
actin and perlecan. Figure 9A shows positivity of the cultured mesangial 
cells for alpha-smooth muscle actin (proliferation marker of mesangial 
cells) and perlecan, thus showing that proliferating mesangial cells 
express perlecan. In a next series of experiments, mesangial cells 
were grown until confluency, serum starved for 24 h followed by 24 h 
stimulation with FGF2. Figure 9B shows a dose-dependent increase in 
proliferation of mesangial cells in response to FGF2. Based on these 
data we used the FGF2 concentration of 0.5 ng/ml in the subsequent 
in vitro experiments. The FGF2-induced proliferative response was 
blunted by the addition of exogenous competitive bovine kidney-derived 
HS (Figure 9C). This was due to reduced binding of FGF2 to the cells as 
demonstrated by reduced binding of 125I-labeled FGF2 to the mesangial 
cells (not shown). These data suggest that due to competition between 
mesangial and exogenous HS for binding of FGF2, less FGF2 was 
bound to the endogenous HS proteoglycans, resulting in decreased 
proliferation of the mesangial cells. To show that proliferation of the 
mesangial cells was dependent on active FGF2 binding by endogenous 
HS, cells were cultured in the presence of chlorate. Chlorate inhibited 
the sulfation of the side chains of the proteoglycans in a dose-dependent 
manner (Figure 9D) which should lead to loss of binding sites for 
growth factors including FGF2. Indeed, chlorate prevented the FGF2-
induced proliferative response of mesangial cells, which appeared to 
be dependent on the duration of FGF2 stimulation (Figure 9E). These 
results indicate that the proliferation of mesangial cells is dependent 
on FGF2 binding to endogenous HS proteoglycans such as perlecan 
(Figure 9A). The interaction between FGF2 and HS proteoglycans on 
mesangial cells may therefore play a key role in the development of 
FGS.
Glomerular expression of perlecan and FGF2 in human CTD
In order to strengthen the importance of our findings, in a translational 
approach we finally evaluated perlecan and FGF2 expression in four 
explanted human CTD kidneys and compared the expression with three 
control human kidney tissues. In the glomeruli of all CTD kidneys we 
observed increased perlecan and FGF2 expression (Figure 10). Both 
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perlecan and FGF2 were minimal to absent in control renal tissue. 
These data suggest that also in human CTD the perlecan – FGF2 axis 
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Figure 10. Glomerular perlecan and FGF2 expression in human CTD. Four 
human CTD kidneys and three control human kidneys were stained for perlecan and 
FGF2. Control renal tissue barely expressed perlecan and FGF2 within the glomeruli. In 
contrast, in CTD both perlecan and FGF2 is expressed along the glomerular capillary 
wall.
DISCUSSION
In this study we provide evidence that HSPGs such as perlecan serve 
as functional docking platforms for FGF2 and contribute to glomerular 
and arterial tissue remodeling in experimental and human CTD. The 
concept of extracellular regulation of growth factors by proteoglycans 
has been studied predominantly in tissue remodeling related to 
embryonic development (12,13), ontogenesis (14,15) and angiogenesis 
(16,17). Our data indicate that HSPGs modulate growth factors in the 
renal transplant setting as well. This is an important finding that opens 
the possibility to target proteoglycans by therapeutic intervention to 
ameliorate the development of CTD.
Development of CTD in renal allografts is the result of tissue 
remodeling affecting all functional-structural compartments of the 
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kidney including the tubulointerstitium (tubular atrophy and interstitial 
fibrosis), glomeruli (focal glomerulosclerosis), and larger arteries 
(neointima formation) (2-4). We recently demonstrated compositional 
changes of the HSPGs collXVIII, perlecan and agrin in tissue remodeling 
in experimental CTD by immunofluorescence (5). We now investigated 
functional aspects of proteoglycans in experimental CTD as well as in 
renal cell culture assays. Depending on their highly variable composition, 
HS carbohydrate side chains can bind a variety of ligands including 
FGF2 (10), which is known to be involved in renal tissue remodeling. 
In experimental allografts with CTD, a massive increase in matrix 
HSPG-mediated binding capacity for FGF2 was observed. Enhanced 
binding capacity for this growth factor was the result of increased 
HSPG expression, and modified HS sulfation [most likely increased 
N- and 2-O sulfation leading to loss of JM-403 staining (24,25) and 
increased FGF2 binding (26)]. This finding suggests that upon allo-
transplantation the kidney mobilizes matrix HSPGs to become docking 
molecules for heparin-binding growth factors such as FGF2. This was 
also reported by Morita et al. (27) showing increased FGF2 binding in 
fibrotic areas of native kidney diseases. 
The laser microdissection approach on isolated glomeruli, 
arterial mediae and neointimae revealed spatial differences in HSPG 
expression, which were not seen, and would have been missed, in 
whole kidney homogenates. We observed increased glomerular and 
neointimal perlecan expression in allografted kidneys. This regional 
HSPG regulation opposes the uniform induction of pro-fibrotic pathways 
(Coll I, Coll IV, Tgf-β1) seen in glomeruli, mediae and whole kidney 
tissue, which probably reflects a more generalized response upon allo-
transplantation. Like perlecan, FGF2 showed a restricted glomerular and 
neointimal expression pattern as well. The marked FGF2 and perlecan 
expression observed in glomeruli of allografted kidneys suggests a 
role in the proliferative response of mesangial cells. In other settings 
perlecan/FGF2 has been shown to induce proliferation in a number of 
cell types including chondrocytes, neural stem cells, retinal pigmental 
epithelial cells and vascular smooth muscle cells (17, 28-30). In the kidney 
FGF2 has been shown to be proliferative for fibroblasts and mesangial 
cells (29,30). In vitro studies showed that the expression of cell surface 
HSPG was a prerequisite for the proliferation of renal fibroblasts in 
response to FGF2 (31). We therefore studied the functional role of the 
FGF2-proteoglycan interaction in mesangial cell proliferation in vitro. 
FGF2 was shown to induce mesangial cell proliferation in a dose- and 
sulfation-dependent manner indeed favoring for a role of the FGF2-
proteoglycan interaction in mesangial cell proliferation. Although FGF2 
binding on allograft sections was shown to be heparitinase-sensitive 
(indicating that FGF2 interacts with HSPGs), the exact identity of the 
FGF2-binding HSPG(s) is as yet unknown. Since both collXVIII and 
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perlecan are upregulated in FGS (5 and this study), and the cultured 
mesangial cells express perlecan, we propose that FGF2 binds to (one 
of) these proteoglycans. Our ELISA data provide evidence that at least 
perlecan is able to bind FGF2. The exact mechanism by which HSPGs 
enhance FGF2-induced mesangial cell proliferation is unknown. We 
propose that binding of FGF2 to mesangial (matrix) HSPGs facilitates 
the interaction between FGF2 and its surface receptor on mesangial 
cells, as has been demonstrated for other cell types (28-33). This is 
supported by our observation that removing the FGF2 binding capacity 
of proteoglycans on mesangial cells by chlorate treatment resulted 
in a significant delay, but not complete abrogation of FGF2-induced 
proliferation.
Based on our data, HSPGs could be interesting therapeutic targets to 
limit CTD, especially focusing on the potential of inhibiting growth factor 
signaling. To study the possibility that exogenous glycosaminoglycans 
may hamper growth factor responses, heparin(oids) have been shown 
to reduce progressive renal failure in experimental renal diseases, 
including renal transplantation (34-36). Increasing research interest 
is focusing on the possibility to produce small HS-mimetics, which 
may more specifically target a particular component of HS/heparin 
bioactivity (37). The use of HSPGs as targets, for example using 
antibodies that recognize and thereby block specific HS-motifs/
domains, may also have clinical potential. This strategy has been 
exemplified in vitro by the demonstration that 6-O-sulfate specific anti-
HS antibodies produced in a phage-display library can inhibit leukocyte 
rolling and firm adhesion to glomerular endothelial cells, whereas anti-
HS antibodies with different specificities do not (38). Mutant growth 
factors, which are made incapable of glycosaminoglycan binding, could 
be used to specifically inhibit cell survival/proliferation. In addition, 
small inactive growth factor fragments could be generated that block 
the HSPG-binding sites of their in vivo active counterparts. Together, 
there are various options for the use of HSPGs in therapeutic strategies, 
but further proof of efficacy in vivo needs to be provided.
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Table 1. Composition of low-density array
Gene name General name Gene symbol Assay ID
Matrix molecules
collagen, type I, alpha 1 Collagen I Col1a1 Rn01463848_m1
collagen, type IV, alpha 1 Collagen IV Col4a1 Rn01482925_m1
Proteoglycans
perlecan Perlecan LOC313641 Rn01515780_g1
agrin Agrin Agrn Rn00598349_m1
versican Versican Vcan Rn01493755_m1
biglycan Biglycan Bgn Rn00567229_m1
syndecan 1 Syndecan 1 Sdc1 Rn00564662_m1
syndecan 4 Syndecan 4 Sdc4 Rn00561900_m1
Growth factors 
fibroblast growth factor 2 FGF2 Fgf2 Rn00570809_m1
transforming growth factor, beta 1 Tgf-b1 Tgfb1 Rn01475963_m1
Reference genes
β actin Beta-actin Actb Rn00667869_m1
β 2 microglobulin B2m B2m Rn00560865_m1
eukaryotic 18S rRNA 18S 18s Hs99999901_s1
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Table 2. Basic characteristics of the HS epitopes recognized by the anti-HS mAbs and 
FGF2
Anti-HS mAb or HS-binding protein Basic characteristics of the HS epitope
Anti-HS mAb JM-403 GlcUA-rich sequences with N-unsubstituted GlcN units in low sulfated HS (24)
Anti-HS mAb 3G10
Desaturated Uronate residues after digestion 
with heparitinase (GlcNAc/NS α1-4 GlcA linkage; 
ref.25)
FGF2 2-O sulfation in heparin and heparan sulfates (26)









IN SITU DELIVERY OF STAT1 DECOY 







The development of chronic transplant dysfunction impedes long-
term graft survival after renal transplantation. Chronic transplant 
dysfunction (CTD) is histologically characterized by glomerulopathy, 
interstitial fibrosis, tubular atrophy and intimal thickening. The 
pathogenesis of CTD is still not fully understood, although endothelial 
cell damage and subsequent dysfunction of allograft endothelial cells, 
is believed to play an important role in its development. Prevention 
of endothelial dysfunction after renal transplantation may prevent or 
attenuate the development of CTD, and especially intimal thickening. 
Here, we tested the hypothesis that prevention of activation of graft 
endothelial cells by targeting the pro-inflammatory transcription factor 
STAT-1 reduces development of CTD. 
Methods
Dark Agouti kidney allografts were transplanted into Wistar Furth 
recipient rats and retrieved 56 days after transplantation. Prior to 
transplantation, kidney allografts were perfused in situ with STAT1 or 
scrambled (control) decoy oligodeoxynucleotides (dODNs). Dark Agouti 
isografts served as controls for the development of CTD.
Results
Although STAT-1-dODNs penetrated the target endothelial cells, no 
beneficial effects on graft survival and function and no amelioration 
of histopathological characteristics of CTD were observed, compared 
to scrambled dODNs. Remarkably, development of transplant 
vasculopathy was limited in both allografts treated with STAT1- and 
scrambled dODNs. The underlying reason for this finding is as yet 
unknown. 
Conclusions
The limited development of a neointima may have obscured the 
potential efficacy of STAT1-dODNs to attenuate the development 
of transplant vasculopathy. Prolonged exposure of the allograft 
vasculature to STAT1-dODNs might increase its efficacy. We therefore 
propose the use of a delivery system that specifically targets activated 
endothelial cells, to deliver dODNs repeatedly in future studies.




Chronic renal transplant dysfunction (CTD) is histologically 
characterized by glomerulopathy, interstitial fibrosis and tubular 
atrophy (IF/TA) and transplant vasculopathy (TV) (1,2). TV consists of 
the formation of an occlusive neointima characterized by accumulation 
of smooth muscle cells (SMCs) between the endothelial cells (ECs) 
and the internal elastic lamina (IEL) (3). The SMCs in the neointima 
secrete extra cellular matrix (ECM) leading to the narrowing of the 
artery and eventually to ischemia in downstream renal tissue. To date, 
no adequate therapy to prevent or attenuate the development of CTD 
after renal transplantation is available.
Several risk factors such as acute rejection, donor age and CMV 
infection are known to contribute to the pathogenesis of CTD after 
renal transplantation (4,5). EC damage, and subsequent dysfunction 
of allograft endothelium, is believed to play an important role in the 
pathogenesis of CTD, as endothelial dysfunction is considered one of the 
initial triggers that eventually contributes to the development of TV (5,6). 
Damage to the endothelium is caused by ischemia/reperfusion injury as 
a result of transplantation, the use of several immunosuppressive agents 
and (subclinical) rejection of the transplanted kidney. Dysfunctional 
allograft ECs display increased expression of adhesion molecules 
and secrete inflammatory chemokines and cytokines. Furthermore, 
they start to express co-stimulatory molecules involved in T and B 
cell activation. In turn, activated recipient T-helper cells stimulate 
the expression of MHC class II molecules on the endothelium, thus 
potentially evoking a sustained alloimmune reaction (7). Prevention of 
endothelial dysfunction potentially leads to (partial) prevention of the 
influx of inflammatory cells into the transplanted kidney, decreases 
inflammation and, eventually, retards the development of CTD.
The aim of the current study was to prevent TV development after 
experimental renal transplantation by preventing EC activation and 
dysfunction in the perioperative period. To this end, we attempted 
to block the pro-inflammatory transcription factor STAT1 in kidney 
endothelium by infusing decoy oligodeoxynucleotides (dODNs) that 
scavenge STAT1, prior to transplantation. Treatment efficacy was then 
studied in an experimental renal transplant model in rats in which 
CTD-related TV develops within 8 weeks after transplantation (8). 
STAT1 was selected as a target, since STAT1-dODNs were previously 
shown to delay acute rejection and prolong allograft survival in an 
experimental rat heart transplantation model (9-11). STAT1 controls 
the expression of many pro-inflammatory genes; neutralizing STAT1 
will therefore result in diminished expression of multiple target genes 
simultaneously. STAT1-dODNs scavenge endogenous STAT1, thereby 
preventing STAT1 from binding to the promoter regions of STAT1 target 
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genes and subsequent transcription of these genes (Figure 1). Decoy 
ODNs thus mimic the genomic binding site of STAT1 in such a way that 
the activity of STAT1 and subsequent expression of its target genes is 
blocked. The advantage of STAT1-dODNs is that they are rapidly taken 
up into cells without any additives followed by immediate action. We 
hypothesized that in situ treatment of donor kidneys with STAT1–dODNs 
prior to transplantation provides an attractive, feasible, and effective 
therapeutic approach to retard CTD after kidney transplantation. 
METHODS
Rats
Inbred female (120–185 gram) and male (190–210 gram) Dark 
Agouti (DA) rats were obtained from Harlan (Horst, the Netherlands) 
and inbred male Wistar Furth (WF) rats (230–295 gram) from Charles 
River Laboratories Inc. (l’Arbresle, Cedex, France). Rats were housed 
in a temperature-controlled room with a 12:12-h light-dark cycle. 
Rats had free access to standard chow and drinking water. Animal 
experiments were performed in compliance with the Principles of 
Laboratory Animal Care (NIH Publication No. 86-23, revised 1985), the 
University of Groningen guidelines for animal husbandry and the Dutch 
Law on Experimental Animal Care.
Table 1. Clinical variables before (pre-Tx) and 8 weeks after transplantation
DA-to-DA Isograft DA-to-WF Allograft
DA Vehicle WF STAT1-dODN Scrambled-
dODN
(pre-Tx) (8 wk after Tx)  (pre-Tx) (8 wk after Tx) (8 wk after Tx)
n=6 n=6 n=23 n=5 n=5
Urinary protein 
(mg/day)
2.5 ± 1.0 18.4 ± 16.7 4.2 ± 1.7 80.3 ± 49.3 116.8 ± 113.7
Urinary volume 
(ml)
7.5 ± 1.0 19.9 ± 3.5 8.8 ± 2.2 33.9 ± 8.4 43.0 ± 14.4*
Creatinin clearance 
(ml/min)
3.1 ± 0.8 2.6 ± 0.8 3.0 ± 0.9 0.6 ± 0.2* 0.9 ± 0.6*
Serum urea 
(mmol/l)
4.3 ± 0.4 8.8 ± 2.3 5.1 ± 0.7 28.3 ± 18.1 30.9 ± 24.5
Kidney weight (g) 0.9 ± 0.1 1.5 ± 0.2 0.8 ± 0.2 2.4 ± 0.9 2.8 ± 0.9*
Values are means ± SEM. Abbreviations: DA, Dark Agouti; WF, Wistar-Furth; Tx, transplantation. Statistical 
analyses (ANOVA) were performed using transplanted (Tx) animals at 8 wk. * P < 0.05 vs. isograft.
Kidney transplantation and perfusion with decoy ODNs
Female DA kidneys were orthotopically transplanted into male 
DA or WF recipients as described previously (8). Donor rats were 
anesthetized with isoflurane/O2, and left kidneys were flushed in situ 
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with pre-warmed saline and subsequently perfused with either a STAT1-
dODNs or scrambled-dODN solution. Kidneys perfused with dODNs 
were left in situ for 10 min. The donor rats were then terminated by 
exsanguination. Kidneys were preserved in ice-cold saline (20 min) 
to allow for a standard cold ischemia time and then orthotopically 
transplanted into the recipient. The graft renal vein, artery, and ureter 
were anastomosed end-to-end to the recipients’ left renal vein, artery, 
and ureter, respectively, using 10-0 prolene sutures. Warm ischemia 
time was 25 min. A wash out period to prevent any spillover of the 
ODNs into the systemic circulation followed the completion of the 
venous anastomosis before complete declamping. To this end, the distal 
venous clamp was partially released to avoid extensive blood loss. Both 
adrenal glands of the recipient remained in situ. All transplanted rats 
were given buprenorphine (Temgesic; 0.01 mg/kg) subcutaneously 
directly after transplantation, 8–10 h and 24 h after transplantation for 
pain relief. Recipients received cyclosporine A (5 mg/kg bodyweight) 
(Sandimmune, Novartis, the Netherlands) subcutaneously during the 
first 10 days after transplantation. The recipients’ contralateral kidney 
was removed 14 days after transplantation. Total follow-up was time 8 
weeks, unless animals had to be sacrificed earlier due to graft failure.
STAT1 Transcription Factor
STAT1 DNA binding site
Gene transcription (+)
STAT1 DNA binding site
STAT1 Transcription Factor
STAT1 decoy ODN STAT1 decoy ODN
No gene expression (-)
A
B
Figure 1. Schematic view of decoy oligodeoxynucleotides (dODNs). (A) After 
translocation to the nucleus, the transcription factor STAT1 binds to the DNA and 
promotes gene transcription. (B) In the presence of a STAT1-dODN, the transcription 
factor STAT1 binds to the ODN thereby preventing gene transcription.
Renal function measurements
For renal function measurements, rats were placed in individual 
metabolic cages (Bioquant; Merck, Darmstadt, Germany) with free 
access to water for the collection of 24-h urine samples. Blood samples 
were taken immediately following collection of 24-h urine samples. 
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Rats were placed in metabolic cages at three time points: before 
transplantation, 4 weeks after transplantation and 8 weeks after 
transplantation. Urinary and serum concentrations of total protein, 
creatinine and urea were analyzed by a multitest analyzer system 
(Roche Modular; F. Hoffmann-La Roche&Co, Basel, Switzerland). 
Decoy oligodeoxynucleotides
Double-stranded ODNs (purity 95%) were prepared from 
complementary single-stranded phosphorothioate-bonded ODNs 
(obtained from Biomers, Ulm, Germany) as previously described (10). 
The resulting dODN solution (400 mmol in TEN buffer) was divided 
into 50 μl aliquots and frozen until further use. These were defrosted 
and dissolved in saline yielding a final concentration of 10 mmol. The 
sequences of the single-stranded ODNs were as follows (bold letters 
denote phosphorothioate-bonded bases):
STAT-1 dODN: 5’-CATGTTATGCATATTCCTGTAAGTG-3’
STAT-1 scrambled control dODN: 5’-TGTCATACTCGTACACAC-3’
Uptake of nucleic acid into kidney ECs was verified by using Atto590–5′-
end labeled dODNs (Biomers), the sequence of which was identical to 
that of the unlabeled STAT1 consensus dODN. Kidneys were perfused 
in situ with Atto590–labeled dODNs, followed by 3 periods of ischemia 
(10 min 1st warm ischemia, 20 min cold ischemia, and finally 25 min 2nd 
warm ischemia). Afterwards, kidneys were snap frozen and sectioned. 
Uptake of dODNs by ECs was verified by immunofluorescent staining 
for RECA-1 (12) (endothelial marker) on cryosections of kidneys that 
were perfused in situ with Atto590–labeled dODNs. Staining for RECA-
1 was visualized with a goat-anti-mouse-Alexa488 secondary antibody 
(Life Technologies Europe BV, Reiswijk, The Netherlands).
Assessment of renal morphological damage and transplant 
vasculopathy
At the end of the study (8 wk after transplantation), the rats were 
anesthetized after which the transplanted kidneys were perfused 
with saline and the rats were killed by exsanguination. A tissue slice 
through the midportion of the kidney was fixed in zinc fixative and 
processed for paraffin embedding. Paraffin sections (3 μm) were 
stained with hematoxylin and eosin, α-SMA (myofibroblasts) and ED1 
(macrophages).
Severity of TV (i.e. percentage obliteration of the arterial lumen) 
was assessed in all cross-sectionally cut, elastin-positive arteries after 
α-SMA/elastin (Lawson) double staining. Percentage obliteration was 
determined using computerized image analysis (Advanced QUIPS; Leica 
Imaging Systems, Cambridge, UK) in all arteries with a clearly visible 
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internal elastic lamina (IEL) identified within a section. Percentage 
obliteration was calculated as follows: (surface area NI) / (surface area 
NI + remaining lumen) x 100%. Arteries cut diagonally (i.e. arteries 
with a compressed lumen) were excluded from quantitative analysis.
To obtain a measure of inflammation, the numbers of glomerular and 
interstitial macrophages (ED-1+ cells) were quantified using computer-
assisted morphometry. ED1 positivity (i.e. number of positive pixels for 










Figure 2. Presence of fluorescently-labeled dODNs in endothelial cells after 
infusion of dODNs in the kidney. (A) Decoy ODNs are taken up by endothelial cells 
of arteries in the kidney. (B) Decoy ODNs are taken up by endothelial cells of glomeruli 
in the kidney. (C) Decoy ODNs are taken up by endothelial cells of peritubular capillaries 
in the kidney. (red = dODNs, green = endothelial cells and blue = nuclei).
Immunohistochemistry
Immunohistochemistry was performed on 3 µm paraffin sections. 
Sections were stained for α-SMA (clone 1A4, Sigma Chemical Co, St 
Louis, MO, USA) and ED-1 (Serotec Ltd, Oxford, UK). Sections were 
dewaxed and antigen retrieval was performed by incubation in 0.1 M 
Tris/HCl pH9 overnight at 80°C. Endogenous peroxidase was blocked 
with 0.1% H2O2 for 10 min at room temperature. Sections were 
incubated for 1 h with primary antibodies. Horseradish peroxidase 
(HRP)-labeled conjugates were used as secondary antibodies. Color 
development was performed with 3,3′-diaminobenzidine tetrachloride. 
Sections were counterstained with Mayer’s hemalum (Merck) and 




Data are expressed as mean ± standard error of the mean (SEM). 
Differences between allografts with STAT1, scrambled ODNs and 
isografts were analyzed using ANOVA with Tukey posthoc. p < 0.05 was 
considered statistically significant. Statistical analyses were performed 
using SPSS (version 16.0.2; IBM Nederland B.V., Nieuwegein, the 
Netherlands).
RESULTS
Uptake of dODNs by endothelial cells
To confirm that dODNs are taken up by ECs in kidneys upon in situ 
perfusion, kidneys were perfused with fluorescently-labeled dODNs, 
after which they were snap frozen and investigated by fluorescent 
microscopy for the uptake of dODNs by ECs (Figure 2). The presence of 
labeled dODNs in ECs in arteries was confirmed by membrane labeling 
of the ECs with RECA-1 (Figure 2A). We also found the labeled dODNs 























Figure 3. Survival of allografts and isografts after renal transplantation. DA 
kidneys were perfused with either STAT1-dODN or scrambled-dODN and subsequently 
transplanted into a WF recipient (allograft). For DA-to-DA isograft transplantations, DA 
kidneys were perfused with vehicle. Survival of recipients (isograft and allograft) is 
plotted as a percentage of total transplanted rats. *p < 0.05 vs isograft.
Graft survival
Kidneys of DA donor rats were perfused with dODNs during 
transplantation. DA allograft kidneys (kidney from a DA donor 
transplanted into a WF recipient) were perfused in situ during the 
transplantation procedure with either STAT1-dODNs or scrambled-
dODNs in experimental renal transplantation
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dODNs. Isograft kidneys (kidney from a DA donor transplanted into a 
DA recipient) were perfused in situ with vehicle (TEN buffer dissolved 
in saline) during transplantation. All animals in the isograft control 
group survived until 8 weeks after transplantation (Figure 3). Survival 
of allografts after renal transplantation was 42% and 45% for animals 
treated with either STAT1-dODNs or scrambled-dODNs, respectively. 
Survival was not affected by treatment with STAT1-dODNs compared 





































































































Figure 4. Renal function in allografts and isografts as measured by creatinine 
clearance and proteinuria. (A) Creatinine clearance (ml/min) of isografts and 
allografts before and after transplantation. (B) Development of proteinuria (mg/24 h) 
in isografts and allografts after transplantation. Data are presented as mean ± SEM.
Renal function
Renal function was similar in all experimental groups before 
transplantation (Table 1). Four weeks after transplantation, creatinine 
clearance was decreased in all experimental groups (Figure 4A). 
Creatinine clearance of isograft recipients returned to baseline 8 
weeks after transplantation. Renal function was not improved in 
allograft recipients 8 weeks after transplantation. There was no 
difference in creatinine clearance between the allograft recipients 
treated with STAT1-dODNs or scrambled dODNs (Figure 4A). Before 
transplantation, proteinuria was similar in all experimental groups 
(Table 1). Four and eight weeks after transplantation, allograft 
recipients had a non-significant increase in proteinuria compared to 
isograft recipients (Figure 4B). No difference was observed between 




The uptake of STAT1-dODNs by ECs can block the upregulation of 
chemoattractants, such as MCP-1, and adhesion molecules important 
in EC-leukocyte interactions. To investigate the influx of macrophages 
after in situ perfusion with dODNs during renal transplantation, an ED1 
staining was performed (Figure 5). ED1+ macrophages were present in 
glomeruli and in the interstitium of allografts and isografts (Figure 5A). 
Macrophage infiltration was quantified in the cortex of transplanted 
kidneys. Compared to isografts, allografts had significantly increased 
numbers of ED1+ macrophages present in the renal cortex (interstitium 
and glomeruli) 8 weeks after transplantation (Figure 5B). There was, 
however, no significant difference between the allografts perfused with 

























Figure 5. Macrophage infiltration in allografts and isografts 8 weeks after 
renal transplantation. (A) Representative images of ED1 staining in the renal cortex 
of allografts perfused with STAT1-dODNs, scrambled-dODNs and isografts perfused 
with vehicle. (B) Quantification of ED1+ cells in the renal cortex of allografts perfused 
with STAT1-dODNs or scrambled-dODNs and isografts perfused with vehicle. Scale bar 
represents 100µm. Data are presented as mean ± SEM. **p < 0.01, ***p < 0.001
Development of transplant vasculopathy
To investigate if in situ perfusion of renal allografts with dODNs 
attenuated the development of TV in arteries, the severity of TV was 
investigated (Figure 6A and B). Arteries in transplanted kidneys from 
allografts and isografts showed minimal neointima formation (Figure 
6A). There was no difference in neointima formation between the 
different experimental groups (Figure 6B). 











































Figure 6. Neointima formation and interstitial fibrosis in allografts and 
isografts 8 weeks after renal transplantation. (A) Representative images of 
arteries in the renal cortex of allografts perfused with STAT1-dODNs or scrambled-
dODNs and isografts perfused with vehicle. The neointimal and medial smooth muscle 
cells were visualized by α-SMA staining. (B) Quantification of neointima formation in 
allografts perfused with STAT1-dODNs or scrambled-dODNs and isografts perfused 
with vehicle. (C) Representative images of interstitial fibrosis (visualized by staining 
for α-SMA) in the renal cortex of allografts perfused with STAT1-dODNs or scrambled-
dODNs and isografts perfused with vehicle. Scale bar represents 100µm. Dotted line 
represent the internal elastic lamina (IEL). Data are presented as mean ± SEM.
Development of interstitial fibrosis
The development of interstitial fibrosis was investigated using 
immunohistochemical staining for α-SMA to identify interstitial 
myofibroblasts. Compared to isografts, allografts had more interstitial 
fibrosis (Figure 6C). There was no significant difference in the amount 
of interstitial myofibroblasts between the allografts perfused with 




At this moment there is no adequate therapy to prevent or attenuate 
the development of CTD after renal transplantation. In the current study, 
treatment of ECs with anti-inflammatory dODNs during transplantation 
was investigated. The aim was to prevent EC activation by blocking the 
transcription factor STAT1 with in situ perfusion with STAT1-dODNs 
during transplantation. Prevention of endothelial dysfunction may 
attenuate the development of CTD after renal transplantation. We used 
an experimental allogeneic renal transplantation model in which CTD 
develops within 8 weeks after transplantation. Despite an adequate 
delivery of STAT1-dODNs we did not observe a beneficial effect of in 
situ perfusion during transplantation with STAT1-dODNs.
STAT1-dODNs can specifically neutralize STAT1 and thereby block 
the expression of genes controlled by STAT1 (9-11,13-15). We have 
chosen STAT-1 as a target to attenuate the development of CTD because 
STAT1 controls the expression of many pro-inflammatory genes. 
Moreover, STAT1-dODNs have been shown to delay acute rejection and 
prolong cardiac allograft survival in a rat heart transplantation model 
(9-11). The advantage of dODNs is that they are transported into their 
target cells without any additives and immediately thereafter can act 
on their target transcription factor. The uptake of dODNs into cells is 
accomplished without the need for a transfection reagent, through 
unknown mechanisms.
In this study we did not observe a beneficial effect of treatment 
of ECs with STAT1-dODNs compared to scrambled-dODNs on survival 
or renal function after experimental renal transplantation. There was 
also no difference between the STAT1- and scrambled dODNs-treated 
allografts on the development of TV or the number of infiltrating 
macrophages in the renal cortex. However, in an experimental model 
for CTD after cardiac transplantation, Stadlbauer et al showed that 
TV could be effectively attenuated with STAT1 dODNs (10). In their 
study, rats were treated with STAT1-dODNs during transplantation and 
sacrificed after 100 days. In the study of Stadlbauer et al, the animals 
received cyclosporine during the entire study. In the current study, 
animals only received cyclosporine for 10 days after transplantation. 
After the first 10 days, animals did not receive any immunosuppressive 
agents. The withdrawal of cyclosporine in our study could explain 
why we did not observe a beneficial effect of STAT1–dODNs during 
transplantation on the development of CTD. The dODNs were 
probably degraded by the time cyclosporine was withdrawn. The 
most likely reason for this would be the relative instability of nucleic 
acids in a target tissue over a longer period (11). In the absence of 
cyclosporine, inflammation directed against the allograft continues 
and probably abrogates the initial anti-inflammatory effect of the 
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dODNs. Furthermore, the development of TV was surprisingly minimal 
in this study, and at variance with our prior experience in this model 
(8,16). Without clear neointima formation in allografts, it is obviously 
difficult to demonstrate a potential beneficial effect of dODNs on the 
development of TV. Reasons for the lack of neointima formation are 
unclear. One explanation might be that the prolonged first warm 
ischemia used during in situ perfusion of the dODNs acts as ischemic 
preconditioning of the transplanted kidney, which has been previously 
shown to have protective and anti-inflammatory effects (17). Selection 
by mortality may also have been involved. In fact, survival was poor 
in both groups, with mortality likely due to renal failure, i.e. excluding 
the animals with more severe renal damage from the final analysis.
Treatment of the donor kidney with dODNs that target transcription 
factors which control the expression of immunoregulatory molecules 
that play a central role in the leukocyte–EC interaction, could be 
an attractive and feasible therapeutic approach for retarding the 
development of CTD after renal transplantation. However, in this study 
we could not find a beneficial effect of in situ perfusion of donor ECs 
with STAT1 dODNs during transplantation. For future experiments, the 
development of a system in which only activated ECs are targeted 
for the uptake of dODNs is required. This system would allow for 
intravenous intervention to attenuate the development of CTD with 
dODNs. Moreover, with this system dODNs could be repeatedly 
delivered to activated ECs. Activated ECs express vascular adhesion 
molecule (VCAM), an adhesion molecule which can be internalized. 
We therefore plan to construct an dODN delivery vehicle which will 
be used to target activated ECs specifically using antibodies directed 
against VCAM. After binding, the complex including the dODNs will be 
internalized, after which the dODNs can scavenge transcription factors 
such as STAT1. In a collaborative study, we are currently working on 
targeting activated ECs in vitro using this approach.
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CHRONIC TRANSPLANT DYSFUNCTION AFTER RENAL 
TRANSPLANTATION
Chronic transplant dysfunction (CTD) continues to be one of the 
leading causes of late graft failure after renal transplantation (1,2). 
CTD is characterized by a progressive decline in glomerular filtration 
rate, generally going along with proteinuria and hypertension. As 
these clinical signs are not specific, diagnosis can only be made 
after histopathogical evaluation of a renal biopsy. The morphologic 
characteristics of CTD involve the development of chronic fibrotic 
changes in the renal parenchyma as evidenced by transplant 
vasculopathy (TV), focal segmental glomerulosclerosis (FSGS) and 
interstitial fibrosis and tubular atrophy (IF/TA). 
Currently, the therapies available for transplant patients aim at 
the reduction of alloreactivity-mediated inflammation (i.e. rejection). 
Additional therapies to attenuate or halt the process of renal fibrosis 
have not been explored yet. Therefore, it is of crucial importance to 
reveal which cell types and which pathophysiological mechanisms play 
a role in the development of renal fibrosis after transplantation. New 
insights into these mechanisms are indispensable for the creation of 
novel anti-fibrosis therapies and can be helpful to design interventional 
strategies aiming at the regeneration of the injured kidney. This, in turn 
will lead to better graft survival and thereby contribute to the quality 
of life as well as survival in transplant patients. Therefore, in this thesis 
we sought to identify cellular players and molecular pathways involved 
in the pathogenesis of CTD after renal transplantation with special 
emphasis on the development of TV.
ORIGIN OF CELLS IN TRANSPLANT VASCULOPATHY
TV is manifested by the accumulation of α-smooth muscle actin 
(α-SMA)+ expressing cells between the endothelial cells and the 
internal elastic lamina, forming a neointima. These α-SMA+ cells in the 
neointima are intermingled with recipient-derived mononuclear cells 
and secrete extra cellular matrix (ECM). This intimal accumulation of 
cells and ECM eventually leads to luminal stenosis and consequently 
ischemic graft failure.
Injury to the graft endothelium is thought to be one of the initial 
triggers for the development of TV after renal transplantation (3). Graft 
endothelial cells (ECs) are the first line of cells encountered by the host 
immune system. Recipient driven allo-responses can cause activation 
and dysfunction of ECs in the graft. This can in turn lead to increased 
leukocyte adhesion and subsequent migration of these cells to the 
transplanted organ (4). Persistent inflammation will eventually result in 
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the development of CTD. In the process of regeneration, damaged graft 
ECs are supposed to be replaced by either proliferating adjacent ECs 
or by recipient-derived circulating endothelial progenitor cells (EPCs). 
The existence of EPCs in the peripheral blood and their contribution 
to angiogenesis was described for the first time by Asahara et al. (5). 
Since then it has been shown that these EPCs can be mobilized from the 
bone marrow into the circulation and home to sites of injury in various 
organs (6,7). EPCs positively influence repair processes after injury 
and probably have a beneficial effect after renal transplantation. Since 
evidence for the replacement of donor ECs by recipient-derived ECs 
in arteries of transplanted kidneys is scarse and conflicting (8-10), we 
investigated the origin of arterial ECs in human renal transplantectomy 
samples with CTD (chapter 2). We found that the contribution of 
regeneration of arterial ECs by recipient-derived cells was relatively 
minor and variable (mean of 14%, range 4%-32%). In chapter 4, we 
used a previously described rat model for the development of CTD after 
renal transplantation (11,12) to further investigate the mechanisms of 
neointima formation and the origin of cells involved in the development 
of CTD. Kidneys from Dark Agouti donors were transplanted into Wistar 
Furth recipients and these allografts developed CTD within 12 weeks 
after transplantation. The histopathological characteristics of renal 
allografts in this experimental model resemble those of CTD after human 
renal transplantation as evidenced by the formation of TV, FGS and IF/
TA. To study chimerism of donor and recipient-derived cells, kidneys 
from Dark Agouti donors were transplanted into Fischer 344 recipients, 
the latter being transgenic for human placental alkaline phosphatase 
(hPAP). In this experimental model for renal CTD we did not observe 
EC chimerism in arterioles and arteries, independent of the presence 
of TV. Differences between human transplantectomy samples and the 
experimental model for CTD suggest that the contribution of recipient-
derived cells varies between species or are caused by differences in 
the use of immunosuppression therapy. Another explanation is that 
the amount of recipient-derived ECs is dependent on the severity of 
vascular injury (9).
According to the response-to-injury paradigm, neointimal SMCs are 
derived from the graft arterial media (3,13). This paradigm implies that 
medial SMCs migrate across the internal elastic lamina after injury 
and form a neointima. In contrast to this paradigm, previous studies 
from our group in experimental transplant models (aorta and heart) 
showed that all neointimal SMCs were of recipient origin (14,15). The 
contribution of recipient-derived SMCs after renal transplantation is 
still under debate. In human renal allografts, two contrasting studies 
regarding the origin of neointimal cells exist. Grimm et al. (16) reported 
that approximately one third of the neointimal SMCs are of recipient 
origin. Bittmann et al. (17) only found graft-derived neointimal SMCs. 
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In an attempt to resolve this controversy in chapter 2, we investigated 
the origin of neointimal SMCs in human renal transplantectomy 
samples with CTD. We noted both donor and recipient-derived cells in 
the neointima of the graft. We also found recipient-derived neointimal 
SMCs, although the frequency was ~6 fold lower compared to the 
study of Grimm et al. (16). It remains to be elucidated whether these 
differences in percentages of recipient-derived neointimal cells are 
due to technical aspects of the in situ hybridization assay for the Y 
chromosome or because of sample differences. Nevertheless, since 
the efficiency of the in situ hybridization assay is never 100% (~38% 
in 4 µm sections in the study of Grimm et al., ~31% in 1,5 µm sections 
in our study), both studies probably underestimate the percentage of 
recipient-derived neointimal cells. We assume that both studies have 
underestimated the percentage of recipient-derived cells and that the 
actual number of recipient-derived neointimal cells is higher. Future 
collaborative efforts in which both techniques and materials are shared 
could further shed light on this discrepancy. In chapter 4, we also 
studied the possible contribution of recipient-derived cells to neointima 
formation in an experimental renal transplantation model in rats. In 
this model, we showed that neointimal SMCs are of graft origin, since 
α-SMA/hPAP double positive recipient-derived cells were absent in 
the neointima. The hPAP positive cells found in the neointima were 
infiltrating leukocytes. A likely explanation for differences between 
the numbers of recipient-derived neointimal SMCs in human and 
experimental CTD is that the number of recipient-derived cells may 
vary with the severity of vascular injury, which is in line with our data 
concerning EC chimerism. This is underlined by evidence that even 
without an alloimmune response, vascular injury caused by prolonged 
cold ischemia can initiate the development of TV (18). Most likely any 
form of vascular injury can initiate or enhance the development of TV.
Recipient-derived neointimal SMCs are most likely derived from 
circulating peripheral blood mononuclear cells (PBMCs). Knowledge of 
the phenotype of recipient-derived cells that contribute to neointima 
formation is relevant, since these cells form an easily accessible target 
for pharmaceutical intervention. Previous studies showed that in α-SMA+ 
cells cultured from PBMCs in vitro, the expression of CD68 and CD14 
is retained. This suggests that circulating smooth muscle precursors 
are residing within the myeloid lineage (19-21). Since we found 
recipient-derived neointimal SMCs in human renal transplantectomy 
samples (chapter 2), we cultured PBMCs from healthy controls and 
renal transplant patients with and without CTD in fibrogenic culture 
medium to investigate if we can induce a phenotypic switch to α-SMA+ 
cells in chapter 3. PBMCs from renal transplant patients indeed 
appeared to have the potential to differentiate into α-SMA+ cells in 
vitro. Subsequently, we investigated whether monocytes are the 
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likely source of α-SMA+ cells. Therefore, circulating monocyte (sub)
populations were studied by FACS analysis in renal transplant patients 
with and without CTD. To determine monocyte heterogeneity in renal 
transplant patients and healthy controls, total PBMC were analyzed by 
FACs analysis for the expression of CD14 and CD16 (22,23). In a previous 
study, reduced numbers of CD14+/CD16++ nonclassical monocytes were 
found in renal transplant recipients compared to patients on dialysis 
(24). In this study, the numbers of CD14+/CD16++ also independently 
correlated with subclinical atherosclerosis. However, a possible role 
of these cells in the development of CTD after renal transplantation 
has not been investigated so far (24). Characterization of monocyte 
subsets in renal transplant patients showed that patients with CTD have 
lower numbers of CD14+/CD16++ nonclassical monocytes compared 
to patients without CTD. The numbers of CD14+/CD16++ nonclassical 
monocytes are increased in patients with end stage renal disease on 
dialysis, compared with age-matched controls (25). The decrease in 
CD14+/CD16++ monocytes in renal transplant recipients, as opposed 
to an increase as seen in patients with chronic kidney disease, may 
be explained by the immunosuppressive therapy of renal transplant 
patients. In vitro and in vivo data suggests that glucocorticoids 
can deplete CD16+ monocytes by inducing apoptosis (26,27). This 
however, does not explain the difference in CD14+/CD16++ nonclassical 
monocyte numbers between transplant patients with and without CTD. 
We propose that the decrease in CD14+CD16++ monocytes in patients 
with CTD may reflect their preferential recruitment to the damaged 
kidney. This is currently under investigation using biopsy samples 
with and without CTD. Further analysis of CD14+/CD16++ nonclassical 
monocytes revealed that in healthy controls these monocytes have 
higher gene expression levels of the mesenchymal markers α-SMA and 
SM22α compared with CD14++/CD16- classical monocytes. Therefore, 
we propose that this subpopulation of monocytes is capable of 
differentiating into α-SMA+ cells. In line with this, the frequency of 
circulating CD14+/CD16++ monocytes correlated with the number of 
α-SMA+ cells present after PBMC culture. It has been previously shown 
that CD16- and CD16+ monocytes are functionally different (28-30). 
Ancuta et al. (29), found that CD14+/CD16++ monocytes in particular 
have the highest expression of CX3CR1. The CD14+/CD16++ monocytes 
in renal transplant patients in this study also had a higher expression 
of CX3CR1 compared to CD14++/CD16- monocytes. Interestingly, 
the expression of CX3CR1 is also found on smooth-muscle-like cells 
cultured from PBMCs (21), indicating that CD16+ monocytes may indeed 
have the potential to differentiate into α-SMA+ cells. The function of 
α-SMA+ cells in vivo is however still unclear. It was previously reported 
that α-SMA+ cells derived from the circulation in mice subjected to 
arterial injury have a macrophage phenotype with smooth-muscle-like 
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characteristics (31,32). These bone marrow-derived α-SMA+ cells never 
fully differentiated into SMCs, as evidenced by a lack of expression 
of smooth muscle-specific markers such as myosin heavy chain and 
calponin. These macrophages with smooth-muscle-like characteristics 
contributed to inflammatory processes in a paracrine fashion by 
increased expression of matrix metalloproteinases and inflammatory 
cytokines. More research is needed to confirm if CD16+ monocytes have 
a similar role in the development of CTD after renal transplantation by 
differentiating into macrophages with smooth-muscle-like properties 
with a similar proinflammatory paracrine function, thereby contributing 
to the development of CTD.
Since graft-derived SMCs predominated in the neointima in human 
transplantectomy samples and in experimental renal allografts with 
CTD, we propose that donor-derived SMCs should be the target 
when designing new therapies to attenuate the development of CTD. 
Possible sources of donor-derived neointimal cells include migrated 
medial SMCs, activated adventitial fibroblasts, or vascular progenitor 
cells residing in the adventitia. Migration of medial SMCs is in line 
with the response-to-injury paradigm proposed by Ross et al. (13) 
for the development of atherosclerosis. According to this hypothesis, 
medial SMCs migrate into the subendothelial intimal space in response 
to transplantation-induced vascular injury, where they contribute to 
the formation of an occlusive neointima. Although there is no direct 
experimental proof for proliferation and migration of medial SMCs into 
the neointima, in vivo adenoviral delivery of anti-proliferative A20 to 
medial SMCs in rat carotid arteries with balloon angioplasty attenuated 
activation of medial SMCs and neointimal hyperplasia (33). In line 
with these results, an inverse correlation between the expression of 
A20 in SMCs and the development of TV was also found in kidneys 
with chronic rejection after experimental renal transplantation (12). 
Alternatively, vascular progenitor cells residing in the adventitia of 
arterial vascular walls and vein grafts have also been shown to be a 
source of neointimal SMCs (34-36). Due to the lack of markers specific 
for medial SMCs and adventitial fibroblasts it is not yet feasible to 
use lineage tracing to investigate the anatomical origin of neointimal 
cells. Since the anatomical source of donor-derived neointimal cells is 
unknown, we explored in chapter 5 the medial micro-environment in 
allografts with CTD for the presence of fibrogenic growth factors that 
could lead to SMC accumulation and eventually neointima formation. 
We used laser-dissected neointimal and medial tissues to reveal spatial 
differences in gene expression. Within the neointima, we found an 
increased mRNA expression of Tgfβ1, Ctgf and Pdgfb. Evaluation of 
the allograft media revealed an increased expression of Tgfβ1 and 
Ctgf compared with isograft medial tissue. Although expression of 
Pdgfb was not increased in the allograft media, the receptor for Pdgfb, 
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Pdgfrβ was markedly increased. We therefore investigated the source 
of PDGF-B in arteries early after transplantation, when a neointima 
has not yet been formed. Protein expression analysis of PDGF-B in 
arteries without a neointima 16 days after transplantation showed the 
presence of PDGF-B in the media of allografts. This suggests that injury 
to medial SMCs shortly after transplantation induces the expression 
of endogenous PDGF-B. PDGF-B can subsequently cause proliferation 
of medial SMCs and act as a chemoattractant (37,38), leading to 
neointima formation. However, medial SMCs can only contribute to 
neointima formation after switching from a contractile to a synthetic 
phenotype. This phenotypic modulation is induced by growth factors 
and cytokines produced in response to vascular injury (39). PDGF-BB is 
a known mediator of SMC phenotypic modulation (40). The contractile 
phenotype of SMCs is required for regulation of vascular tone (41). The 
synthetic phenotype of SMCs is characterized by a reduced expression 
of contractile proteins, a high degree of proliferation and the ability to 
migrate (42). Based on these characteristics, synthetic SMCs can thus 
possibly contribute to the development of TV. Therefore, in chapter 4 
we investigated indicators of phenotype switching of allograft medial 
SMCs as a result of the altered medial microenvironment. To this end, 
gene expression of the SMC-specific gene SM22α and expression of 
ECM molecules was investigated in laser-dissected medial SMCs from 
arteries with a neointima from rat renal allografts. Consistent with 
a synthetic phenotype, we found reduced expression of SM22α and 
increased expression of ECM molecules in medial allograft SMCs 
compared with medial SMCs of control kidneys. We also noted an 
increased gene expression of Krüppel-like factor 4 (KLF4), a transcription 
factor known to downregulate transcription of SMC genes. KLF4 can 
repress myocardin-induced activation of SMC genes by selectively 
decreasing binding of serum reponse factor (SRF) to DNA within intact 
chromatin (43). The differentiated, contractile phenotype of SMCs is 
largely dependent on SRF/myocardin to induce gene expression of 
SMC differentiation genes (44). Previous in vitro assays showed that 
SM22α expression is downregulated in SMCs stimulated with PDGF-
BB, which was mediated by KLF4 (45). These data support our in vivo 
observations. PDGF-BB expressed in the allograft media early after 
transplantation may have a role in phenotype switching of medial SMCs 
after renal transplantation thereby contributing to the development of 
a neointima. Interestingly, gene expression of KLF5 was not increased 
in the allograft media arteries with a neointima. Like KLF4, KLF5 is 
also implicated as a regulator of phenotype modulation of SMCs and 
can induce proliferation (46). Ki67 evaluation in our study revealed 
only few proliferating neointimal and medial SMCs at 12 weeks after 
transplantation. The lack of proliferation is in line with the unchanged 
expression of KLF5 in medial allograft SMCs. These data suggest that 
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neointima formation after transplantation-related injury is primarily 
driven by migration rather than by enhanced proliferation of synthetic 
SMCs.
Prevention of TV by protecting ECs
In both human transplantectomy samples and in experimental 
CTD, the majority of neointimal cells are donor-derived and originate 
most likely from the arterial media. According to the response-to-
injury paradigm by Ross et al. (13) prevention of EC dysfunction or the 
regeneration of ECs by replacement by either donor or recipient-derived 
cells might prevent the development of TV. Therefore, in chapter 7, we 
aimed to attenuate the development of CTD by blocking activation of ECs 
during transplantation. We infused STAT1 decoy oligodeoxynucleotides 
(dODNS) (47,48) in situ during the transplantation procedure to block 
transcription of all target genes of the transcription factor STAT1. 
STAT1 dODNs are taken up by ECs, scavenge STAT1 and block the 
transcription of all target genes of STAT1 simultaneously. STAT1 is a 
transcription factor which is involved in the regulation of inflammation-
related genes such as MCP-1 and E-selectin. Using this approach we 
did not observe a beneficial effect of in situ perfusion of grafts with 
STAT1-dODNs just before transplantation on the development of TV and 
the number of infiltrating macrophages in the renal cortex. Previous 
experiments by others however, did show that TV could be attenuated 
with STAT1-dODNs in an experimental model for the development of 
CTD after cardiac transplantation (47). In our study, the tapering of 
cyclosporine, and hence, contribution of allo-factors to the CTD, could 
explain the absence of a beneficial effect of STAT1-dODN treatment. 
We propose that in our study dODNs are probably degraded at time 
of tapering immunosuppression. After tapering, immunresponses 
directed against the allograft continues and probably abrogates the 
initial anti-inflammatory effect of the dODNs. For future experiments, 
the development of a system allowing repeated delivery of STAT1-
dODNs to activated ECs might be an attractive therapeutic approach 
to target this problem. Repeated delivery of dODNs may retard the 
development of CTD after renal transplantation.
ORIGIN OF CELLS IN FOCAL SEGMENTAL GLOMERU-
LOSCLEROSIS
Scarring of the glomerulus, or focal segmental glomerulosclerosis 
(FSGS, (49)), is the final common pathway of glomerular damage of 
various native kidney diseases and after renal transplantation (also 
referred to as transplant glomerulopathy). Transplant glomerulopathy 
is characterized by hypertrophic glomeruli, mesangial matrix 
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expansion, and duplication and thickening of the glomerular basement 
membranes (50). The presence of de novo FSGS is associated with 
transplant dysfunction and early graft loss (51,52). Intact capillaries, 
repaired by either donor- or recipient-derived cells are important since 
degeneration of glomerular capillaries usually precedes the progression 
of glomerular sclerosis (53). In chapter 2, we determined the origin 
of glomerular ECs in human explanted transplantectomy samples. We 
found that the percentages of chimerism were highly variable between 
the different patients that were included in our study. In experimental 
transplantation (chapter 4) we also observed EC chimerism in 
glomerular capillaries. An average of two recipient-derived ECs were 
found in 62% of the glomeruli. As suggested earlier, EC chimerism 
appears to be dependent on the severity of endothelial damage (54). 
Graft endothelial cells are damaged due to rejection-induced damage, 
followed by replacement (55). Replacement by recipient-derived 
cells is probably accomplished by circulating progenitor cells which 
differentiate into endothelial cells in order to repair the damaged 
glomerular endothelium. However, there are also studies reporting 
no contribution at all of recipient-derived cells to endothelial repair in 
glomeruli (56). 
Chimerism of mesangial cells in CTD after renal transplantation was 
not investigated in this thesis. However, previous studies described 
mesangial cell chimerism in human renal transplant biopsy samples, 
experimental glomerulonephritis and in transgenic mice developing 
spontaneous glomerulosclerosis (55,57,58). In human renal biopsy 
samples mesangial chimeric cells were detected in 43% of patients 
(55). Also, in chimeric rats it was demonstrated that bone marrow can 
transform to mesangial cells in vivo (57). Furthermore, bone marrow-
derived cells from mice with glomerulosclerosis transplanted into 
mice with normal glomeruli could even transfer the glomerulosclerotic 
disease and glomerular hypertrophy (59). This indicates that these 
bone marrow progenitors carry the diseased phenotype and are able 
to initiate FSGS in healthy glomeruli.
ORIGIN OF CELLS IN INTERSTITIAL FIBROSIS AND 
TUBULAR REPAIR
Interstitial fibrosis and tubular atrophy (IF/TA) is the result of chronic 
tissue remodeling of the interstitium of the transplanted kidney (60). 
IF/TA is characterized by interstitial accumulated ECM accompanied 
by massive infiltration of inflammatory cells, tubular atrophy and 




Repair of injured peritubular capillaries by either donor- or recipient-
derived cells appears to be important as loss of peritubular capillaries 
is associated with the development of CTD after renal transplantation 
(61). Previously, chimerism of ECs has mainly been investigated in 
human biopsy samples of renal transplant patients with acute rejection 
(9,10,62). In chapter 4, we used an experimental mode for renal CTD 
to evaluate EC chimerism in peritubular capillaries. We found bone 
marrow-derived endothelial cells in peritubular capillaries. The presence 
of these recipient-derived ECs probably reflects repair mechanisms in 
order to maintain endothelial integrity of the graft. Studies investigating 
EC chimerism after human renal transplantation also reported these 
cells to be present in peritubular capillaries after acute and chronic 
rejection (9,63,64). The percentages of recipient-derived ECs in these 
studies have been linked to the severity of vascular rejection (9,63) or 
duration of ischemia time (10,62).
Ischemia/reperfusion injury during the transplant procedure causes 
marked damage to tubular epithelial cells in renal allografts. However, 
tubular epithelial cells have a remarkable capacity to regenerate 
(65). Surviving epithelial cells can repopulate affected tubules within 
days after injury. Since recipient-derived progenitor cells could also 
participate in this regeneration process, we investigated tubular 
chimerism in human nephrectomy samples after renal transplantation 
in chapter 2. We found a minor contribution of recipient-derived cells 
to tubular regeneration, confirming other studies performed in human 
biopsies of patients suffering from acute and chronic rejection after 
renal transplantation (16,17,55,66-69). In most of these studies the 
presence of recipient-derived tubular cells was not associated with 
previous episodes of rejection. The contribution of circulating cells 
to the process of fibrosis in the tubulo-interstitium is controversial. 
We previously demonstrated presence of both graft- and recipient-
derived myofibroblasts in the pathogenesis of interstitial fibrosis 14 
days after experimental renal transplantation (70). Therefore, we 
now also investigated the contribution of recipient-derived interstitial 
myofibroblasts in CTD after experimental renal transplantation in 
chapter 4. This study revealed that both donor- and recipient-derived 
cells contributed to the same extent to interstitial myofibroblast 
accumulation in renal allografts with CTD. Potential sources of donor-
derived interstitial myofibroblasts are: endothelial and/or tubular 
epithelial cells (via a process called endothelial or epithelial to 
mesenchymal transition, respectively), activated pericytes, or resident 
interstitial fibroblasts (71-74).
In experimental renal fibrosis recipient-derived interstitial 
myofibroblasts appear to be, at least in part, bone marrow-derived 
(75,76). The presence of these cells was confirmed in human renal 
transplantation biopsy samples (16). They appear in the acute phase 
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after renal transplantation and can be found as early as 14 days after 
renal transplantation (70). At this early post transplant time-point in 
rats, 39% of the interstitial myofibroblasts are recipient-derived and 
this number increases to ~53% in the chronic phase, 12 weeks after 
transplantation as demonstrated in chapter 4. Moreover, we showed 
that bone marrow-derived myofibroblasts produced procollagen I, 
suggesting an active role of these cells in postischemic remodeling. 
Resident renal myofibroblasts also produce TGF-β1, thereby 
possibly contributing to the environment in which bone marrow-
derived myofibroblasts can become functionally active in producing 
ECM proteins (75). From these data it can be inferred that, from a 
therapeutic point of view, recipient-derived myofibroblasts form a 
target for potential intervention which can start already in the early 
phase after transplantation.
ROLE OF PROTEOGLYCANS IN THE PATHOGENESIS OF 
CTD
Tissue remodeling and fibrosis are not only accompanied by an 
increased deposition of ECM, but also by an altered expression and 
composition of proteoglycans. Heparan sulfate proteoglycans (HSPGs) 
can contribute to tissue remodeling by functioning as docking platforms 
for growth factors and cytokines. Until now, the regulation of growth 
factors by HSPGs has been mainly studied in tissue remodeling linked to 
biological processes such as embryonic development, ontogenesis and 
angiogenesis (77-79). In chapter 6, we studied the spatial relationship 
of several HSPGs in CTD after experimental renal transplantation. 
The development of TV in renal allografts was accompanied by an 
increased expression of the HSPG perlecan in the neointima and in the 
media. Also, the expression of versican was increased in the media of 
allografts from arteries with a neointima. The increased expression of 
versican is in line with a migratory phenotype of medial SMCs (80). HS 
carbohydrate side chains can bind a variety of ligands including FGF2, 
depending on their composition (81). We show that in experimental 
allografts with CTD the expression of FGF2 as well as the binding 
capacity of HSPGs for FGF2 is increased. The enhanced binding capacity 
for FGF2 is the result of an increased expression of HSPGs combined 
with modifications in HS sulfation patterns. Matrix HSPGs can thus 
become docking molecules for heparin-binding growth factors such as 
FGF2 after experimental renal transplantation. An in vitro culture assay 
confirmed the functional role of HSPGs in FGF2-driven proliferation of 
rat mesangial cells. This increased binding capacity for FGF2 is also 
present in fibrotic areas of human native kidney diseases (82). These 
data indicate that HSPGs can also modulate growth factors in the 
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renal transplant setting, which makes them an important therapeutic 
target to ameliorate the development of CTD. Binding of growth 
factors to HSPGs could be inhibited by blocking peptides. Alternatively, 
therapeutic delivery of HSPG mimetics could capture growth factors, 
thereby inhibiting their action. 
FUTURE PERSPECTIVES
Detrimental renal events following the process of renal transplantation 
are inevitable. A major task therefore is to explore whether we can halt 
these processes following injury in an early phase after transplantation 
in order to limit the progressive nature of renal fibrosis which occurs 
in the chronic phase. Fortunately, the kidney has the capacity to 
regenerate at the tubular level, as evidenced by regeneration of these 
structures in the early phase after ischemia/reperfusion. This is of 
major importance, since prolonged injury combined with a defective 
repair will definitely lead to tissue remodeling and fibrosis. However, 
therapies aimed at regeneration of injured tissue should take into 
consideration that the contribution of recipient-derived cells in this 
process is quite low, as shown in this thesis. Therapies should target 
surviving kidney cells which should be stimulated to proliferate and 
redifferentiate. This can, for example, be achieved by exogenous 
delivery of Wnt7b, which can stimulate epithelial cell proliferation (83).
Despite the use of immunosuppressive agents fibrotic events take 
place in the late phase after transplantation in all compartments of the 
kidney. In order to prevent or attenuate the development of CTD multiple 
cell populations should be targeted simultaneously, since we showed 
that both donor- and recipient-derived contribute to fibrosis. Although 
we found that the contribution of recipient-derived cells to neointima 
formation was relatively low, a paracrine contribution of these cells 
to neointima formation cannot be excluded. Recipient-derived smooth 
muscle precursors can influence the phenotype of SMCs by secreting 
growth factors such as PDGF-BB or possibly by microvesicles containing 
miRs, which target genes essential for a contractile phenotype of 
SMCs, such as myocardin. It was shown previously that monocytes 
can secrete microvesicles containing miRNAs which affect other cell 
types (84). The contribution of recipient-derived cells to fibrosis may 
be inhibited by blocking their recruitment to the injured kidney. This 
can be done by elimination of recipient-derived smooth-muscle-like 
cells in the circulation or by inhibiting activation of allograft ECs in 
order to prevent influx of recipient-derived cells.
The anatomical source of donor-derived cells that contribute to 
fibrosis in renal CTD needs additional experimental proof. Inhibition of 
phenotypic modulation or lineage tracing with markers more specific 
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for SMC could provide a definitive answer if medial SMCs are indeed the 
source of neointimal SMCs. Nevertheless, the contribution of donor-
derived cells to fibrosis may be attenuated by inhibition of activation 
and migration of the collagen producing cells, which are in our view 
interstitial fibroblasts and medial SMCs. The switch from fibroblasts to 
myofibroblasts and the switch from contractile SMCs to synthetic SMCs 
could be prevented by inhibition of growth factors such as TGF-β1 
or PDGF-BB. Another option is blocking transcription factors such as 
SMAD3 (85) to inhibit fibroblast activation, and KLF4 (39) to inhibit 
SMC phenotypic modulation. Also, microvesicles containing miRNAs 
have been shown to be involved in EC-SMC communication in vivo (86). 
Healthy ECs secrete microvesicles that contain miRNA-143/145 which 
stimulate a contractile phenotype. It is known that miRNA-143/145 
enhance a contractile phenotype of SMCs by, amongst other genes, 
downregulating KLF4 (87). Dysfunctional ECs probably downregulate 
miRNA-143/145 and thereby possibly stimulate phenotypic modulation 
to a synthetic SMC which aids neointima formation. Microvesicles 
containing miRNA-143/145 which block phenotypic modulation of 
SMCs, could therefore be an attractive therapeutic option to attenuate 
the development of TV after renal transplantation. Once the formation 
of scars in the kidney has started other means of treatment have to 
be employed. In this phase it may be crucial to specifically target the 
ECM producing fibroblast with anti-fibrotic components using markers 
for myofibroblasts such as PDGFRβ (88,89).
In this thesis, we have delineated the cell types and possible 
pathways contributing to the renal lesion after transplantation. The 
exciting task ahead is to intervene in these processes in order to 
alleviate the burden of destructive renal events in the renal transplant 
patient.
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Niertransplantatie is op dit moment de beste behandelmethode voor 
patiënten met eindstadium nierfalen. Door betere afweeronderdrukkende 
middelen, meer geavanceerde chirurgische technieken en verbeterde 
zorg voor de patiënt is het aantal keer dat de getransplanteerde nier 
binnen een jaar na transplantatie wordt afgestoten sterk gedaald. 
Echter, mede als gevolg van deze verbetering, is nu chronische 
transplantaatdisfunctie (CTD) het grootste probleem geworden. CTD 
is de meest voorkomende oorzaak (ongeveer 30%) van het niet 
meer goed functioneren van de getransplanteerde nier. CTD wordt 
gekenmerkt door verlittekening in verschillende compartimenten van 
de nier. Momenteel zijn er voor transplantatiepatiënten geen therapieën 
beschikbaar die gericht zijn op het verminderen of voorkomen van 
CTD. Het is daarom van groot belang om onderzoek te doen naar 
de verschillende celtypen  en mechanismen die een rol spelen bij 
de ontwikkeling van CTD na niertransplantatie. Nieuwe inzichten in 
deze mechanismen zijn essentieel voor de ontwikkeling van nieuwe 
therapieën. Verbeterde therapieën zullen leiden tot een betere 
transplantaatoverleving en zal daardoor bijdragen aan de kwaliteit van 
leven en overleving van transplantatiepatiënten. 
Een van de belangrijkste kenmerken van CTD is transplantaat-
vasculopathie (TV). Bij TV vernauwen bloedvaten in de getransplanteerde 
nier ernstig als gevolg van verlittekening. Door deze vernauwing kan 
in de getransplanteerde nier schade door zuurstoftekort ontstaan, 
hetgeen kan leiden tot verlies van functie. Het doel van het onderzoek 
dat beschreven staat in dit  proefschrift is om de cellulaire en moleculaire 
spelers te identificeren die betrokken zijn bij de ontwikkeling van CTD 
na niertransplantatie, met nadruk op de ontwikkeling van TV.
HERKOMST VAN CELLEN DIE BIJDRAGEN AAN DE 
ONTWIKKELING VAN TRANSPLANTAATVASCULOPA-
THIE
TV manifesteert zich door een ophoping van cellen aan de binnenzijde 
van de vaatwand die zorgen voor verlittekening vlak/direct onder de 
endotheelcellaag. TV wordt ook wel neointima formatie genoemd. 
Endotheelcellen vormen een aaneengesloten laag aan de binnenkant 
van een bloedvat en zijn onder andere betrokken bij de regulatie van 
stolling en de functie van gladde spiercellen. De endotheelcellen in de 
getransplanteerde nier zijn de eerste cellen waar het immuunsysteem/
de immuuncellen van een transplantatiepatiënt mee in aanraking komt. 
Omdat de endotheelcellen in de transplantatienier lichaamsvreemde 
cellen zijn, kan een immuunreactie vervolgens leiden tot activatie/
beschadiging en disfunctie van deze cellen. Wanneer door dit proces 




ontstekingscellen van de transplantatiepatiënt gemakkelijker zich 
verplaatsen uit het bloedvat naar het weefsel van de getransplanteerde 
nier. Aanhoudende ontsteking zal uiteindelijk leiden tot de ontwikkeling 
van CTD.
Het is daarom belangrijk om de beschadigde endotheelcellen te 
vervangen door nieuwe endotheelcellen. Theoretisch kunnen deze 
cellen uit de bloedcirculatie van de ontvanger of uit de donornier 
zelf komen, doordat aangrenzende endotheelcellen gaan delen. In 
hoofdstuk 2 hebben we bestudeerd waar endotheelcellen in een 
humane getransplanteerde nier met CTD vandaan komen. We vonden 
dat het grootste deel van de endotheelcellen uit de transplantatienier 
zelf kwam en maar een klein percentage uit de bloedcirculatie van 
de ontvanger. In hoofdstuk 4 hebben we dit verder onderzocht 
in een dier experimentele studie. In de grote bloedvaten (arteriën) 
van getransplanteerde nieren in ratten vonden we alleen maar 
endotheelcellen die afkomstig waren uit de transplantatienier zelf. Dit 
betekent dat de bijdrage van cellen uit het bloed van de ontvanger aan 
het herstellen van de endotheellaag in een bloedvat verschilt tussen 
mens en rat. Dit kan komen door verschil in afweeronderdrukkende 
therapie. Een andere verklaring is dat de hoeveelheid cellen in de 
circulatie die bijdragen aan herstel afhangt van de hoeveelheid schade 
aan de transplantatienier zelf.
De neointima bestaat met name uit gladde spiercellen. In de wand 
van bloedvaten zijn gladde spiercellen met name betrokken bij het 
samentrekken en ontspannen van een bloedvat en dus belangrijk in de 
regulatie van bloeddruk. Eén van de theorieën over hoe een neointima 
ontstaat is dat de gladde spiercellen in de wand van een bloedvat na 
schade gaan migreren in de richting van de endotheelcellen en zodoende 
het bloedvat vernauwen. Of cellen uit de bloedcirculatie ook kunnen 
bijdragen aan neointimaformatie is nog onduidelijk. In hoofdstuk 2 
hebben we daarom onderzoek gedaan naar de mogelijke herkomst van 
de gladde spiercellen in de neointima van transplantatienieren met 
CTD. We laten zien dat er vanuit de transplantatiepatiënt cellen zijn die 
kunnen bijdragen aan neointima formatie. De bijdrage van deze cellen 
was ongeveer 6%. In hoofdstuk 4 hebben we hetzelfde fenomeen 
onderzocht, maar dan in getransplanteerde nieren bij ratten. In deze 
studie waren alle gladde spiercellen in de neointima  afkomstig uit 
de transplantatienier zelf. Net als de verschillen in het herstel van 
de endotheelcellen, is een mogelijke verklaring voor dit verschil in de 
bijdrage van cellen uit de bloedcirculatie aan neointimaformatie tussen 
mens en rat, dat de bijdrage van circulerende cellen  varieert met de 
mate van schade aan de transplantatie nier, met een grotere bijdrage 
van circulerende cellen bij een meer beschadigde nier. 
Omdat we in humane getransplanteerde nieren vonden dat de 
gladde spiercellen in de neointima niet alleen afkomstig waren uit de 
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donornier, maar ook uit de circulatie van de transplantatie patiënt 
(hoofdstuk 2) hebben we in hoofdstuk 3 witte bloedcellen van 
gezonde mensen en niertransplantatiepatiënten met en zonder CTD 
bestudeerd. Witte bloedcellen werden in kweekmedium gestimuleerd 
met groeifactoren om te onderzoeken of ze konden uitgroeien tot 
gladde spiercellen. Witte bloedcellen van niertransplantatiepatiënten 
bleken inderdaad het vermogen te hebben om te differentiëren naar 
gladde spiercellen. Vervolgens hebben we onderzocht of monocyten, 
een specifiek type witte bloedcel, de bron zouden kunnen zijn van deze 
gladde spiercellen in celkweek. Karakterisatie van deze monocyten 
bij niertransplantatiepatiënten toonde aan dat patiënten met CTD een 
lagere frequentie van een bepaalde monocyten subfractie hebben 
dan getransplanteerde patiënten zonder CTD. Deze bloedcellen 
die kenmerken van gladde spiercellen kunnen verkrijgen dragen 
waarschijnlijk bij aan de ontwikkeling van een neointima door zich 
als gladde spiercel in de neointima te verplaatsen en door verhoogde 
productie van groeifactoren die weer de gladde spiercellen in de wand 
van een arterie beïnvloeden. 
De meeste gladde spiercellen in de neointima komen, zowel in 
de humane als experimentele setting, vanuit de transplantatienier 
zelf. Het is niet bekend waar deze cellen vandaan komen en daarom 
onderzochten we in hoofdstuk 5 de bloedvaten van getransplanteerde 
nieren van proefdieren met chronische afstoting in detail, gericht op 
de mechanismen die kunnen leiden tot gladde spiercelstapeling in de 
neointima. We gebruikten hiervoor een laser-dissectie microscoop, 
waarmee we de verschillende compartimenten van een bloedvat 
apart konden uitsnijden. Op die manier hebben we verschillende 
kandidaatgenen in de verschillende compartimenten bestudeerd, die 
betrokken zouden kunnen zijn bij de vorming van een neointima. 
We gaan er hierbij van uit dat de veranderingen in genexpressie in 
de bloedvaten na transplantatie veroorzaakt wordt door schade aan 
de vaatwand tijdens het afstotingsproces. Gladde spiercellen in de 
vaatwand bleken in plaats van contractiele eigenschappen een switch 
te hebben gemaakt naar een zogenaamd synthetisch fenotype dat 
gekenmerkt wordt door een verlaagde capaciteit om samen te trekken 
en een verhoogde capaciteit om te delen en te migreren. Op deze 
manier kunnen synthetische gladde spiercellen dus de ontwikkeling 
van TV bevorderen.
PREVENTIE VAN TV DOOR HET BESCHERMEN VAN 
ENDOTHEELCELLEN
In hoofdstuk 7 richtte ons onderzoek zich op het verminderen van de 




van de activatie van endotheelcellen kort na transplantatie. Om dat 
te kunnen doen behandelden we donornieren kort voor transplantatie 
met een decoy voor een transcriptiefactor om de genexpressie van 
genen die betrokken zijn bij ontsteking te kunnen blokkeren. De 
hypothese was dat de decoy wordt opgenomen door de endotheelcellen 
in de transplantatienier en daarmee vervolgens het afschrijven van 
ontstekingsgenen voorkomt. Alleen had de behandeling geen gunstig 
effect op de ontwikkeling van transplantaatschade en ontsteking in 
de nier. Eerdere experimenten in een model voor harttransplantatie, 
uitgevoerd door anderen, toonden aan dat transplantaatvasculopathie 
wel verminderd kan worden met deze decoy. Het zou kunnen zijn dat het 
verminderen van de afweeronderdrukkende middelen, die we gebruiken 
bij de proefdieren, het uitblijven van een gunstig effect veroorzaakt. 
Wij gaan er van uit dat in ons model de decoy’s worden afgebroken 
op het moment dat de ratten niet meer met afweeronderdrukkende 
middelen worden behandeld. Voor toekomstige experimenten stellen 
we voor om de decoy op meerdere tijdspunten na transplantatie toe 
te dienen.
DE ROL VAN PROTEOGLYCANEN IN DE PATHOGENESE 
VAN CTD
Verlittekening tijdens het afstotingsproces gaat ook gepaard met 
een veranderde expressie en samenstelling van proteoglycanen. 
Proteoglycanen kunnen bijdragen aan de remodellering van weefsel na 
schade door te functioneren als een hechtingsplaats voor groeifactoren 
en ontstekingseiwitten. Tot nu toe is de regulatie van proteoglycanen 
in het vaatbed voornamelijk bestudeerd in biologische processen zoals 
embryonale ontwikkeling en vaatgroei, maar over de rol bij TV was 
niets bekend. Wij hebben daarom onderzocht in hoofdstuk 6 of TV 
gepaard gaat met veranderde expressie en functie van proteoglycanen. 
De ontwikkeling van TV in getransplanteerde nieren ging inderdaad 
gepaard met een verhoogde expressie van proteoglycanen in de 
neointima en de media van bloedvaten. We hebben ook laten zien 
dat tijdens experimentele chronische afstoting niet alleen de expressie 
van groeifactoren, maar ook de bindingscapaciteit van proteoglycanen 
voor groeifactoren verhoogd is. In gebieden met verlittekening kunnen 
proteoglycanen dus een verzamel- en afgifteplaats worden voor 
groeifactoren. Deze gegevens wijzen erop dat proteoglycanen het 
proces van afstoting kunnen moduleren, waarmee ze meteen ook een 





Ondanks het gebruik van afweeronderdrukkende middelen na 
transplantatie ontstaat er op de lange duur toch verlittekening in de 
verschillende compartimenten van de nier (CTD). Om dit proces te 
voorkomen of te verminderen moet de toekomstige behandeling zich, 
al dan niet tegelijkertijd, richten op meerdere celtypen in de nier. De 
achterliggende gedachte hierbij is dat wij gevonden hebben dat de 
cellen die bijdragen aan verlittekening afkomstig zijn uit de nier zelf 
en uit de bloedcirculatie. Hoewel wij vonden dat de bijdrage van cellen 
afkomstig uit de bloedcirculatie relatief laag was, kan een rol voor deze 
cellen bij de vorming van neointima absoluut niet worden uitgesloten. 
Wij veronderstellen dat deze cellen  door de productie van eiwitten die 
ontsteking en verbindweefseling bevorderen cellen in hun omgeving 
stimuleren. Bovengenoemde insteek in behandelingsmethoden kan 
een gunstig effect hebben op het functioneren en dus de overleving 
van het getransplanteerde orgaan en daarmee de kwaliteit van leven 
















α-SMA  α-Smooth muscle actin
CsA   Cyclosporin A
CTD  Chronic transplant dysfunction
DA   Dark agouti rat
dODNs   Decoy oligodeoxynucleotides 
ECs   Endothelial cells
ECM  Extracellular matrix 
EPCs  Endothelial progenitor cells
F344  Fischer344 rat
FGS   Focal glomerulosclerosis 
FISH  Fluorescent in situ hybridization
hPAP  Human placental alkaline phosphatase
HS   Heparan sulfate
HSPGs  Heparan sulfate proteoglycans
IEL   Internal elastic lamina
IF/TA  Interstitial fibrosis and tubular atrophy
KLF4  Krueppel-like factor 4
PBMCs  Peripheral blood mononuclear cells
MYH11  Smooth muscle myosin heavy chain 11 
PDGFB  Platelet derived growth factor B
R26   R26-hPAP-transgenic F344 rat 
SM22α  Smooth muscle protein 22 α
SMCs  Smooth muscle cells
SMPCs  Smooth muscle precursor cells
SRF   Serum response factor
TGF-β1  Transforming growth factor - β1 
TV   Transplant vasculopathy
VCAM  Vascular adhesion molecule 
vWF  von Willebrand factor
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Vele mensen hebben meegeholpen aan de totstandkoming van dit 
proefschrift. Ik wil graag van de gelegenheid gebruik maken om hen 
te bedanken voor hun steun, inzet en vertrouwen.
Natuurlijk is het schrijven van een dankwoord niet makkelijk omdat 
je de juiste woorden moet vinden, en je het risico loopt om mensen 
te vergeten. Voor dit laatste alvast mijn excuses, iedereen die ik nu 
vergeet: Bedankt!
Als eerste wil ik mijn eerste promotor, Prof. Dr. Jan-Luuk Hillebrands, 
bedanken voor de afgelopen jaren. Beste Jan-Luuk, ik heb ontzettend 
veel waardering voor jou en je werk. Je bijna oneindige enthousiasme 
en energie zijn altijd inspirerend. Zonder jou was dit nooit gelukt!
Mijn copromotor Dr. Eliane Popa, gelukkig was jij er altijd om de 
planning in de gaten te houden… Beste Eliane, ik kon elk moment van 
de dag bij je binnenlopen om dingen te overleggen, dit heb ik altijd erg 
fijn gevonden. Bedankt voor je inzet van de afgelopen jaren. Ik heb 
veel van je geleerd.
Ook wil ik mijn tweede promotor Prof. Dr. Gerjan Navis en copromotor 
Dr. Jaap van den Born van de afdeling Nefrologie bedanken voor hun 
inzet en begeleiding. Gerjan, nieuwe geniale ideeën borrelden altijd 
ten overvloede na een bespreking. Jaap, je positieve instelling is een 
voorbeeld voor iedereen, niets is onmogelijk.
De leden van mijn leescommissie, Prof. Dr. Roel Goldschmeding, 
Prof. Dr. Peter Heeringa en Prof. Dr. Anton-Jan van Zonneveld wil ik 
bedanken voor de tijd en moeite die ze hebben genomen om mijn 
proefschrift te beoordelen.
Naast mijn begeleider wil ik graag nog een aantal andere mensen 
bedanken die betrokken zijn geweest bij mijn onderzoek. Dr. 
Marc Seelen, bedankt voor het helpen met het verkrijgen van de 
bloedsamples. Prof. Dr. Roel Goldschmeding en Dr. Tri Nguyen, 
bedankt voor het helpen met de CTGF kleuring. Special thanks to 
our collaborators Prof. Dr. Markus Hecker and Dr. Andreas Wagner in 
Heidelberg. Thanks for providing us with the decoy ODNs, even though 
the results were not as expected I learned a lot.
Mijn paranimfen, Merel en Guido. Lieve Merel, de afgelopen jaren heb 
ik het geluk gehad om jou als vriendin te leren kennen. Ik zal nooit de 
vele uren vergeten die wij samen hebben doorgebracht. Lunchen met 
Sander, vrijdagmiddag borrelen in der Witz en dat zaterdagmiddag 




vriendschap, ik weet zeker dat je een geweldig plastisch chirurg gaat 
worden! Guido, onze vriendschap gaat al even terug. Ik weet nog dat 
ik bij de Medische Biologie begon met mijn eerste stage, terwijl jij net 
begon met promoveren. Bedankt voor al je raad en advies als collega, 
maar vooral ook als vriend. 
Prof. Dr. Harry van Goor. Beste Harry, tijdens mijn promotie hebben 
we weinig samengewerkt, dit zijn we nu ruimschoots aan het inhalen! 
Na een humoristisch mailtje van jou kan ik er weer even tegenaan. Ik 
weet zeker dat het randje van Miriam een blijvertje is… Maar zonder 
grappen, ik vind onze samenwerking/vriendschap geweldig.
De nier vrouwen, Heleen en Patricia. Mijn allereerste ASN in Philadelphia 
samen met jullie was een geweldige ervaring. Ik heb het altijd jammer 
gevonden dat we niet langer hebben kunnen samenwerken.
Onderzoek doen is niet mogelijk zonder de hulp van collega’s. Bedankt 
voor de fijne tijd, niet alleen op de afdeling, maar ook daarbuiten. Als 
eerste, Prof. Dr. Ruud Bank. Beste Ruud, bedankt voor de mogelijkheid 
om me verder te ontwikkelen als onderzoeker binnen deze afdeling. Ik 
heb het hier erg naar mijn zin. Geweldig om zoveel vrijheid te hebben 
tijdens je werk. Jasper, bedankt voor al je hulp tijdens het opwerken 
van alle bloedsamples. Dan de collega´ s van mijn onderzoeksgroep; 
Bram, Diana, Ieneke, Jelena, Jurjen, Linda, Masum, Nadine, Nynke, 
Rutger, Saskia en Saed. En last but not least, mijn kamergenoot 
Sander. Ik kan me geen betere kamergenoot wensen, alles kan ik 
met je overleggen hoe onbelangrijk ook. Alles-is-een-liedje en nieuwe 
klassiekers zorgen daarnaast altijd voor een vrolijke noot.
Ook wil ik graag de overige de collega´ s van de Medische Biologie 
bedanken, allereerst Annet, Suzan en Hans. Dan Dr. Marco Harmsen. 
Beste Marco, bij jou ben ik dit hele traject begonnen. Na mijn eerste 
stage bij de Medische Biologie, heb ik aan je gevraagd of je contacten 
in het buitenland had waar ik mijn volgende stage zou kunnen lopen. 
Het antwoord was: Rotterdam… Ik heb daar een supertijd gehad, 
bedankt daarvoor. Ook mijn collega AIO’s van de Medische Biologie, 
Jan-Reinier en Ee Soo bedankt voor alle koffiemomentjes en borrels.
Verder wil ik graag de vele analisten bedanken die op een of andere 
manier bij mijn onderzoek betrokken zijn geweest; Anita, Josée, 
Henriette, Marja, Martin, Peter, Inge, Xavier, Corien, Jelleke, Alice, 
Henk Moorlag, Jelle, Roelof-Jan, Henk Moes, Geert en Klaas.
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Tijdens mijn onderzoek heb ik een aantal studenten mogen begeleiden, 
Rutger, Arjan, Chi Wai en Bauke. Bedankt voor jullie inzet en het werk 
wat jullie voor mij hebben verzet.
Ook wil ik mijn collega’s op het Pathologie O&O lab en de afdeling 
(experimentele) Nefrologie bedanken. Als eerste, Marian, bedankt 
voor alle coupes die je hebt gesneden en gekleurd. Ook alle (ex) AIO’s 
en postdocs, bedankt voor alle gezelligheid op de afdeling en tijdens 
niercongressen: Anna, Anne-Roos, Arjan, Astrid, Azi, Betty, Carolien, 
Dorien, Edwin, Eelke, Else, Esther, Fariba, Femke, Ferdau, Gemma 
Gerda, Guiseppe (in memoriam), Jeffrey, Jelena, Jill, Joris, Kim, Kiran, 
Laura, Lieneke, Maartje, Marije, Michel, Pauliene, Pramod, Saleh, 
Saritha, Solmaz, Tjitske, Wendy, Wynand en Yuan. Jill, hoe kan het 
nou toch dat we nu bij dezelfde afdeling werken, maar elkaar minder 
spreken dan eerst! Bedankt voor alle koffie momentjes de afgelopen 
jaren. I also want to thank Kiran for letting me join in Indian parties 
and habits. I had a lot of fun doing experiments with you.
Ook wil ik de mensen van het CDP bedanken voor hun inzet en hulp bij 
mijn experimenten. In het bijzonder wil ik André, Annemieke en Michel 
bedanken voor hun expertise en hulp.
Vrienden, teveel om allemaal op te noemen, maar wel zeker zo belangrijk 
voor een beetje ontspanning! Aan een aantal wil ik graag speciaal 
aandacht schenken. Marije en Mirjam, bedankt voor alle gezellige 
avonden cupcakes maken en wijntjes drinken. Dit gaan we nog heel 
lang doen. Niekjan & Marije, bedankt voor alle gezellige dagen die 
we met jullie en jullie kinderen hebben doorgebracht, misschien snel 
weer een weekendje weggaan? Margo, ondanks dat we elkaar niet elke 
week spreken, hebben we nog steeds maar een woord nodig om elkaar 
te begrijpen. Ruud, bedankt voor de gezellige tijd in Rotterdam en 
tijdens alle weekenden en roadtrips daarna. Johan, bedankt voor een 
luisterend oor en natuurlijk voor de gezelligheid tijdens alle keren dat 
we een nieuw restaurant gingen uittesten. Guido & Karin, Christiaan 
& Sarah, bedankt voor alle gezelligheid tijdens etentjes en vooral ook 
tijdens skivakanties. 
Dan de geweldige chaos die de familie Boersema heet; Pappa & Mamma, 
Henk & Marian, Mark & Rejauna en Marjolein & Sicco. Iedereen is altijd 
welkom, kerstdiners waar ik iedereen voor mag uitnodigen, stedentrips 
met het hele gezin en ga zo maar door. Ik hou van jullie! Natuurlijk 
hoort ook mijn ‘nieuwe’ familie op deze plaats, Jan & Yvonne en Willem 




En dan als laatste Marten, jou ben ik het meest verschuldigd. Bedankt 
voor al je steun en begrip de afgelopen jaren. Zonder jou had ik dit 
zeker niet kunnen doen. Ik hoop dat de jaren die we nog samen hebben 
net zo geweldig worden als de afgelopen tijd! 
